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Abstract
Receptor tyrosine kinases (RTKs) are a family of 58 transmembrane proteins in humans that play crucial roles
in many biological processes and diseases. Different RTKs utilize subtly (but importantly) distinct molecular
mechanisms for transmembrane signaling, and understanding these differences is crucial for devising new
ways to intervene pharmacologically when aberrant RTK signaling causes cancer and other diseases. In this
thesis, I focus on three RTK families: the ALK/LTK family, the Wnt-binding RTKs, and the EGF receptor –
where I concentrate on efforts to understand its C-terminal regulatory region.
My studies of ALK, for anaplastic lymphoma kinase, were motivated by the fact that this RTK sub-group has a
unique domain architecture in its extracellular region. Little is known about the mechanisms of ligand binding
to – and activation of – ALK, and the nature of its ligand(s) is(are) still not completely clear. Using
biochemical, biophysical and structural biology approaches, I characterized the low-resolution structure of the
ALK extracellular region. I further identified the binding mode of ALK binding to heparin, a recently
discovered modulatory ligand for ALK. Based on a low-resolution structural analysis of ALK/heparin
complex, I propose a model for ligand-induced ALK dimerization and activation.
Ryk is one of the five RTKs that are now known to be Wnt receptors. In this thesis, I studied the Drosophila
homolog of Ryk, Derailed (Drl), and its binding to ligand DWnt5. We were able to express and purify
milligrams of active DWnt5 – thus overcoming a major obstacle in this field. We further characterized Drl/
DWnt5 interactions. Using hydrogen/deuterium exchange approaches, I identified the DWnt5-binding
interface on Drl. My efforts to understand the molecular mechanisms of Drl/DWnt5 binding using
experimental and computational approaches suggest that DWnt5 may interact with Drl through a binding
mode that differs from Wnt binding to other receptors.
Across the RTK family, many receptors contain a long carboxy-terminal tail (C-tail) that harbors
autophosphorylation sites for docking of downstream signaling molecules. This region is generally considered
to be intrinsically disordered. I studied the dynamics of the EGFR C-tail, and showed that it is highly
unstructured – but contains some somewhat ‘structured’ regions. I also showed that phosphorylation of the
EGFR C-tail promotes receptor dimerization. Using hydrogen exchange, I identified possible C-tail docking
sites on the kinase domain that may be responsible for this effect. I also studied binding of downstream SH2
domain-containing molecules to the EGFR C-tail, with results that indicate that not all features of SH2
domain binding to the C-tail can be recapitulated by simple phosphopeptides; binding of SH2 domains to the
C-tail exhibits binding affinities and stoichiometries that are not captured by simple peptide-level studies.
Moreover, my binding competition assays suggest that there may be cooperativity in binding of multiple SH2
domains to a single phosphorylated C-tail.
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ABSTRACT 
DIVERSITY OF RECEPTOR TYROSINE KINASE SIGNALING MECHANISMS 
Zhengyi Wu 
Mark A. Lemmon 
 
Receptor tyrosine kinases (RTKs) are a family of 58 transmembrane proteins in humans that play 
crucial roles in many biological processes and diseases.  Different RTKs utilize subtly (but 
importantly) distinct molecular mechanisms for transmembrane signaling, and understanding 
these differences is crucial for devising new ways to intervene pharmacologically when aberrant 
RTK signaling causes cancer and other diseases.  In this thesis, I focus on three RTK families: 
the ALK/LTK family, the Wnt-binding RTKs, and the EGF receptor – where I concentrate on 
efforts to understand its C-terminal regulatory region. 
My studies of ALK, for anaplastic lymphoma kinase, were motivated by the fact that this 
RTK sub-group has a unique domain architecture in its extracellular region.  Little is known about 
the mechanisms of ligand binding to – and activation of – ALK, and the nature of its ligand(s) 
is(are) still not completely clear.  Using biochemical, biophysical and structural biology 
approaches, I characterized the low-resolution structure of the ALK extracellular region.  I further 
identified the binding mode of ALK binding to heparin, a recently discovered modulatory ligand for 
ALK.  Based on a low-resolution structural analysis of ALK/heparin complex, I propose a model 
for ligand-induced ALK dimerization and activation. 
Ryk is one of the five RTKs that are now known to be Wnt receptors.  In this thesis, I 
studied the Drosophila homolog of Ryk, Derailed (Drl), and its binding to ligand DWnt5.  We were 
able to express and purify milligrams of active DWnt5 – thus overcoming a major obstacle in this 
field.  We further characterized Drl/DWnt5 interactions.  Using hydrogen/deuterium exchange 
approaches, I identified the DWnt5-binding interface on Drl.  My efforts to understand the 
molecular mechanisms of Drl/DWnt5 binding using experimental and computational approaches 
suggest that DWnt5 may interact with Drl through a binding mode that differs from Wnt binding to 
other receptors. 
 
 
iv 
Across the RTK family, many receptors contain a long carboxy-terminal tail (C-tail) that 
harbors autophosphorylation sites for docking of downstream signaling molecules.  This region is 
generally considered to be intrinsically disordered.  I studied the dynamics of the EGFR C-tail, 
and showed that it is highly unstructured – but contains some somewhat ‘structured’ regions.  I 
also showed that phosphorylation of the EGFR C-tail promotes receptor dimerization.  Using 
hydrogen exchange, I identified possible C-tail docking sites on the kinase domain that may be 
responsible for this effect.  I also studied binding of downstream SH2 domain-containing 
molecules to the EGFR C-tail, with results that indicate that not all features of SH2 domain 
binding to the C-tail can be recapitulated by simple phosphopeptides; binding of SH2 domains to 
the C-tail exhibits binding affinities and stoichiometries that are not captured by simple peptide-
level studies.  Moreover, my binding competition assays suggest that there may be cooperativity 
in binding of multiple SH2 domains to a single phosphorylated C-tail. 
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Chapter 1 Introduction 
1 
2 
1.1 General principles of RTK-mediated cell signaling 
1.1.1 The discovery of RTKs 
Receptor tyrosine kinases (RTKs) are a family of trans-membrane proteins that play essential 
roles in many biological procedures.  Although first discovered in the early 1970s (insulin 
receptor), the mechanisms (and nature) of RTKs did not begin to become clear until the late 
1970s (Schlessinger 2014).  Two different lines of research during that time accelerated the 
understanding of RTKs.  One centered on the newly discovered v-src-encoded protein product, 
the first cellular oncoprotein (Brugge and Erikson 1977; Collett and Erikson 1978), which was 
found in the late 1970s to be a kinase different from all other kinases known at that time – 
phosphorylating tyrosines instead of serines and threonines(Eckhart, Hutchinson, and Hunter 
1979; Hunter and Sefton 1980; Hunter and Eckhart 2004). 
The insights into the mechanisms as to how tyrosine kinase causes cells to transform 
came from the second seemingly unrelated research area.  Researchers interested in cell-to-cell 
communications found that EGF has mitogenic effects when applied to epithelial cells, suggesting 
that a (then hypothetical) receptor on the cell surface might recognize EGF and trigger 
transforming events inside cells (Das 1980).  Later, this receptor (the EGF receptor) was isolated 
from epidermoid carcinoma of the uterus.  Sequencing of EGFR revealed an ectodomain 
responsible for EGF binding, a transmembrane region, and a cytoplastic domain that resembles 
Src in its amino acid sequence (Downward et al. 1984; Ullrich et al. 1984).  Given this sequencing 
result, it became clear how EGF might exert its mitogenic effects.  Binding of EGF to the 
ectodomain of EGFR somehow activates the intracellular kinase domain of the receptor, which 
then phosphorylates cytoplasmic substrates and, like the Src oncoprotein, causes cells to 
proliferate. 
Today it is clear that RTKs constitute an entire family of cell-surface receptors – with 58 
RTKs in the human proteome, which fall into 20 different families (Lemmon and Schlessinger 
2010).  RTKs regulate crucial cellular processes such as proliferation, differentiation, cell 
metabolism, migration and cell-cycle control.  They are the entry point to the complicated 
signaling networks inside cells.  Aberrant regulation, amplification, and/or mutations of RTKs 
3 
result in numerous diseases, including cancers, diabetes, inflammations, cardiac diseases, 
development disorders.  Thus, RTKs are also important drug targets.  
Figure 1.1 The family of receptor tyrosine kinases in humans.  The 58 receptor tyrosine kinases 
can be grouped into 20 subfamilies.  All RTKs have an extracellular region containing various 
domains, a single transmembrane helix, and a tyrosine kinase domain (shown in red) and C-
terminal tail (shown in black line) in the intracellular region.  Figure is adapted from (Lemmon and 
Schlessinger 2010). 
1.1.2 RTK activation involves receptor dimerization 
Early studies suggested that growth factors bind to receptors and induce receptor dimerization, 
leading to their activation.  For instance, upon binding of EGF, the EGF receptor undergoes 
significant conformational changes (from a ‘tethered’ to an ‘extended’ conformation’) and exposes 
regions in the extracellular region that mediate receptor-receptor interactions to form dimers.  
Similar paradigms were also reported for other RTKs, such as KIT, VEGF, and TrkA (the NGF 
4 
receptor).  Receptor dimerization brings two kinase domains in the dimer into close proximity, 
leading to their activation.  The exact mechanism of how the kinase domains are activated in the 
‘dimer complex’ varies from one RTK to another.  For instance, the kinase domains in EGFR 
dimer form an asymmetric dimer in which one kinase domain (‘receiver’) is activated by the other 
(‘activator’) through an allosteric mechanism (X. Zhang et al. 2006).  In some other RTKs an auto-
inhibitory component blocks the activity of the kinase domain.  Upon receptor dimerization, this 
component becomes trans-phosphorylated, releasing the auto-inhibitory effect so that the kinase 
domain can adopt its active form. 
Although this simplified view of ligand-induced receptor dimerization and kinase domain 
activation is conceptually straightforward, it is important to note that this pattern is not true for 
every RTK.  For instance, the insulin receptor forms disulfide-linked dimers on the cell surface in 
the absence of its ligand.  Binding of insulin to insulin receptors induces conformational changes 
within the receptor dimers that are responsible for signaling (Ward et al. 2007).  In addition, there 
is evidence suggesting that the Tie2 and Eph family RTKs form higher-order oligomers on the cell 
surface, although the exact stoichiometry and structures remain unknown, as does the influence 
on signaling (Barton et al. 2006; Himanen and Nikolov 2003). 
There are also members of RTKs for which it is not clear whether or how the ligand-
induced receptor dimerization paradigm applies.  For instance, it is not known whether Ryk family 
receptors follow this paradigm.  Ryk family receptor binds to Wnts through the Wnt-inhibitory 
factor (WIF) domain in the extracellular region, but the intracellular region contains an inactive 
pseudokinase domain (REF).  Several other RTKs (mostly implicated in Wnt signaling) also have 
intracellular pseudokinases.  For other RTKs such as anaplastic lymphoma kinase (ALK) the 
nature of the activating ligand is not known – although kinase domain dimerization appears to 
lead to activation. 
1.1.3 RTKs propagate signals through autophosphroylated tyrosines 
The kinase domain in the intracellular region of RTKs (excepting pseudokinases) is activated 
upon receptor dimerization.  Subsequently it phosphorylates tyrosine residues in the adjacent 
receptor within the RTK dimer.  In some RTKs, phosphorylation of specific tyrosines in the 
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activation loop further enhances their kinase activity.  In others, only tyrosines in the C-terminal 
region (or ‘tail’) of the receptor are phosphorylated – by trans-autophosphorylation within the 
receptor dimer.  In most cases (with IR as the primary exception), the resulting phosphotyrosines 
serve as ‘docking sites’ for downstream molecules to assemble signaling complexes.  Multiple 
signaling molecules are thus recruited to the cell membrane where they act.  Recognition of (and 
recruitment by) phosphotyrosines is largely mediated by Src homology 2 (SH2) domains and 
phosphotyrosine binding domains (PTB) (Pawson, Gish, and Nash 2001; Schlessinger and 
Lemmon 2003). 
 As SH2 domain-containing proteins were identified as signaling molecules recruited by 
RTKs, the entire RTK-mediated signaling network as we now understand it was gradually 
uncovered.  The current consensus view is that those SH2 domain-containing proteins promote 
further signaling events, in a linear fashion (thus ‘signaling pathway’) – although it is clear that 
several pathways operate in parallel.  A key example of such a linear cascade is the MAPK 
pathway, in which signal follows the path RTK-Grb2-Sos-Ras-Raf-MAPKK/MEK-MAP Kinase.  
Other canonical signal pathways that RTKs can invoke include the PI3K/Akt and PLCγ/Ca2+/PKC 
pathways.  Which pathway(s) an RTK initiates will be determined by its complement of 
phosphotyrosines and the selectivity of SH2 domains in downstream signaling molecules.  
Peptide-based studies have indicated that this selectivity of SH2 domain binding is encoded in 
part by the primary sequence flanking the tyrosine residue, in particular the nature of the side-
chain at the positions immediately following and three residues following the phosphotyrosine 
(Zhou 1993; Songyang and Cantley 2004).  It has thus been hypothesized that different RTKs 
have different ‘codes’ for characteristic subsets of downstream molecules, which define which 
specific signaling pathways they switch on.  It is worth noting that some RTKs are more restricted 
and specific than others.  For instance, the EGF receptor is thought to contain ‘codes’ that can 
recruit many different SH2 domains, whereas ErbB3 primarily harbors YxxM motif in its C-tail, 
suggesting it mainly recruits p85 SH2 domain in phosphoinositide 3-kinase (PI3K) (Prigent and 
Gullick 1994; Hellyer, Cheng, and Koland 1998). 
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1.1.4 RTKs are implicated in many diseases and are drug targets 
Not only do RTKs regulate many biological procedures, but they are also involved, and even 
responsible for, many human diseases.  For example, the ErbB/EGFR family RTKs are well 
known for their oncogenic relevance.  Point mutations, deletions and insertions in EGF receptor 
have been linked to non-small cell lung cancer (NSCLC) and to the sensitivity to kinase inhibitors 
(Thatcher et al. 2005).  Structural studies have rationalized some of the effects of these mutations 
and alterations.  For example, the L834R (L858R) EGFR mutation destabilizes a conserved set of 
autoinhibitory hydrophobic interactions in the inactive kinase and thus effectively activates EGFR 
(Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004; Sharma et al. 2007; Yun et al. 2007).  In 
another form, about 200 residues are deleted form the extracellular region, resulting in an EGFR 
variant (variant III, or vIII), which appears to show constitutive kinase activity despite the lack of 
dimerization arm (Burgess et al. 2003).  Other activating alterations are found in the 
juxtamembrane regions of EGFR, which presumably affect the asymmetric dimerization of the 
receptor (Red Brewer et al. 2009). 
 ErbB2 or HER2, another member of the ErbB family, is thought to be an orphan receptor 
(it adopts an extended conformation in its extracellular region in the absence of ligand bound).  
ErbB2, when overexpressed in NIH3T3 cells, has a strong transforming capacity (Di Fiore et al. 
1987).  It is also aberrantly expressed in ~30% of breast cancers as a result of gene amplification, 
and its overexpression level is correlated with poor prognosis in breast cancer patients (Slamon 
et al. 1989) – as well as response to the ErbB2-targeted antibody Herceptin. 
 ALK is another RTK that is strongly associated with various cancers.  ALK was originally 
discovered in anaplastic large-cell non-Hodgkin’s lymphoma (ALCL) in the form of fusion protein.  
Nucleophosmin (NPM) becomes fused to the ALK kinase domain by chromosomal translocation, 
resulting in production of a soluble dimeric (and thus constitutively activated) form of ALK’s 
tyrosine kinase (Morris et al. 1994).  Other ALK fusion proteins are also found, such as with 
echinoderm microtubule-associated protein-like 4 (EML4) in EML4-ALK (Soda et al. 2007) in 
other tumors.  In addition to fusion proteins, activating point mutations in full-length ALK have 
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been found to cause neuroblastoma, by activating the kinase domain in a manner similar to that 
seen for EGFR in lung cancer (Hallberg and Palmer 2013; Mossé et al. 2008; Bresler et al. 2014). 
 In addition to ErbB family and ALK, many other RTKs are involved in cancers and other 
diseases.  The realization that this is the case has led to RTKs becoming important drug targets – 
with the goal of limiting cancer by reducing aberrant signaling activity of oncogenic RTKs.  Two 
main forms of therapeutics have been specifically developed for RTKs - antibodies targeting the 
extracellular regions and kinase inhibitors targeting the kinase domains.  Antibodies can either 
compete with ligand binding or directly bind to a different region in ECR to inactivate receptors 
and promote immune responses.  Kinase inhibitors are small molecules that are usually ATP 
analogues that compete with ATP for binding to the active site of the kinase.  For example, 
Imatinib (Gleevec®) targets both PDGFR and Kit (as well as the non-receptor tyrosine kinases 
Abl and Arg), and is widely used to treat chronic myelogenous leukemia that is caused the 
Philadelphia chromosome – which leads to expression of Bcr-Abl fusion as a result of a 
chromosomal translocation (Heinrich et al. 2000).  Gefitinib, an EGFR-specific kinase inhibitor, 
was initially shown to be not effective in the general population of lung adenocarcinoma patients, 
but was found to be efficacious in a small subset of patients classified as Asian female never-
smokers (in the early stage of the cancer, Gefitinib has a superior efficacy compared to 
chemotherapy).  Sequencing results showed that tumors from these responding patients harbor 
mutations in the kinase domain of EGFR, which we now know to be activating (Fukuoka et al. 
2003; Kris et al. 2003; Thatcher et al. 2005).  Crizotinib, a kinase inhibitor originally developed at 
Sugen as an inhibitor of the Met tyrosine kinase, has turned out to be useful as an ALK inhibitor in 
ALK-translocated NSCLC, for which it has Food and Drug Administration approval – as well as 
other cancers including neuroblastoma, where it is helpful for certain patients (Bresler et al. 2011; 
Bresler et al. 2014). 
Kinase inhibitors have shown promising effects by inhibiting several TKDs.  It is worth 
noting, however, that acquired resistance to these drugs almost always develops, leading to 
relapse of the cancer.  Biochemical and structural analyses of the kinase domain in those 
resistant tumors have shown that new mutations can emerge that decrease inhibitor binding, or 
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increase (competing) ATP binding, resulting in an overall reduced inhibitor efficacy.  Fully 
understanding the mechanisms of drug resistance is a key step towards personalized treatment 
of cancers involving TKD mutations in RTKs and other kinases. 
 
1.2 EGF receptor and ErbB family receptors 
The ErbB family of RTKs has four members in mammals: EGFR, ErbB2 (or HER2), ErbB3 
(HER3) and ErbB4 (HER4).  The four receptors share high sequence identity and a common 
protein architecture including an extracellular region, a single transmembrane helix, and an 
intracellular region that contains a tyrosine kinase domain and an intrinsically disordered C-
terminal region of 230 amino acids or so.  EGFR can be activated directly by several growth 
factor ligands, including EGF itself, transforming growth factor α (TGF-α), amphiregulin (ARG), 
epiregulin (EPR), epigen (EGN), betacellulin (BTC), and heparin-binding EGF-like growth factor 
(HB-EGF).  ErbB3 and ErbB4 are both regulated by neuregulins (NRGs).  ErbB2, on the other 
hand, has no known soluble ligand.  It is generally considered to be an ‘orphan’ receptor and is 
thought to function through heterodimerization with other ErbB family receptors when they bind to 
their ligands.  Among these four receptors, ErbB3 is unique in that its kinase domain lacks key 
residues thought to be important for catalyzing phosphotransfer – notably the catalytic base 
aspartate through to abstract the proton from the substrate side-chain hydroxyl group.  Thus, 
ErbB3 is usually termed a ‘pseudokinase’.  Recent studies have shown that ErbB3 does retain 
some kinase activity despite lacking the catalytic base, although it is significantly weaker than the 
EGFR tyrosine kinase (Shi et al. 2010).  Whether such low level of activity is biologically relevant 
(or, whether the kinase domain in ErbB3 has a function completely different from catalyzing the 
transfer of phosphate group) remains unclear – although mutations that block ErbB3’s kinase 
activity do not appear to abolish all of its ability to signal (Shi, unpublished data). 
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Figure 1.2 The ErbB family receptor tyrosine kinases, their ligands and downstream effectors 
(figure adapted from (Yarden and Sliwkowski 2001)).   
 Crystal structures of EGFR extracellular regions with- and without bound ligand revealed 
high-resolution snapshots of the ligand-induced receptor dimerization process for this receptor 
(Burgess et al. 2003; Cho and Leahy 2002; Ogiso et al. 2002; Schlessinger 2002; Garrett et al. 
2002).  Each bound ligand contacts two points (domain I and III) in a single receptor molecule.  
Domains I and III themselves are rigid. However, ligand binding changes their positions with 
respect to one another in a global conformational change that exposes the dimerization arm in 
the intervening domain II.  Receptor dimerization is almost exclusively mediated by this projected 
dimerization arm, thus EGFR dimerization is termed ‘receptor-mediated’. 
 Ligand-induced dimerization of the EGF receptor brings two kinase domains close 
together in the resulting dimer complex.  However, until 2006, it was not clear how the kinase 
domain was activated by this event – even though it was already known by that time that 
phosphorylation of the activation loop in EGFR was not required for its activation (Burke and 
Stern 1998; Gotoh et al. 1992; Moriki, Maruyama, and Maruyama 2001; Stamos 2002).  The key 
insights that explain EGFR activation came from the Kuriyan lab (X. Zhang et al. 2006).  A series 
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of crystallographic analyses of the EGFR kinase domain, combined with mutational studies, led to 
the conclusion that the two kinase domains in an EGF-induced dimer form an asymmetric dimer 
in which the carboxy-terminal lobe (C-lobe) of one TKD contacts the amino-terminal lobe (N-lobe) 
of the other TKD, through interactions resembling those seen in complexes between cyclins and 
cyclin-dependent kinases (CDKs) (De Bondt et al. 1993).  When the two kinase domains form this 
asymmetric dimer, one kinase domain activates the other through an allosteric mechanism (X. 
Zhang et al. 2006).  This allosteric mode of activation explains why EGFR does not require 
phosphorylation of the activation loop in order to activate its kinase. 
 In addition to the C-lobe/N-lobe interactions the intracellular juxtamembrane region (iJM) 
also plays an important role in EGFR activation.  Among RTKs, JM regions differ significantly in 
their length, sequence, and function.  In some cases, the iJM region contains tyrosines to which 
SH2 domains can bind.  In some of these and other cases, the iJM regions can also serve an 
autoinhibitory role by folding against the N-lobe and/or C-lobe of the kinase domain to inhibit its 
activation.  For example, in the case of Flt3 (FMS-like tyrosine kinase 3, a VEGF receptor), 
crystal structures suggest that the iJM region projects into the cleft between the N- and C-lobes, 
also contacting the A-loop, the αC-helix and the glycine-rich loop (Griffith et al. 2004).  Together, 
these interactions prevent the A-loop from transitioning to the active conformation and thus ‘lock’ 
the kinase in its inactive form.  In EGFR, the iJM region plays a key activating role (Red Brewer et 
al. 2009) – rather than exerting an inhibitory effect.  Crystallographic studies of the EGFR TKD 
showed that a segment in the iJM region of the ‘receiver’ kinase directly contacts the C-lobe of 
the ‘activator’, to form a so-called ‘latch’ that stabilizes the asymmetric (activating) interactions 
between the two kinase domains (Red Brewer et al. 2009).  This region (residues 664-672) 
essentially functions as a ‘juxtamembrane latch’ and enhances the kinase activity by promoting 
the formation of asymmetric dimers. 
 In addition to the kinase domain, EGFR has a carboxy-terminal tail (C-tail) in its 
intracellular region.  The C-tail contains ~230 amino acids (residues 956-1186) and accounts for 
~20% of the full-length receptor.  This region contains all of the known regulatory 
autophosphorylation sites of EGFR with the exception of Y845 (in the activation loop – which is 
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phosphorylated, but does not regulate kinase activity).  These phosphotyrosines function as 
docking sites to recruit downstream signaling molecules.  Multiple SH2 domain-containing 
proteins can bind to these pTyr sites (Lemmon, Schlessinger, and Ferguson 2014).  The C-tail 
region is generally considered to be disordered.  Therefore, it is generally assumed that all of the 
exposed phosphotyrosine residues can individually initiate assembly of signaling complexes, with 
the specificity governed by the primary sequence flanking the phosphorylation site as mentioned 
above (Gajiwala 2013).  In addition to its role of propagating signaling, the C-tail is also 
considered to negatively regulate kinase activity.  One piece of evidence supporting this 
hypothesis is that truncation mutations in the C-tail region alter the kinase activity, suggesting that 
some parts of the C-tail may modulate kinase activity directly (Walton et al. 1990; Alvarez et al. 
1995)  However, the complete picture of the regulatory role of the C-tail remains to be 
understood. 
1.3 ALK family receptors 
1.3.1 ALK and LTK receptors fall into a separate subgroup of RTKs 
Anaplastic lymphoma kinase (ALK) was originally identified in ALCL (anaplastic large cell 
lymphoma) cell lines.  The protein was originally described as a then-novel kinase domain of ALK 
fused to the N-terminal portion of the NPM (nucleophosmin) protein.  This fusion arises because 
of a translocation event between chromosomes (2;5)(p23;q35) (Morris et al. 1994).  The NPM-
ALK protein is thought to oligomerize, such that the kinase domain of ALK becomes activated – 
resulting in the transforming ability of this fusion protein (Morris et al. 1994).  Subsequent studies 
revealed that the composition of full-length ALK is similar to that of other RTKs, with an 
extracellular ligand-binding domain, single transmembrane α helix, an intracellular kinase 
domain, and an extended C-tail (Iwahara et al. 1997; Morris et al. 1997).  Based on sequence 
homology, ALK is grouped with LTK (leucocyte tyrosine kinase), another RTK, and together they 
form their own subgroup within the RTK family.  In mammals, ALK is believed to play a role in 
normal development of the nervous system (Vernersson et al. 2006), but its function in D. 
melanogaster is much better understood (Palmer et al. 2009).  The transcription and expression 
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of ALK is highly regulated – peaking after birth, and diminishing after three weeks of age in mice 
(Vernersson et al. 2006). 
 ALK exhibits a unique domain architecture in its extracellular region (ECR).  It contains 
two MAM (meprin, A5 protein and receptor protein tyrosine phosphatase mu) domains and an 
LDLa (low-density lipoprotein class A) motif between them.  Although LTK does not contain the 
two MAM domains and the LDLa motif, both the ALK and LTK ECRs also contain a glycine-rich 
region proximal to the cell membrane. 
1.3.2 ALK-mediated signaling 
Since the original discovery of ALK in ALCL, ALK has been linked to many human diseases.  ALK 
fusion proteins, ALK overexpression and gain-of-function ALK mutations have all been linked to 
cancers including ALCL, IMTs (inflammatory myofibroblastic tumors), NSCLC (non-small cell lung 
cancer), DLBCLs (diffuse large B-cell lymphoma), and neuroblastoma (Hallberg and Palmer 
2013).  Despite its implication in these diseases, and its status as a potentially important drug 
target, the regulation of the ALK RTK remains poorly understood.  The most thoroughly studied 
ALK receptor is Drosophila ALK (dALK).  In Drosophila, ALK plays a critical role in the formation 
of the visceral musculature of the gut during embryonic development (Palmer et al. 2009).  Two 
groups simultaneously reported that a secreted protein called jelly belly (Jeb), which also contains 
an LDLa domain, might function as a ligand for Drosophila ALK (Englund et al. 2003; Lee et al. 
2003).  Activation of dALK signaling in flies is thought to be initiated by Jeb binding to the ALK 
extracellular region.  This binding is suggested to be mediated by the LDLa domain in Jeb, since 
Jeb lacking the LDLa domain failed to bind to the receptor (Englund et al. 2003).  Genetic and 
other studies suggest that Jeb/dALK signaling also plays key roles in an anterograde signaling 
pathway governing neuronal circuit assembly in the Drosophila visual system (Bazigou et al. 
2007).  Despite this evidence for Jeb as an ALK ligand in Drosophila, no structural/biochemical 
studies have been reported characterizing its binding to the receptor.  It is not clear what the 
binding affinity and stoichiometry are, and whether Jeb binding to dALK induces receptor 
dimerization has not been established.  Although there is significant sequence identity between 
Drosophila and human ALK, no mammalian homologue of Jeb can be identified. 
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 In humans, several molecules have been postulated as ALK ligands, including 
pleiotrophin (PTN), midkine (MK) and more recently heparin (Iwahara et al. 1997; Stoica et al. 
2001; Stoica et al. 2002; Murray et al. 2015).  However, the roles and physiological relevance of 
these ligands seem much less clear than in the case of Jeb and Drosophila ALK.  PTN and MK 
are small, heparin-binding, growth factors that are involved in neural development, cell migration 
and angiogenesis (Chauhan, Li, and Deuel 1993; Czubayko et al. 1996; Stoica et al. 2002).  
Controversial data as to whether PTK and MK activate ALK were reported in the literature  
(Mourali et al. 2006; Mathivet, Mazot, and Vigny 2007; Dirks et al. 2002; Moog-Lutz et al. 2005; 
Motegi et al. 2004).  In addition, PTK and MK are also known to bind and signal through 
RPTPβ/ζ (receptor protein tyrosine phosphatase β/ζ), leading to the possibility that PTK and MK 
regulate ALK indirectly by modulating their dephosphorylation (Perez-Pinera et al. 2007).  Very 
recently, the Schlessinger lab reported that heparin itself can bind, oligomerize, and activate 
mammalian ALK (Murray et al. 2015).  This leaves two questions unanswered: whether PTN and 
MK bind to ALK through heparin, and whether binding and activation by heparin itself is 
physiologically relevant. 
 LTK receptor lacks the MAM domains and LDLa motif – elements that typically mediate 
protein-protein interactions, and therefore was thought to be an orphan receptor.  Recently, a 
large-scale screening of extracellular proteome led to the identification of two proteins FAM150A 
and FAM150B, which bind and stimulate LTK (H. Zhang et al. 2014).  The molecular basis for 
these proteins binding and activating LTK is yet to be established, and it is not clear whether they 
are also ligands for human ALK – but this study effectively deorphanized LTK. 
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Figure 1.3 Overview of molecular mechanisms of ALK signaling. Left: In Drosophila, ALK is 
activated by binding of the ligand jelly belly (Jeb).  Activation of dALK promotes Ras/MAPK 
pathway and ERK phosphorylation and regulates various target genes.  Right:  In mammals, ALK 
is activated by its proposed ligands, MK and PTN.  ALK mediates various signaling cascades 
including RAS/MAPK, PI3K/Akt, JAK/STAT, and PLCγ pathways.  In the absence of ligands, ALK 
is proposed to be cleaved by caspase 3, promoting apoptosis, and has been suggested to 
function as a dependence receptor (Mourali et al. 2006).  Figure from (Palmer et al. 2009). 
 
1.4 RTKs as Wnt receptors 
1.4.1 Wnt and RTKs 
The 19 Wnt family proteins in humans play important yet diverse roles in embryonic development 
and adult homeostasis of all metazoans – including segment polarity and neural tube 
development during embryogenesis, stem cell maintenance, cell fate determination, and cell 
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proliferation.  Mutations and aberrant regulation of Wnts are involved in many diseases (Clevers 
and Nusse 2012; MacDonald, Tamai, and He 2009; Nusse and Varmus 2012). 
 It is now clear that that Wnt signaling involves an array of different receptors, some of 
which are summarized in Figure 1.4.  The best known (canonical) pathway involves Frizzled (Fz) 
receptors (Bhanot et al. 1996) and low-density lipoprotein receptor-related proteins (LRP5/6 in 
human and arrow in Drosophila) as co-receptors (Tamai et al. 2000; Pinson et al. 2000; Wehrli et 
al. 2000).  Wnt binds to Fz and LRP5/6 at the cell surface, causing the recruitment of Dishevelled 
(Dvl) to the Frizzled receptor(Chen et al. 2003).  This further promotes Axin recruitment to the 
LRP cytoplasmic tail and dissociation of the so-called ‘destruction complex’ that normally 
phosphorylates β-catenin and targets it for proteasomal degradation.  β-catenin is thus stabilized 
by Wnt signaling, and is translocated to the nucleus to regulate TCF-controlled gene transcription.  
Independent of LRP and β-catenin, Wnts also mediate the planar cell polarity (PCP) pathway 
(through Rho, Rac and Jnk)(Veeman, Axelrod, and Moon 2003), and Ca2+ signaling(Kühl et al. 
2000). 
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Figure 1.4 A. β-catenin/TCF dependent (‘canonical’) Wnt signaling in which a Wnt (yellow) 
engages a Frizzled and LRP (green) as a co-receptor, leading to LRP phosphorylation and 
membrane recruitment of Axin and Dvl – promoting dissociation of the ‘destruction complex’ and 
β-catenin stabilization.  B. Ror family RTKs inhibit β-catenin/TCF signaling and activate Jnk  C. 
Frizzled receptors also mediate Wnt regulation of planar cell polarity (PCP), through Dvl, Rho, 
Rac, and Jnk – as well as Ca2+ signaling (‘non-canonical Wnt pathways’).  D. Ryk family RTKs 
also mediate Wnt signaling – involving Src in some cases.  Figure is adapted from (Clevers and 
Nusse 2012). 
As work on human receptor tyrosine kinases (RTKs) has advanced, it has become clear 
that 4 or 5 of the 58 human RTKs function as Wnt receptors.  Ror1 and Ror2 (for Receptor 
tyrosine kinase-like orphan receptor) have a cysteine-rich domain (CRD) in their extracellular 
regions (ECRs), resembling the extracellular CRD known to be responsible for Wnt binding to 
Frizzleds and suggesting a similar mode of interaction (Minami et al. 2010).  MuSK (for muscle-
specific kinase) also has a related CRD and is clearly linked to Wnt signaling (Jing et al. 2009; 
Banerjee et al. 2011).  In addition, PTK7/CCK4 (Peradziryi et al. 2011; Bin-Nun et al. 2014) has 
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been linked to Wnt signaling, as has Ryk (for Receptor tyrosine kinase-related), which has a 
putative WIF (for Wnt Inhibitory Factor) domain in its ECR, suggesting its capability of binding to 
Wnt ligands (Cheyette 2004; Fradkin, Dura, and Noordermeer 2010). 
1.4.2 Ryk and its invertebrate orthologs 
The first clue to the functions of Ryk family RTKs came in Drosophila, where the Ryk ortholog 
Derailed (Drl) was shown to control CNS axon path finding (Thomas et al. 1999; Yoshikawa et al. 
2003).  Drl is a receptor for Drosophila Wnt5 (DWnt5).  Both Drl and its homolog Derailed-2 (Drl-2) 
function as Wnt receptors in nervous system development, but play different roles depending on 
the cell types in which they are expressed.  It is also known that Ryk plays a role in mammalian 
PCP signaling (Macheda et al. 2012), and Ryk is reported to cooperate with Fz7 to mediate 
Wnt11 regulation of convergent extension in Xenopus (Kim, Her, and Han 2008).  Human Ryk is 
involved in CNS development (Liu et al. 2005) and regulates axon regeneration after CNS injury 
(Hollis and Zou 2012).  Dysregulation of Ryk has also been reported in ovarian cancer (Katso, 
Russell, and Ganesan 1999; Katso et al. 1999; Wang et al. 1996). 
The Ryk family is unique among RTKs, being the only family with an extracellular WIF 
domain (Cheyette 2004).  Moreover, Ryk’s intracellular kinase domain lacks key residues for 
catalysis of phosphotransfer, and is presumed to be kinase-dead – like the other putative Wnt 
receptors Ror2 and CCK4/PTK7).  Understanding the molecular mechanism of Wnt/Ryk signaling 
is therefore likely to reveal a new paradigm in RTK signaling that involves pseudokinases.   
Drl, being Ryk’s ortholog in Drosophila, shares 34% sequence identity in the extracellular 
WIF domain and 48% sequence identity in the kinase domain.  Despite the known crystal 
structure of WIF domain (Liepinsh et al. 2006), little is known about the molecular mechanisms of 
Drl/DWnt5 interactions.  Moreover, unlike most Wnt molecules, our data suggest that DWnt5 is 
not modified by lipid groups.  Therefore, understanding how DWnt5 and Drl bind has the potential 
not only to unveil the molecular mechanism of Ryk signaling, but also to reveal a new mechanism 
for signaling by Wnt family ligands. 
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1.5 Diversity of the molecular mechanisms of RTKs 
As illustrated in previous sections, the general principles of RTK activation and signaling appear 
straightforward – most known RTKs utilize a variation on the ligand-induced receptor dimerization 
paradigm to activate their kinase domain and thus transduce signals across cell membranes 
(Lemmon and Schlessinger 2010).  However, such a generalization is somewhat oversimplified, 
since there is significant diversity in the molecular mechanisms for different RTKs.   
1.5.1 Diversity in the extracellular region of RTKs 
The receptor dimerization paradigm itself varies in different receptors.  For example, in the EGF 
receptor, ligand binding induces conformational changes but the bound ligand is not directly 
involved in receptor dimerization (Lemmon and Schlessinger 2010).  At the other extreme, nerve 
growth factor (NGF) sits at the interface between two TrkA molecules in an exclusively ‘ligand-
mediated’ receptor dimer (Wehrman et al. 2007).  Between these extremes is KIT, the receptor 
for stem cell factor (SCF), which requires both receptor-mediated and ligand-mediated 
interactions for dimerization (Yuzawa et al. 2007).  In addition to the very different natures of the 
receptor dimerization interface (whether ligand-mediated or receptor-mediated), the 
ligand/receptor binding stoichiometry can also vary.  For instance, some EGF receptors can form 
a dimer with a 1:2 molar ratio of ligand/receptor (Alvarado, Klein, and Lemmon 2010).  Moreover, 
there is evidence suggesting the existence of oligomrization of EGF receptor without ligand 
bound (Clayton et al. 2005; T W Gadella and Jovin 1995).  Such preformed dimers are 
themselves not active but may be important for certain ligands.  Therefore, for EGF receptor, 
these seemingly controversial results do suggest the diversity of its ‘receptor dimerization’, 
although a complete mechanistic view is still missing (Bessman et al. 2014).  It is not clear 
whether such diversity generally exists in all RTKs, but it is safe to say that some RTKs utilize 
diverse receptor dimerization mechanisms to carry out their biological functions – and it is 
certainly true that there is diversity in the nature of domain types found in RTK ECRs and in the 
nature of their activating ligands. 
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1.5.2 Diversity in the kinase and pseudokinase domains 
The mechanisms of kinase domain activation are also diverse across the ‘RTKome’.  For 
instance, EGFR uniquely utilizes asymmetric dimerization to activate its kinase domain through 
an allosteric mechanism.  Other TKDs are activated by quite different mechanisms.  For example, 
the FGFR, insulin receptor and IGF1 receptor TKDs are autoinhibited as a result of interactions 
between parts of their activation loop and the active site – which serves to block access of protein 
(and ATP) substrates (Lew et al. 2009; Hubbard et al. 1994).  In each of these cases, 
phosphorylation of a key tyrosine in the activation loop disrupts this autoinhibitory interaction and 
leads to the activation of the kinase domain.  In the case of PDGFR and Kit, the juxtamembrane 
region interacts with the kinase domain to stabilize an inactive form or autoinhibit the kinase.  
Phosphorylation of tyrosines in the juxtamembrane region disrupts this interaction and allows the 
kinase domain to form active conformation (Chan et al. 2003; Hubbard 2004).  In Tie2, the C-
terminal tail interacts with the active site of the kinase domain to stabilize the inactive 
form(Shewchuk et al. 2000).  In all of these cases, once the auto-inhibitory interactions are 
removed, the resulting active kinase domains all adopt similar conformations (Huse and Kuriyan 
2002).   
 It is worth noting that no kinase domain has to use one of those mechanisms exclusively.  
Rather, multiple autoinhibitory mechanisms can co-exist in one TKD.  For instance, in the case of 
EGFR, in addition to the allosteric activation mechanism, the juxtamembrane region also 
regulates kinase activity – although unlike JM regions in other RTKs, the EGFR JM region 
promotes kinase activity in the receptor dimer (Red Brewer et al. 2009).  In addition, the C-
terminal tail in EGFR has been shown to modulate kinase activity.  Taking these considerations 
together, it seems that each part of the intracellular region of any given RTK plays some 
regulatory role.  Only through a more thorough analysis of full-length RTKs in cellular contexts – 
with all other possible players taken into consideration – will our understanding of this diversity in 
kinase domain regulation be complete. 
 As mentioned above, among all 58 known RTKs in the human proteome, eight lack one 
or more conserved residues in the kinase domain that are known to be important for catalyzing 
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phosphotransfer reactions, and are thus termed ‘pseudokinases’ (Mendrola et al. 2013; Boudeau 
et al. 2006; Zeqiraj and van Aalten 2010).  All of these pseudokinases (except for ErbB3) appear 
to be kinase inactive – and most do not even bind ATP (Murphy et al. 2014) – raising key 
questions as to how these RTKs might signal.  For ErbB3, although low-level kinase activity was 
detected in vitro, it has yet to be determined what (if any) role this low-level activity plays in 
biological contexts – and unpublished results from the Lemmon laboratory so far suggest that it 
may be vestigial.  Moreover, many of these pseudokinase RTKs (PTK7/CCK4, Ror1,Ror2, and 
Ryk) appear to be Wnt receptors, suggesting a new Wnt signaling paradigm involving 
pseudokinases.  The exact characterization of Wnt binding to these receptors, however, is still 
unclear.  Despite these unknowns in pseudokinases and Wnt receptors, it is highly likely that 
pseudokinases are equipped with a different receptor signaling mechanism.  For ErbB3, given its 
low level kinase activity and its ability to form heterodimers with other ErbB family receptor, it is 
possible that ErbB3 could still phosphorylate some tyrosines within a receptor complex.  In 
addition, the allosteric nature of the pseudokinase domain allows for the possibility that other yet-
to-be-discovered molecules bind to and enhance ErbB3 kinase activity.  For pseudokinases that 
are completely kinase-dead, the kinase domain can still function as an ‘activator’, through the 
allosteric mechanism, to activate other kinases.  
 To sum up, in RTKs, the kinase domains utilize a variety of mechanisms, not necessarily 
mutually exclusively, to regulate their kinase activity and/or their partner molecules.  
Understanding these mechanisms will shed more light on RTK-mediated cell signaling and 
provide insights into the development of novel therapeutics targeting these kinases and 
pseudokinases.  Studies at both the molecular and systems levels are required to tackle these 
important yet challenging questions. 
 
1.5.3 RTKs have diverse ligands 
The current consensus view of RTK activation mentioned in this Chapter is centered on ligand-
induced receptor dimerization.  Unlike well-studied RTKs such as EGFR, searches for ligands is 
still ongoing for some ‘orphan’ RTKs.  For instance, since the 1990s, potential ligands for ErbB2 
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have been under extensive investigation, yet ErbB2 remains an orphan receptor today.  Jelly 
belly may be one of the missing ligands for Drosophila ALK – although it remains unclear whether 
it can regulate the receptor directly – and no human ortholog of jelly belly has been identified.  To 
complicate the situation with ALK ligands even further, heparin, a completely different class of 
molecule, has recently been reported to bind and activate human ALK (Murray et al. 2015).  The 
other member of ALK family receptor, LTK, was recently deorphanized as well by the discovery of 
two novel secreted proteins, which are completely different from Jeb or heparin (H. Zhang et al. 
2014).  Clearly, there is much to learn for this RTK family.  Across the RTK family more broadly, 
several receptors contain domains that are typically found in Wnt-interacting molecules, 
suggesting that these RTKs might be Wnt receptors as well.  Nevertheless, exactly which Wnt 
binds and regulates each receptor is still unclear.  Also, if the different RTKs share the same 
ligand, might these receptors form ligand-induced heterodimers?  These examples suggest that, 
just as RTKs are diverse in the nature of their extracellular regions, their ligands have diverse 
functions and share few common features.  Investigating the diversity of RTK ligands, and how 
they regulate their cognate RTKs are thus crucial for understanding how the entire family of RTKs 
functions and how they cooperate with other components in cellular contexts. 
1.5.4 Diversity at the systems level 
The majority of research on RTKs in the last few decades was done using a reductionism 
approach.  Indeed, such methodology is ideal to tackle complex questions when, say, a full-length 
membrane protein was technically difficult to prepare, or, the phosphorylation level of a protein 
containing five phosphorylation sites was too complicated to quantitate, or a signaling pathway 
containing both positive and negative feedback loops was too variable to comprehend (even 
today, few biologists are familiar with chaos theory).  In the case of RTKs, biochemical and 
structural studies have focused mainly on an individual part of the receptor (such as the ligand-
binding extracellular region, the transmembrane α-helix, the kinase domain, or the C-terminal tail), 
or individual pairs of molecules (such as ligand/receptor, JM/kinase domain, kinase 
domain/inhibitor, C-tail/SH2 domain, etc.).  The majority of our understanding of RTKs remains at 
this rather focused level, whereas the biological systems regulated by the RTKs are highly 
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complex.  It is now clear that simply adding up the behavior of the individual components will not 
lead to a proper picture of the system – the complexity of biological systems such as these really 
originates from the interplay between individual components, so a systems view is crucial. 
 Take EGF receptor for example, the next step towards a better understanding of its 
mechanism would be to lift one level up to study the full-length receptor.  The receptor 
dimerization model based on the crystal structure of ligand-bound ECR fails to reflect the 
negative cooperativity of ligand binding – a phenomenon known since the 1970s when ligand 
binding to the cell-surface EGFR and insulin receptor was first found to yield concave-up 
Scatchard plots.  Importantly, negative cooperativity provides a mechanism for receptors to 
differentially respond to/interpret concentration gradients of growth factors.  However, this feature 
is only seen for the full-length receptor in membranes, suggesting that it may arise from the 
interactions between different components of the receptor and between them and other 
molecules proximal to cell surface.  Clearly, any analysis with only part of the full-length receptor 
will miss this feature.  Therefore, a better understanding of the full-length RTK should be (and is 
becoming) one of the frontiers of RTK research. 
 To really understand RTK signaling in cells, one needs to go an additional step further, 
and understand the systems-centered RTK signaling.  The complexity of signaling networks is 
brought about by feedback loops between the ‘nodes’ in the network (Kholodenko 2006; 
Kholodenko, Hancock, and Kolch 2010).  Multiple pathways are connected by various feedback 
and feedforward loops, resulting in what is termed ‘cross talk’ by those focused on individual 
pathways.  For example, a recent study illustrated this cross-talk between EGFR and insulin 
receptor-mediated signaling events (Borisov et al. 2009).  It has long been observed that, 
although EGFR and IR signaling ‘pathways’ share many common downstream signal-processing 
proteins, the responses to these two ligands are completely different.  Whereas EGF stimulates 
EGF receptor, leading to activation of ERK through the MAPK cascade in HEK293 cells, insulin 
hardly affects ERK.  However, insulin and EGF can both potentiate MAPK/ERK activation at low 
levels of EGF in HEK293 cells.  This study, using combined experimental and computational 
approaches, showed that at low physiological concentrations of EGF, cross talk between the two 
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pathways enhanced ERK activation in response to the increase of PtdInsP3 concentration 
resulting from insulin stimulation.  Such an effect of insulin became insignificant at saturating 
concentration of EGF. 
Feedback loops result not only in interplays between different signaling pathways, but 
also create intricate dynamic spatiotemporal behaviors of the signaling network, such as 
oscillation, bistability and excitability.  These behaviors significantly enhance the robustness of 
the system in response to perturbations, and define the properties of the system and its 
responses.  Understanding these effects is also therapeutically important because the flip side of 
robustness is the difficulty to perturb the cells once they turn cancerous – although cancer itself 
may be a manifestation of loss of robustness.  Despite the importance of such a network view, 
studies of RTKs at the systems level remain challenging.  Tackling complex systems requires a 
high-level of mathematical thinking and scientific reasoning, and demands ‘cross-talk’ between 
experimentalists and modelers – modelers need experimental data to instruct and fit models, 
while experimentalists need modelers in order to make sense of complicated systems-level 
datasets.  Therefore, an iterative approach is essential – in which predictions are made and 
tested – in order to make progress in understanding the newly-emerged diversity and complexity 
of RTK-mediated signaling. 
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Chapter 2 Towards understanding the molecular basis for 
activation mechanisms of anaplastic lymphoma kinase 
(This chapter is collaborative work done with Dr. Camilla Oxley in the Lemmon laboratory)  
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2.1 Introduction 
Anaplastic lymphoma kinase (ALK) and leukocyte tyrosine kinase receptor (LTK) form an 
important RTK sub-family as described in Chapter 1.  ALK plays central roles in the nervous 
system and embryo development.  ALK fusion proteins and mutants have been implicated in 
many diseases, such as various human cancers including large cell lymphoma, NSCLC (non-
small cell lung cancer), breast cancer, and neuroblastoma (Palmer et al. 2009).  
It has become clear that ALK is an important drug target in cancer.  Extensive studies 
focusing on the aberrant tyrosine kinase activity of ALK mutants as well as development of 
potential kinase inhibitors have been conducted (Bresler et al. 2011; Hallberg and Palmer 2013).  
For example, a recent study integrated biochemical analysis, clinical studies and computational 
approaches to investigate oncogenic activity and kinase inhibitor sensitivity of various ALK 
mutants found in pediatric neuroblastoma (Bresler et al. 2014).  Compared to its kinase activity, 
however, very little is known regarding ALK’s extracellular region and its ligand(s).  The 
architecture of the ALK extracellular region (ECR) is unique (Figure 1.3), and there is currently no 
clear view of how its unique domain-set functions in receptor activation and response to ligands.  
It is not clear which domain(s) in the ECR are involved in ligand binding.  In fact, it is still unclear 
what is/are ALK’s ligand.  In Drosophila melanogaster, a secreted protein named jelly belly (Jeb) 
was identified as a potential ligand over a decade ago (Lee et al. 2003; Englund et al. 2003), but 
the biochemical and structural bases for Jeb binding to (and activation of) ALK remains to be 
established.  In mammals, ALK is considered an ‘orphan’ receptor.  There is no mammalian 
ortholog of Jeb, and no alternative ligand has been convincingly identified.  Several putative 
protein ligands have been proposed (namely midkine, pleiotrophin), but there are contradictory 
reports regarding their effectiveness and relevance in the literature (Iwahara et al. 1997; Stoica et 
al. 2002).  A recent study identified a heparin-binding motif in N-terminus of mammalian ALK and 
found that heparin binding can promoted receptor phosphorylation in certain cell lines, suggesting 
that heparin could be a ligand for mammalian ALK (Murray et al. 2015) – although the biological 
significance of this observation has not been established. 
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LTK – ALK’s partner in this small family of RTKs – has been implicated in neuronal 
development, autoimmunity and cancers (Weiss et al. 2012; Li et al. 2004).  Until very recently an 
orphan receptor like ALK, ligands for LTK have been identified in a signaling screen of the 
extracellular proteome.  Two related secreted proteins, FAM150A and FAM150B were identified 
as ligands that bind and activate LTK, with FAM150A binding to LTK with a picomolar range 
dissociation constant (Zhang et al. 2014).  This work sets the stage for understanding the 
molecular basis for ligand-dependent activation of LTK.  It should be noted, however, that LTK 
lacks the MAM and LDLa domains in the extracellular region that characterize ALK. 
 In this Chapter, the studies described aimed to shed more light on the structural features 
of ALK extracellular region, with the goal also of understanding ligand binding and activation – 
using biochemical and biophysical approaches. 
2.2 ALK possesses a unique domain architecture in its extracellular region 
In addition to an LDLa domain and two MAM domains flanking it, ALK has a glycine-rich region 
proximal to membrane.  By using the Phyre2 server (Kelley and Sternberg 2009), a protein 
structure homology recognition server, we further detected a tumor necrosis factor-like domain 
(TNF-like) and an epidermal growth factor–type (EGF-type) module in the membrane–proximal 
region in ALK ECR.  These two domains appear to exist in LTK receptors as well.  Figure 2.1 
shows the query results returned from Phyre2 server.   
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Figure 2.1 Structure homology detection in the membrane-proximal region of ALK ECR.  Top: a 
list of 3D models that are structurally homologous to EGF-type module in ALK. Bottom: a TNF-
like domain was found in the ALK ECR, with 81.2% confidence and 19% identity. 
In our sequence analysis, the ALK ECR contains a sequence (residues 680 – 794 in 
human ALK) that is highly homologous to a TNF-like domain, with 81.2% confidence in Phyre2 
and 19% sequence identity.  TNF-like domains are found in both tumor necrosis factors and C1q 
family proteins.  Structurally, two conserved cysteine residues form a disulfide linkage and 
stabilize an anti-parallel β sheet in TNF-like domains.  These domains typically self-associate to 
form a homotrimer (Oren et al. 2002).  The EGF-type module in ALK was found in the C-terminal 
region of the ALK ECR (residues 906 -986 in human ALK).  Six conserved cysteine residues 
predicted to form three disulfide bonds based on their positions were found in this region (Nagata 
et al. 1994; Downing et al. 1996).  Phyre analysis showed ~ 95% confidence of existence of an 
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EGF-type module in this region, with a sequence identity around 40% compared to a structurally 
available EGF-like domain. 
In sum, ALK family receptors indeed possess a unique domain composition in its 
extracellular region (illustrated in Figure 2.2).  How these domains, typically playing a role in 
protein-protein interactions in other proteins, function in ALK remains unknown. 
 
 
Figure 2.2 Domain composition of the extracellular region (ECR) of ALK and LTK receptors.  ALK 
contains two MAM domains flanking an LDLa domain, plus one TNF-like domain, one glycine-rich 
region and one EGF-type module in the membrane-proximal region. 
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2.3 Drosophila ALK and human LTK ECR are monomeric in solution 
Most well-understood receptor tyrosine kinases follow the ‘ligand-induced receptor dimerization’ 
paradigm in their activation mechanisms (Schlessinger 2000; Lemmon and Schlessinger 2010).  
It is worth noting, however, that there are certain ‘outliers’ of this pattern.  One example is the 
insulin receptor (IR), which exists as a pre-formed dimer linked by disulfide bonds.  Ligand 
binding to the IR induces conformational changes in the pre-formed dimer that result in activation 
of the intracellular kinase domain of IR (Lawrence, McKern, and Ward 2007; Ward et al. 2007).   
ALK and LTK are grouped into the insulin receptor super-family due to sequence 
similarity between ALK and IR in the kinase domains (Iwahara et al. 1997), most notably the 
YxxxYY sequence in the activation loop.  However, the extracellular compositions of ALK and IRs 
differ significantly.  Therefore, there is not reason to expect that ALK follows the same ‘pre-
formed dimer’ mechanism as IR – although this remains a possibility.  Indeed, it is worth noting 
that the MAM, LDLa and EGF-like domains modules are all typically involved in protein-protein 
interactions.  This suggests three hypotheses for how these domains might function.  In one, 
these domains could mediate receptor-receptor interactions to form a pre-formed ALK dimer, and 
ligand binding is required to induce conformational changes in the dimer in order to render the 
kinase domain active.  In a second hypothesis, the MAM, LDLa, and/or EGF-like domains could 
interact intramolecularly to occlude a dimerization site, as in the tethered EGFR extracellular 
region, and ligand binding could serve to expose a dimerization site.  In the third and simplest 
hypothesis, activating ligands induce dimerization simply by binding to equivalent sites in two 
receptor molecules – effectively cross-linking them in a ligand-mediated dimer.  In order to 
distinguish between these hypotheses, we undertook a biophysical analysis of ALK family 
extracellular regions – to determine oligomerization state and domain organization. 
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Figure 2.3 Size exclusion chromatography (SEC) analysis of Drosophila ALK (A: green) and 
human LTK (B: purple) ECR proteins.  SEC standard profile is shown in gray dotted line. 
In size exclusion chromatography (SEC) proteins elute based on their hydrodynamic radii.  
Therefore (for spherical proteins), the elution time of a protein sample is approximately correlated 
to its molecular weight.  We measured the SEC profiles of ECR proteins from Drosophila ALK (s-
DmALK) and human LTK (s-HsLTK), together with an SEC standard.  Figure 2.3 shows the 
chromatograms of s-DmALK and s-HsLTK superimposed with a standard sample.  Based on the 
standard run, the elution of the two protein samples is consistent with their theoretical molecular 
mass (s-DmALK: 120 kDa, s-HsLTK ECR: 45 kDa, ignoring glycosylation effects).  This simple 
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result argues that neither ECR protein is a covalently-linked dimer in solution, although it does not 
exclude the possibility of weak (Kd ≥ 1-5 µM) non-covalent dimerization, where dissociation during 
chromatography would yield a SEC profile suggesting monomeric protein.  In addition, given that 
LTK lacks the MAM and LDLa domains and appears to be monomeric as well, it can be inferred 
that the MAM and LDLa domains do not exist simply to block homotypic interactions mediated by 
the TNF-like, glycine-rich and EGF-type modules in the membrane proximal regions of ALK. 
 
 
Figure 2.4  Analytical ultracentrifugation sedimentation equilibrium studies of s-DmALK protein.  
The natural logarithm of absorbance at 280 nm was plotted against the difference of radius 
squared and the r0 (meniscus) squared, resulting in a logarithmic plot (‘log plot’) whose slope is 
proportional to the weight-averaged molecular mass of the species. 
Given that SEC cannot identify dimers with fast off-rates of weak affinity – or dimers that 
share similar hydrodynamic radius with the monomer (for instance, ligand-induced dimerization of 
EGFR has never been observed by using SEC-based analysis, since the ECR geometry is such 
that the Stokes radius for monomer and dimer are similar), we next used analytical 
ultracentrifugation sedimentation equilibrium (AUC-SE) to analyze the size of the Drosophila ALK 
ECR protein.  This approach has been widely used to measure receptor dimerization, including 
ErbB family receptor dimerization (Ferguson et al. 2000).  In AUC-SE analysis, a logarithmic plot 
of the absorbance against a function to the difference of the radius squared (Figure 2.4) can 
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unambiguously determine the molecular weight (weight-averaged molecular mass) of the 
samples.  A linear plot of such type indicates a monodisperse species in solution, and the slope 
of the plot is proportional to the molecular weight.  Unlike the SEC-based approach, AUC-SE 
provides a measure of shape-independent molecular mass.  Figure 2.4 shows such a plot for 
purified Drosophila ALK ECR protein at concentration of 4 µM.  The plot is linear, suggesting a 
single species, and approximates the straight line anticipated for a 120 kDa monomer (Figure 
2.4).  
 
2.4 Drosophila ALK and human LTK adopt extended conformations 
In efforts to visualize the structure of an ALK-family ECR, we attempted (unsuccessfully) to 
crystalize both human and Drosophila ALK ECR, as well as human LTK ECR proteins.  In 
parallel, we used Small-Angle X-ray Scattering (SAXS) to gain a low-resolution view of the ALK 
and LTK ECRs in solution.  SAXS has been used in studies of the EGF receptor and other ErbB 
family receptors in order to determine domain arrangements, and to monitor conformational 
changes upon ligand binding as well as dimerization (Dawson, Bu, and Lemmon 2007).  Figure 
2.5 shows SAXS data for s-DmALK and s-HsLTK ECR proteins to perform the SAXS analysis.  
Studies of both proteins yielded a linear Guinier region, suggesting that neither protein is 
aggregating – and that the proteins are monodisperse in solution.  From these Guinier plots, we 
also extrapolated values for the scattered intensity at zero angle (I(0)), which is proportional to the 
(shape-independent) weight-averaged molecular weight of a monodisperse species.  The 
resulting values (listed in Table 2.1) were consistent with our SEC and AUC-SE analyses, and 
indicate that both proteins are monomeric. 
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Figure 2.5 SAXS analysss of s-DmALK (A) and s-HsLTK (B).  In each panel, a P(r) curve is 
shown at the left, with a Guinier plot in the center, and a calculated low-resolution envelope (see 
text) at far right. 
SAXS also provides information on the ‘shape’ of the receptor ECRs, which can provide crucial 
hints on the structures and mechanisms of the receptors.  For instance, SAXS analysis of the 
EGFR ECR unveiled the unliganded tethered conformation in which intramolecular interactions 
autoinhibit the receptor – which contrasts with the ‘extended’ conformation of the ErbB2 ECR, 
which SAXS studies showed lacks the tethered conformational features seen in EGF receptor 
(Alvarado, Klein, and Lemmon 2009).  SAXS data provide two key shape parameters.  One is the 
radius of gyration (Rg), which can be directly extrapolated from Guinier plot (reciprocal space Rg) 
or from P(r) curves (real space Rg).  Our Guinier analyses suggest Rg values for s-DmALK and 
s-HsLTK of 45.1 Å and 29.5 Å, respectively (Table 2.1).  In addition, the P(r), or pairwise distance 
distribution, curve yields structural information since it summarizes all the distances between any 
two points in the molecule.  P(r) curves of a spherical protein usually show a unimodal distribution, 
whereas proteins containing multiple domains usually exhibit P(r) curves with multiple peaks.  
The P(r) curve for s-DmALK protein shows a multi-modal pattern, consistent with a conformation 
in which multiple domains are ‘chained’ together in a ‘string-of-beads’-like conformation. This 
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analysis also yields a value for Dmax, which delineates the maximum distance between two points 
on the molecule – effectively the maximum dimension/length of the molecule.  Dmax for s-DmALK 
is 130 Å (Table 2.1), which is also consistent with an elongated ‘beads-on-string’ conformation.  
These data therefore indicate that the multiple domains in the DmALK are relatively independent, 
and further suggest that intramolecular autoinhibitory interactions analogous to the EGFR tether 
are not relevant for ALK. 
The P(r) curve for s-HsLTK appears more unimodal P(r), as expected for an ECR with 
fewer domains, but Dmax is 90 Å – suggesting again an extended structure that contains no 
equivalent of the EGFR intramolecular tether.   
A further view of these structural considerations is provided by conducting 3D shape 
reconstructions using software DAMMIF (Franke and Svergun 2009).  As expected, the low-
resolution (approximately 20 Å) envelope shown in Figure 2.5A of s-DmALK reveals a relatively 
elongated conformation, where multiple ‘beads’ can be clearly seen.  On the other hand, LTK 
exhibits a smoother shape.  This is likely due to the relatively small domains in membrane-
proximal region, and the intrinsically disordered region in LTK. 
 
2.5 Heparin promotes ALK receptor dimerization to form side-by-side dimer 
Human ALK has remained an ‘orphan’ receptor because of the lack of an identified ligand.  As 
mentioned in Chapter 1, several putative ligands have been suggested, including pleiotrophin 
(PTN) and midkine (MK).  Both PTN and MK are heparin-binding molecules.  Quite surprisingly, a 
recent study revealed that it may not be PTN or MK, but heparin itself, that mammalian ALK 
directly binds to (Murray et al. 2015).  In addition, binding of heparin was shown to induce ALK 
receptor phosphorylation in cell-based assays.  Hence, heparin is likely to be a ligand or co-ligand 
for mammalian ALK.  The heparin-binding motif in ALK turned out to be in the N-terminal region 
of ECR (N-terminal to the first MAM domain), where conserved lysine and arginine residues are 
responsible for mediating the electrostatic interactions with negatively charged heparin.  The 
binding stoichiometry varies from 1:1 to 1:5 (ALK:heparin) depending on the length of heparin 
molecule (and thus charge patterns).  Given that heparin binding appears to causes ALK 
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oligomerization, we decided to use SAXS to determine its structural basis – that is of how heparin 
binding induces receptor dimerization/oligomerization? Does this process involve significant 
conformational changes, such as in the case of EGF receptor?  Is receptor dimerization mediated 
by ligand (as in Trk receptor) or by receptor (as in EGF receptor), or both (as in FGF receptor or 
Kit)? 
 
Figure 2.6 SAXS analyses of dog (Canis familiaris) ALK ECR protein (s-CfALK). P(r) curves, 
Guinier plots and shape reconstructions of dog ALK-ECR protein (A), dog ALK-ECR protein in 
complex with heparin (dp15) (B) and dog ALK-ECR protein in complex with sucrose octasulfate 
(SOS) (C).   
In order to address these questions, we collected SAXS data for the ECR of dog ALK (s-
CfALK) and its complexes with dp15 (a heparin molecule containing a 15-mer of disaccharide 
unit) and sucrose octasulfate (SOS) (blue, cyan and orange in Figure 2.6, respectively).  The 
Guinier plots all showed a relatively linear Guinier region, suggesting these samples were all 
monodisperse.  From the Guinier plot, we also extrapolated the forward scattering intensity (I(0)), 
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and further determined the average molecular mass of the samples (summarized in Table 2.1).  
The molecular weight is consistent with the previous result that dp15 dimerizes dog ALK.  Both 
receptor alone and receptor in complex with SOS showed a molecular weight of monomer, 
suggesting that SOS cannot dimerize dog ALK.  This result suggests that the chain length of the 
heparin molecule is crucial for dimerizing the receptor (15 disaccharide units in dp 15, and 1 
disaccharide unit in SOS). 
 
Table 2.1 Molecular masses and shape parameters of ALK proteins 
 
 
Similar to s-DmALK, or SAXS studies showed that s-CfALK also exhibits an elongated 
conformation, with a Dmax value of 140 Å.  The reconstructed envelope of s-CfALK also closely 
resembles that of s-DmALK, arguing that our results for the invertebrate ALK protein are also 
relevant for this mammalian ortholog.  The complex of s-CfALK with SOS displayed a slightly 
larger envelope, with a Dmax value of 150 Å, also with an elongated conformation.  In addition, the 
P(r) curves of s-CfALK alone closely resembled those of s-CfALK bound to SOS – arguing that 
SOS binding does not significantly affect the overall conformation of the receptor.  We suggest 
that the small ~10 Å increase in Dmax of s-CfALK upon SOS binding may reflect changes in the 
local conformation of the N-terminal heparin-binding region – possibly causing it to become more 
extended (and thus increase Dmax).  Indeed, secondary structure predictions indicate that the N-
terminal region of mammalian ALK receptors is largely disordered.  In order to bind to heparin, 
the heparin-binding motif must align its basic residues to match the sulfate groups in SOS.  As a 
result, heparin binding could effectively ‘rigidify’ the heparin-binding region and thus increase the 
dimension of the receptor slightly.  In order to test this hypothesis, we conducted the same SAXS 
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analysis using sCf-ALK from which the N-terminal region had been deleted (dN-sCfALK).  Figure 
2.7 showed the P(r) curves of dN-sCfALK alone and in complex with SOS, and their 
reconstructed envelopes.  Both samples now have the same Dmax and Rg values.  Their low-
resolution shapes also resemble each other quite closely. 
 
Figure 2.7 SOS has minimal effect on dN-sCf-ALK protein conformation.  Top: P(r) curve of dN-
sCf-ALK-ECR alone (red) and in complex with SOS (gray).  Bottom: Shape reconstruction of dN-
sCf-ALK-ECR alone (red) and in complex with SOS (gray).  
In contrast to the s-CfALK/SOS complex, the complex between sCfALK and dp15 (which 
contains 15 disaccharide units) shows a significantly altered P(r) curve and a greatly increased 
I(0) consistent with dimerization.  The major peak in the P(r) curve (Figure 2.6B) is much broader, 
and shows a multi-modal pattern not evident for s-CfALK alone.  Despite this – and clear 
evidence from the I(0) value that s-CfALK is dimeric – the Dmax value increased only to 160 Å (i.e. 
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by only 20 Å).  These findings suggest that s-CfALK dimerizes in a ‘side-by-side’ (rather than an 
‘end-to-end’) geometry to form the dimer upon dp15 heparin binding.  In addition, the fact that the 
Dmax value of s-CfALK only increases 20 Å suggests that the receptor forms a ‘parallel’ dimer, 
with dp15 likely to be linking the N-terminal regions of the two molecules.  Thus, these findings 
provide the structural views – albeit at low resolution – for how a ligand can dimerize ALK, leading 
to its activation in cells. 
2.6 Efforts to make jelly belly, a proposed ligand for Drosophila ALK 
Heparin has been identified as a ligand for mammalian ALK – although it is likely that there are 
others.  It is difficult to see how an RTK could be acutely regulated by modulating heparin levels.  
Moreover, Drosophila ALK lacks the N-terminal heparin-binding motif that appears to be 
conserved in mammalian ALKs.  It has been reported that in Drosophila, a secreted protein called 
jelly belly (Jeb) is a ligand for fly ALK.  This is genetically supported by developmental studies 
where jelly belly and ALK both appear to contribute to mesodermal embryo development.  The 
two molecules also co-localize during that development stage, and loss-of-function mutataions in 
ALK resemble those in Jeb – and vice versa (Englund et al. 2003; Lee et al. 2003).  An alkaline 
phosphatase fusion protein of Jeb was also reported to bind to mammalian cells expressing 
Drosophila ALK, and to activate Erk in these cells (Lee et al., 2003).  Beyond this analysis, 
however, the biochemical properties of Jeb and its interaction with Drosophila ALK have not been 
characterized.  This is largely due to the difficulty of making recombinant Jeb.  I aimed to over-
express recombinant Jeb from insect cells so that I could characterize its binding to s-DmALK, 
and initiate structural studies.  Protein expression turned out to be extremely difficult.  Only a 
trace amount of protein could be produced in Sf9 cells.  Moreover, the majority of the generated 
protein was not secreted.  Having tested several insect cell expression systems and various 
expression conditions, I eventually found a condition under which I express Coomassie Blue 
stainable amounts of Jeb by secretion from baculovirus-infected Trichoplusia ni (T. ni) cells.  The 
secreted protein was N-terminally hexahistidine tagged and I was able to purify it using a Ni-NTA 
affinity column.  Figure 2.8 shows gels of test expressions and Ni-NTA column purifications of 
Jeb.  To the best of our knowledge, this is the first time full-length Jeb was purified from insect 
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cells with such yields.  However, my subsequent SPR-based binding assays failed to detect any 
binding of Jeb to the Drosophila ALK ECR protein. 
 
Figure 2.8 Test expression and Ni-NTA affinity purification of full-length Jeb.  Top: Coomassie-
stained gel and Western blot of Jeb in 100 ml T. ni cell culture shaking at three speed, 70 rpm, 90 
rpm and 100 rpm.  Bottom: Purified Jeb is eluted from Ni-NTA affinity column using 150 mM 
imidazole. 
Since the LDLa domain of Jeb had been implicated by earlier studies as being key for the 
interaction of Jeb with Drosophila ALK (Lee et al., 2003), I also undertook efforts to express the 
isolated Jeb LDLa domain – the only identifiable domain within Jeb.  I used an E. coli expression 
system to generate recombinant protein corresponding to LDLa domain in Jeb.  I tested several 
E. coli strains, expression vectors, and fusion tags and eventually discovered an approach that 
yielded protein by using a specific E. coli strain engineered for expressing disulfide-containing 
protein, and maltose-binding protein (MBP) as the fusion tag (Figure 2.9).  A factor X protease 
cleavage site was engineered between the MBP and the LDLa domain.  Sequence analysis also 
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suggests that the LDLa domain in Jeb is likely to require calcium as a cofactor to properly fold 
and form disulfide linkage – so I refolded the protein under the same conditions that were used 
for refolding calcium-binding LDLa proteins (North and Blacklow 2000).  The resulting protein was 
cleaved by using factor X protease to get rid of the MBP tag.  However, SPR studies again didn’t 
reveal any binding of this LDLa protein to fly ALK ECR. 
 
Figure 2.9 LDLa domain in Jeb. Top: sequence alignment of Jeb LDLa motif (486-540) with 
structurally-available LDLa domains. (1ajj: LDL receptor, LDLa module 5, 1d2l: LDLa module in 
low densitiy lipoprotein receptor-related protein (lrp), 1jrf and 1k7b: LDLa in viral receptor domain 
of Tva, 2jm4: LDLa module in relaxin receptor). Bottom: Coomassie Blue-stained SDS PAGE gels 
of purified Jeb LDLa domain fusion proteins (Jeb residues 454-542 and 489-542) and cleaved 
products (lanes indicated by asterisk).  
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2.7 A possible model for ALK receptor activation 
Significant efforts have been made to search for ALK’s ligand(s).  In Drosophila, Jeb appears 
capable of regulating ALK – with crucial roles in fly embryonic development.  The LDLa domain in 
Jeb was proposed to mediate its interaction with fly ALK, since Jeb/alkaline phosphatase fusion 
proteins lacking LDLa did not bind to the surface of mammalian cells expressing Drosophila ALK 
(Lee et al., 2003).  In addition, the MAM domains and glycine-rich regions of ALK have been 
suggested to be significant in ligand/receptor binding, with mutations in these regions resulting in 
loss-of-function phenotypes (Lorén et al. 2003).  These pieces of data all suggest that Jeb 
functions (at least in part) through ALK-mediated cell signaling.  However, it remains unclear 
whether Jeb can directly activate the receptor – rather than affecting it indirectly. 
In mammals, pleiotrophin (PTK) and midkine (MK) have been proposed as ALK ligands 
(Stoica et al. 2001; Stoica et al. 2002), although contradictory results regarding these molecules 
exist in literature (Mourali et al. 2006; Mathivet, Mazot, and Vigny 2007; Dirks et al. 2002; Moog-
Lutz et al. 2005; Motegi et al. 2004).  Both PTK and MK are heparin-binding proteins – which 
inspired a recent study to determine that heparin can bind to and activate mammalian ALK.  Both 
SPR-based binding assays and cell-based activity assays supported this argument.  However, 
only the N-terminal region containing the heparin-binding motif is responsible for this interaction.  
Deletion of this motif from ALK completely abolished heparin binding and receptor dimerization.  
This raises an important question: what is the function of the rest of ALK receptor, which includes 
two MAM domains, an LDLa domain, an EGF-type module, a glycine-rich region and a TNF-like 
domain?  It seems unlikely that these domains have no function – particularly since Drosophila 
ALK lacks the the heparin-binding motif and Drosophila genetics reveals important roles for 
several of the other domains.  Our cell-based analysis also confirmed that heparin cannot activate 
Drosophila ALK (Figure 2.10), so how does fly ALK get activated? 
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Figure 2.10 Heparin fails to activate Drosophila ALK.  
Given the findings in Drosophila and mammalian ALK, we hypothesize that ALK is a receptor that 
requires multiple co-ligands and/or co-receptors.  Such a paradigm is not uncommon in biology.  
Among RTKs, one example is FGFR, which needs both fibroblast growth factor and heparin or 
heparin sulfate proteoglycans to form receptor dimers (Schlessinger 2000).  Another RTK, RET 
(rearranged during transfection) also needs its ligand glial-derived neurotrophic factor (GDNF) as 
well as a GPI-anchored co-receptor named GDNF-family receptor-α (GFRα) to promote receptor 
dimerization (Lemmon and Schlessinger 2010).  We speculate that heparin functions as a co-
ligand to bring together multiple ALK receptors through charge-charge interactions.  In addition, 
the MAM domains, TNF-like domain, G-rich region and EGF-type module could all interact with 
their counterparts in an adjacent receptor either directly or indirectly.  We consider three possible 
scenarios. (i) The interaction of the two domains is direct – with low affinity, because this 
interaction itself is not sufficient to induce receptor dimerization.  (ii) The interaction of two 
domains across a dimer interface is mediated by a ligand.  (iii) The interaction of two domains is 
induced by a ligand.  That is, a domain in ALK is blocked and binding of a ligand induces 
conformational change, which exposes the domain to allow for domain-domain interactions.  
These three scenarios could co-exist, and evolution may select a subset of them for ALKs in 
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different species. For example, in Drosophila Jeb may contribute to interactions around ‘MAM-
LDLa-MAM’ region, whereas in mammals, the N-terminal region may have evolved to play an 
important role.  A similar pattern may also be true in LTK family receptors.  In zebrafish, LTK 
contains two MAM domains, but mammalian LTK has lost the MAM domains – the membrane 
proximal regions are sufficient to activate the receptor and to respond to FAM150A (Zhang et al. 
2014).  In fact, this suggests that the ligand-binding site in LTK (and possibly in ALK) involves 
some combination of the TNF-like domain, the G-rich region, and/or the EGF-type module.  
Finally, our proposed model also allows for the formation of hetero-complexes involving co-
receptors.  It is worth noting that some membrane-anchored phosphatases also contain MAM 
domains (e.g. phosphatase µ), or even bind to heparin (e.g. phosphatase σ).  Figure 2.11 
illustrates our proposed model of ALK activation mechanism. 
 
Figure 2.11 A proposed model for ALK activation mechanism.  Each of the components in ALK 
ECR could function differently to interact with a co-ligand/co-receptor, or with the same domain in 
a different receptor. 
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2.8 Conclusions 
In this chapter, we aimed to study the molecular basis for ALK activation.  We re-assessed the 
domain composition of ALK and LTK extracellular region, and found that TNF-like domain and 
EGF-type module were likely to exist in ALK ECR.  Using biochemical and biophysical 
approaches, we determined that the ALK and LTK ECR proteins are monomeric in solution, 
suggesting ALK and LTK resemble RTKs like EGF, FGFR, etc, rather than IR superfamily 
receptors.  Small-angle x-ray scattering studies further provided low-resolution structures of the 
ALK and LTK ECRs, revealing that they have elongated conformations.  Using heparin, a recently 
identified ligand for mammalian ALK, we investigated the low-resolution structure of a heparin-
promoted receptor dimer.  Our SAXS analysis suggests that heparin binding causes two ALK 
ECRs to form a parallel ‘side-by-side’ dimer.  Finally, we proposed a model suggesting that ALK 
is a multivalent receptor.  Ligand-induced activation and regulation of ALK receptor are likely to 
involve multiple molecules (co-ligands, or co-receptors). 
2.9 Experimental procedures 
2.9.1 Domain identification of ALK-ECR protein 
Domain identification in ALK ECRs was conducted by submitting to the Phyre2 server a truncated 
ALK sequence corresponding to the membrane-proximal region.  An iterative approach was used 
in order to discover the new domains.  The results coming back from Phyre2 server were further 
analyzed on Tcoffee Expresso server to evaluate the structural similarity using sequence 
information. 
2.9.2 Expression and purification of Drosophila ALK-ECR protein 
Drosophila ALK ECR protein was expressed from baculovirus-infected insect cells (Sf9 or T. ni).  
DNA encoding full-length ALK was subcloned into pFastBac-1 (Invitrogen) for expression of C-
terminal histidine-tagged protein.  Recombinant baculovirus was generated using Bac-to-bac 
system (Invitrogen), following recommended procedures.  Sf9 cells were infected with virus and 
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incubated for three days at 27°C, and then harvested by centrifugation.  The supernatant was 
dialyzed against a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl.  The resulting 
solution was flowed through a Ni-NTA bead packed column.  ALK was eluted with 100 mM 
imidazole buffer containing 20 mM phosphate buffer (pH 8.0), 150 mM NaCl.  The elution was 
slightly concentrated by a concentrator (Millipore, spinning at 2000 g) and then diluted to bring the 
imidazole concentration down to 20 mM and NaCl concentration below 50 mM.  Cation exchange 
chromatography was subsequently used to purify the protein on a TAME column.  A typical 
gradient started from 50 mM NaCl.  ALK was eluted at 130 mM NaCl.  The eluted factions were 
pooled together and concentrated in a concentrator (Millipore, spinning at 2000 g).  The resulting 
sample was then injected onto a Superose 6 gel filtration column (GE Healthcare) for size 
exclusion chromatography.  On the Superose 6 column, ALK eluted at 15.6 ml volume (buffer: 20 
mM HEPES pH 7.5, 150 mM NaCl). 
2.9.3 Expression and purification of jelly belly protein 
Full-length Jeb protein was expressed from baculovirus-infected insect cells (T.ni cells).  DNA 
encoding full-length Jeb was subcloned into pFastBac-1 (Invitrogen) for expression of C-
terminally histidine-tagged protein.  Recombinant baculovirus was generated using Bac-to-bac 
system (Invitrogen), following recommended procedures.  250 ml culture of T. ni cells were 
infected with virus at a cell density of 2x106 cells/ml, in a 1-liter spinner flask.  The infected cell 
culture was incubated for three days at 27°C with a 90 rpm spinning speed, and then cells were 
pelleted.  The supernatant was dialyzed against a buffer containing 20 mM HEPES (pH 7.5), 150 
mM NaCl.  The resulting solution was flowed through a Ni-NTA bead packed column.  Jeb was 
eluted with 150 mM imidazole buffer containing 20 mM phosphate buffer (pH 8.0), 150 mM NaCl.  
In occasions where highly purified protein was needed, size exclusion chromatography was used 
to further purify the protein.  A Superose 6 column (GE Healthcare) was used, with a buffer 
containing 20 mM HEPES, pH 7.5 and 150 mM NaCl.  On the Superose 6 column, Jeb eluted at 
12.5 ml volume (suggesting Jeb is largely disordered). 
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2.9.4 Analytical ultracentrifugation analysis of ALK-ECR protein 
Sedimentation equilibrium experiments were performed using purified ALK ECR proteins.  
Freshly prepared proteins (see above sections for expression and purification) from size-
exclusion chromatography were immediately pooled and concentrated.  Proteins were 
concentrated to 1.3 µM (O.D. 0.2), 2.7 µM (O.D. 0.4) and 4 µM (O.D. 0.6) and loaded into 6 
sector center piece AUC assemblies.  Experiments were performed in a Beckman XL-A 
ultracentrifuge equipment at 4°C using 9000,12000 and 15000 rpm speeds.  Data were collected 
at 280 nm absorbance with a 0.001 cm scan step.  Scans were continued until the reach of 
equilibrium monitored by SedFit software (Schuck 2000).  Log plots were generated by using a in-
house developed script that truncates, transforms and plots data. 
2.9.5 Small-angle x-ray scattering studies of ALK proteins 
For SAXS analyses of fly ALK and human LTK ECR proteins, data were collected at MacChess 
G1 beamline. 50 µl of protein sample was loaded in a flow cell so the sample is oscillating in the 
cell.  A generous oscillation size was used to minimize radiation damage.  Data were collected at 
one second exposure intervals.  Lysozyme and glucose isomerase were used as standard for I(0) 
measurement.  Data were first reduced using software RAW developed at MacChess (Skou, 
Gillilan, and Ando 2014).  The subsequent analyses were performed using in-house developed 
SAXS program suite EZsaxs, EZshape and EZanalysis, which themselves utilize Gnome, Dammif 
and Damaver (Petoukhov et al. 2012; Franke and Svergun 2009). 
For dog ALK SAXS experiments, all data for receptor alone and in complex with heparin 
(gift from Schlessinger lab) were collected at Penn using a Rigaku PSAXS S-Max3000 small-
angle X-ray scattering system equipped with a Osmic mirror optics, an evacuated sample 
chamber kept at 4 °C, and a gas-filled multi-wire detector.  A Rigaku MicroMax-007 HF 
microfocus rotating anode generator was used as x-ray source.  The raw data were first averaged 
and reduced using SAXSGUI software (ver. 2.5.7).  The resulting data were analyzed by using 
ATSAS Primus software (Konarev et al. 2003).  P(r) curves calculation and shape reconstruction 
were conducted using the software suite EZsaxs, EZshape and EZanalysis, which themselves 
utilize Gnome, Dammif and Damaver (Petoukhov et al. 2012). 
 
 
62 
2.10 References 
Alvarado, Diego, Daryl E Klein, and Mark A Lemmon. 2009. “ErbB2 Resembles an Autoinhibited 
Invertebrate Epidermal Growth Factor Receptor..” Nature 461 (7261): 287–91. 
doi:10.1038/nature08297. 
Bresler, Scott C, Andrew C Wood, Elizabeth A Haglund, Joshua Courtright, Lili T Belcastro, 
Jefferson S Plegaria, Kristina Cole, et al. 2011. “Differential Inhibitor Sensitivity of Anaplastic 
Lymphoma Kinase Variants Found in Neuroblastoma..” Science Translational Medicine 3 
(108). American Association for the Advancement of Science: 108ra114–14. 
doi:10.1126/scitranslmed.3002950. 
Bresler, Scott C, Daniel A Weiser, Peter J Huwe, Jin H Park, Kateryna Krytska, Hannah Ryles, 
Marci Laudenslager, et al. 2014. “ALK Mutations Confer Differential Oncogenic Activation 
and Sensitivity to ALK Inhibition Therapy in Neuroblastoma..” Cancer Cell 26 (5): 682–94. 
doi:10.1016/j.ccell.2014.09.019. 
Dawson, Jessica P, Zimei Bu, and Mark A Lemmon. 2007. “Ligand-Induced Structural Transitions 
in ErbB Receptor Extracellular Domains..” Structure (London, England : 1993) 15 (8): 942–
54. doi:10.1016/j.str.2007.06.013. 
Dirks, Willy G, Silke Fähnrich, Yvonne Lis, Elisabeth Becker, Roderick A F MacLeod, and Hans G 
Drexler. 2002. “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase 
(ALK) Gene in Tumor Cell Lines.” International Journal of Cancer 100 (1). Wiley Subscription 
Services, Inc., A Wiley Company: 49–56. doi:10.1002/ijc.10435. 
Downing, A K, V Knott, J M Werner, C M Cardy, I D Campbell, and P A Handford. 1996. “Solution 
Structure of a Pair of Calcium-Binding Epidermal Growth Factor-Like Domains: Implications 
for the Marfan Syndrome and Other Genetic Disorders..” Cell 85 (4): 597–605. 
Englund, Camilla, Christina E Lorén, Caroline Grabbe, Gaurav K Varshney, Fabienne Deleuil, 
Bengt Hallberg, and Ruth H Palmer. 2003. “Jeb Signals Through the Alk Receptor Tyrosine 
Kinase to Drive Visceral Muscle Fusion..” Nature 425 (6957): 512–16. 
doi:10.1038/nature01950. 
Ferguson, K M, P J Darling, M J Mohan, T L Macatee, and M A Lemmon. 2000. “Extracellular 
 
 
63 
Domains Drive Homo- but Not Hetero-Dimerization of erbB Receptors..” The EMBO Journal 
19 (17): 4632–43. doi:10.1093/emboj/19.17.4632. 
Franke, Daniel, and Dmitri I Svergun. 2009. “DAMMIF, a Program for Rapid Ab-Initioshape 
Determination in Small-Angle Scattering.” Journal of Applied Crystallography 42 (2): 342–46. 
doi:10.1107/S0021889809000338. 
Hallberg, Bengt, and Ruth H Palmer. 2013. “Mechanistic Insight Into ALK Receptor Tyrosine 
Kinase in Human Cancer Biology..” Nature Reviews. Cancer 13 (10): 685–700. 
doi:10.1038/nrc3580. 
Iwahara, T, J Fujimoto, D Wen, R Cupples, N Bucay, T Arakawa, S Mori, B Ratzkin, and T 
Yamamoto. 1997. “Molecular Characterization of ALK, a Receptor Tyrosine Kinase 
Expressed Specifically in the Nervous System..” Oncogene 14 (4): 439–49. 
doi:10.1038/sj.onc.1200849. 
Kelley, Lawrence A, and Michael J E Sternberg. 2009. “Protein Structure Prediction on the Web: 
a Case Study Using the Phyre Server..” Nature Protocols 4 (3): 363–71. 
doi:10.1038/nprot.2009.2. 
Konarev, Petr V, Vladimir V Volkov, Anna V Sokolova, Michel H J Koch, and Dmitri I Svergun. 
2003. “PRIMUS: a Windows PC-Based System for Small-Angle Scattering Data Analysis.” 
Journal of Applied Crystallography 36 (5): 1277–82. doi:10.1107/S0021889803012779. 
Lawrence, Michael C, Neil M McKern, and Colin W Ward. 2007. “Insulin Receptor Structure and 
Its Implications for the IGF-1 Receptor..” Current Opinion in Structural Biology 17 (6): 699–
705. doi:10.1016/j.sbi.2007.07.007. 
Lee, Hsiu-Hsiang, Audra Norris, Joseph B Weiss, and Manfred Frasch. 2003. “Jelly Belly Protein 
Activates the Receptor Tyrosine Kinase Alk to Specify Visceral Muscle Pioneers..” Nature 
425 (6957): 507–12. doi:10.1038/nature01916. 
Lemmon, Mark A, and Joseph Schlessinger. 2010. “Cell Signaling by Receptor Tyrosine 
Kinases..” Cell 141 (7): 1117–34. doi:10.1016/j.cell.2010.06.011. 
Li, Na, Kazuhiro Nakamura, Yi Jiang, Hiromichi Tsurui, Shuji Matsuoka, Masaaki Abe, Mareki 
Ohtsuji, et al. 2004. “Gain-of-Function Polymorphism in Mouse and Human Ltk: Implications 
 
 
64 
for the Pathogenesis of Systemic Lupus Erythematosus..” Human Molecular Genetics 13 (2). 
Oxford University Press: 171–79. doi:10.1093/hmg/ddh020. 
Lorén, Christina E, Camilla Englund, Caroline Grabbe, Bengt Hallberg, Tony Hunter, and Ruth H 
Palmer. 2003. “A Crucial Role for the Anaplastic Lymphoma Kinase Receptor Tyrosine 
Kinase in Gut Development in Drosophila Melanogaster..” EMBO Reports 4 (8): 781–86. 
doi:10.1038/sj.embor.embor897. 
Mathivet, Thomas, Pierre Mazot, and Marc Vigny. 2007. “In Contrast to Agonist Monoclonal 
Antibodies, Both C-Terminal Truncated Form and Full Length Form of Pleiotrophin Failed to 
Activate Vertebrate ALK (Anaplastic Lymphoma Kinase)?.” Cellular Signalling 19 (12): 2434–
43. doi:10.1016/j.cellsig.2007.07.011. 
Moog-Lutz, Christel, Joffrey Degoutin, Jean Y Gouzi, Yvelyne Frobert, Nicole Brunet-de 
Carvalho, Jocelyne Bureau, Christophe Créminon, and Marc Vigny. 2005. “Activation and 
Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal 
Antibodies and Absence of Agonist Activity of Pleiotrophin..” The Journal of Biological 
Chemistry 280 (28). American Society for Biochemistry and Molecular Biology: 26039–48. 
doi:10.1074/jbc.M501972200. 
Motegi, Akira, Jiro Fujimoto, Masaharu Kotani, Hitoshi Sakuraba, and Tadashi Yamamoto. 2004. 
“ALK Receptor Tyrosine Kinase Promotes Cell Growth and Neurite Outgrowth..” Journal of 
Cell Science 117 (Pt 15). The Company of Biologists Ltd: 3319–29. doi:10.1242/jcs.01183. 
Mourali, Jaouhar, Alan Bénard, Filipe Calheiros Lourenço, Céline Monnet, Catherine Greenland, 
Christel Moog-Lutz, Claire Racaud-Sultan, et al. 2006. “Anaplastic Lymphoma Kinase Is a 
Dependence Receptor Whose Proapoptotic Functions Are Activated by Caspase Cleavage..” 
Molecular and Cellular Biology 26 (16). American Society for Microbiology: 6209–22. 
doi:10.1128/MCB.01515-05. 
Murray, Phillip B, Irit Lax, Andrey Reshetnyak, Gwenda F Ligon, Jay S Lillquist, Edward J Natoli, 
Xiarong Shi, et al. 2015. “Heparin Is an Activating Ligand of the Orphan Receptor Tyrosine 
Kinase ALK..” Science Signaling 8 (360): ra6–ra6. doi:10.1126/scisignal.2005916. 
Nagata, K, D Kohda, H Hatanaka, S Ichikawa, S Matsuda, T Yamamoto, A Suzuki, and F Inagaki. 
 
 
65 
1994. “Solution Structure of the Epidermal Growth Factor-Like Domain of Heregulin-Alpha, a 
Ligand for p180erbB-4..” The EMBO Journal 13 (15): 3517–23. 
North, C L, and S C Blacklow. 2000. “Solution Structure of the Sixth LDL-a Module of the LDL 
Receptor..” Biochemistry 39 (10): 2564–71. 
Oren, Deena A, Yuling Li, Yulia Volovik, Tina S Morris, Chhaya Dharia, Kalyan Das, Olga 
Galperina, Reiner Gentz, and Eddy Arnold. 2002. “Structural Basis of BLyS Receptor 
Recognition..” Nature Structural Biology 9 (4): 288–92. doi:10.1038/nsb769. 
Palmer, Ruth H, Emma Vernersson, Caroline Grabbe, and Bengt Hallberg. 2009. “Anaplastic 
Lymphoma Kinase: Signalling in Development and Disease..” The Biochemical Journal 420 
(3): 345–61. doi:10.1042/BJ20090387. 
Petoukhov, Maxim V, Daniel Franke, Alexander V Shkumatov, Giancarlo Tria, Alexey G Kikhney, 
Michal Gajda, Christian Gorba, Haydyn D T Mertens, Petr V Konarev, and Dmitri I Svergun. 
2012. “New Developments in the ATSAS Program Package for Small-Angle Scattering Data 
Analysis..” Journal of Applied Crystallography 45 (Pt 2): 342–50. 
doi:10.1107/S0021889812007662. 
Schlessinger, J. 2000. “Cell Signaling by Receptor Tyrosine Kinases..” Cell 103 (2): 211–25. 
Schuck, P. 2000. “Size-Distribution Analysis of Macromolecules by Sedimentation Velocity 
Ultracentrifugation and Lamm Equation Modeling..” Biophysical Journal 78 (3): 1606–19. 
doi:10.1016/S0006-3495(00)76713-0. 
Skou, Soren, Richard E Gillilan, and Nozomi Ando. 2014. “Synchrotron-Based Small-Angle X-Ray 
Scattering of Proteins in Solution..” Nature Protocols 9 (7): 1727–39. 
doi:10.1038/nprot.2014.116. 
Stoica, G E, A Kuo, A Aigner, I Sunitha, B Souttou, C Malerczyk, D J Caughey, et al. 2001. 
“Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor 
Pleiotrophin..” The Journal of Biological Chemistry 276 (20). American Society for 
Biochemistry and Molecular Biology: 16772–79. doi:10.1074/jbc.M010660200. 
Stoica, Gerald E, Angera Kuo, Ciaran Powers, Emma T Bowden, Elaine Buchert Sale, Anna T 
Riegel, and Anton Wellstein. 2002. “Midkine Binds to Anaplastic Lymphoma Kinase (ALK) 
 
 
66 
and Acts as a Growth Factor for Different Cell Types..” The Journal of Biological Chemistry 
277 (39): 35990–98. doi:10.1074/jbc.M205749200. 
Ward, Colin W, Michael C Lawrence, Victor A Streltsov, Timothy E Adams, and Neil M McKern. 
2007. “The Insulin and EGF Receptor Structures: New Insights Into Ligand-Induced Receptor 
Activation..” Trends in Biochemical Sciences 32 (3): 129–37. doi:10.1016/j.tibs.2007.01.001. 
Weiss, Joseph B, Changhui Xue, Ted Benice, Liquan Xue, Stephan W Morris, and Jacob Raber. 
2012. “Anaplastic Lymphoma Kinase and Leukocyte Tyrosine Kinase: Functions and Genetic 
Interactions in Learning, Memory and Adult Neurogenesis..” Pharmacology, Biochemistry, 
and Behavior 100 (3): 566–74. doi:10.1016/j.pbb.2011.10.024. 
Zhang, Hongbing, Lily I Pao, Aileen Zhou, Arthur D Brace, Robert Halenbeck, Amy W Hsu, 
Thomas L Bray, et al. 2014. “Deorphanization of the Human Leukocyte Tyrosine Kinase 
(LTK) Receptor by a Signaling Screen of the Extracellular Proteome..” Proceedings of the 
National Academy of Sciences of the United States of America 111 (44): 15741–45. 
doi:10.1073/pnas.1412009111. 
 
  
 
 
67 
 
 
 
 
 
 
 
 
Chapter 3 Investigating the molecular basis of Ryk/Wnt 
interactions 
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3.1 Introduction 
Ryk (Related to tYrosine Kinase) is a sub-family of receptor tyrosine kinases (Yee et al. 1993; 
Hovens et al. 1992).  It is unique among RTKs in that it is the only receptor that contains a Wnt-
inhibitory factor (WIF) domain in its ectodomain.  The WIF domain suggests a link to the Wnt-
family ligands.  In addition, the kinase domain in Ryk lacks key residues known for carrying 
phosphotransfer catalysis.  Therefore, like other RTKs that are also Wnt receptors (Ror1, Ror2 
and PTK7/CCK4), Ryk appears to be a pseudokinase (Mendrola et al. 2013). 
The WIF domain in Ryk contains about 130 residues and shares 23% sequence identity 
with the human WIF-1 protein.  Studies have shown that Ryk and certain Wnts co-
immunoprecipitate (Lu et al. 2004), and knockdown of Ryk abolishes Wnt-promoted TCF 
pathways, suggesting Ryk and Wnt interacts. 
In Drosophila, Ryk has three homologues, Derailed (Drl), Derailed-2 (Drl-2) and 
Doughnut (Dnt).  Drl plays a key role in mediating axon pathfinding in Drosophila embryonic 
central nervous system (CNS) (Bonkowsky et al. 1999; Callahan et al. 1995).  Expression of Drl 
guides the neurons to project axons through the anterior commissure (instead of the posterior 
commissure).  Flies lacking Drl fail this process and their axons show defective paths (thus the 
name derailed).  The Drl-guided axon pathfinding is mediated by DWnt5, which is expressed 
predominantly in the posterior commissure(Fradkin, Noordermeer, and Nusse 1995).  In addition, 
a Drl-FC fusion protein is able to bind to a DWnt5-expressing region in Drosophila embryos, and 
to co-immunoprecipitate Dwnt5, suggesting that Drl and DWnt5 interact (Yoshikawa, Bonkowsky, 
and Kokel 2001).  In addition to directing axon pathfinding, Drl and DWnt5 also play important 
roles in other Drosophila developmental processes, such as patterning of olfactory receptor 
neurons (ORNs) in the fly antennal lobe (Sakurai et al. 2009; Yao et al. 2007), development of 
mushroom bodies (Moreau-Fauvarque et al. 1998; Grillenzoni et al. 2007), and migration of the 
salivary gland (Harris and Beckendorf 2007). 
 Drl-2 shares 44% sequence identity with Drl in the WIF domain.  Drl-2 is also expressed 
in Drosophila ORNs and functionally complements Drl in the development of the Drosophila 
olfactory system (Sakurai et al. 2009).  The third ortholog, Dnt, shares 64% sequence identity 
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with Drl.  Studies have shown that Dnt can partially rescue embryonic muscle attachement 
defects caused by lack of Drl during fly embryogenesis, suggesting that Dnt and Drl may function 
similarly during embryonic development (Oates et al. 1998). 
 There are several alterations in the kinase domain of Ryk/Drl that suggest that it lacks 
activity: (i) the first GxGxxG motif is altered, (ii) the DFG motif is replaced with the sequence D-N-
A in Ryk and D-S-A in Drl, and (iii) the alanine in VAIK motif (in the ATP-binding pocket) is 
replaced by phenylalanine in Ryk and by leucine in Drl.  Efforts to characterize the kinase activity 
of Ryk/Drl so far all seem to suggest that the kinase domain in Ryk/Drl is completely kinase-dead 
(by contrast with the pseudokinase ErbB3, which still has a low-level kinase activity (Shi et al. 
2010)).  For example, a lysine to alanine Drl mutant (K371A), which would be presumed to disrupt 
the active conformation of the kinase (and abolish kinase activity), did not alter the phenotype 
associated with wild-type Drl (Yoshikawa, Bonkowsky, and Kokel 2001; Taillebourg et al. 2005).  
This variant appears to function competently in Drosophila axon guidance and muscle attachment 
assays, suggesting Drl/DWnt5 signaling doesn’t require the kinase activity of Drl.  Similarly, a 
TrkA-ECR/Ryk-ICR chimeric protein did not show any phosphorylation upon stimulation by NGF, 
the ligand for TrkA – again suggesting that Ryk is kinase-dead (Katso, Russell, and Ganesan 
1999). 
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Figure 3.1 WIF domains in Ryk and Derailed.  A: Domain architecture of Ryk and Derailed. WIF: 
Wnt inhibitory factor domain; S/T rich: serine/threonine rich motif; PTK: protein tyrosine kinase 
domain.  B,C: Sequence alignment of WIF domains in Derailed, Ryk and human Wnt inhibitory 
factor-1 (B), and of Derailed, Doughnut and Derailed-2 in Drosophila (C). 
 Given the evidence for DWnt5/Drl signaling events and the lack of kinase activity in Drl, it 
seems likely that Ryk/Drl signals through a mechanism that differs from that of other RTKs.  
Moreover, other studies have suggested the inactive kinase domain in Ryk/Drl is competent for 
signaling in several contexts.  For instance, the kinase domain of Ryk fused with a nuclear 
localization signal (NLS) can functionally replace full-length Ryk to determine cell fate in neural 
progenitor cells (Zhong et al. 2011).  The TrkA-ECR/Ryk-ICR chimeric protein is able to activate 
the MAPK pathway and induce Erk phosphorylation in response to NGF (Katso, Russell, and 
Ganesan 1999).  Importantly, the chimeric protein with a K334A mutation abolished Erk 
phosphorylation, suggesting it is likely to be the conformation, rather than the activity, of the 
kinase domain that plays the role in Ryk/Drl signaling, since the K334A mutation, which disrupts a 
key salt-bridge, might significantly alter the conformation of the kinase domain.  In Drosophila, it 
has been shown that the Src family kinases are required for DWnt5 signaling in the embryonic 
central nervous system (Wouda et al. 2008), leading to a hypothesis that the pseudokinase 
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domain in Ryk/Drl may function as a scaffold protein to allosterically regulate an associated 
kinase (Src in this case) (Wouda et al. 2008).  Despite these clues, the detailed molecular 
mechanism as to how Wnt binds to and activates Ryk/Drl and how Ryk/Drl signals remains to be 
determined. 
3.2 Expression and Purification of Drosophila Wnt5 protein 
One big obstacle in studying Wnt family proteins and their receptors biochemically and 
structurally is the difficulty of over-expressing and purifying Wnt proteins.  This is thought to be 
due in part to the post-translational modifications of Wnt (lipidation in particular), which usually 
generates insoluble protein samples in in vitro experiments.  While we have experienced the 
same technical difficulty in expressing mammalian Wnt proteins, our efforts in screening various 
expression systems and Wnts from various species led to success in generating milligram 
quantities of soluble Drosophila Wnt5 protein that can be purified to homogeneity. 
 We expressed the full-length DWnt5 protein from Drosophila Schneider 2 (S2) insect 
cells.  We initially tested two expression systems in S2 cells, a metallothionein promoter-based 
inducible system with pMT-based plasmids, or pUAST plasmids (with co-transfection of pAc-
GAL4 to drive the expression and pCoHygro for selection).  The latter system yielded slightly 
higher amounts of protein from S2 cells. 
 To further facilitate biochemical and crystallographic studies of DWnt5, we next 
engineered a second generation of DWnt5 constructs (depicted in Figure 3.2), in order to improve 
protein yield and purity.  We observed that the N-terminal domain (~450 residues) of full-length 
DWnt5 protein is cleaved in generation of the mature protein.  The cleavage might be 
heterogeneous, and the resulting mature protein contains a disordered region N-terminal to the 
beginning of the Wnt homologous domain (based on our HX-MS experiments with DWnt5).  In 
addition, there is a unique insert in the Wnt-homologus domain in DWnt5, which appears to have 
no sequence homology to any known motifs.  Based on these observations, I introduced a TEV 
cleavage site at the beginning of the Wnt-homologus domain (Figure 3.2), to allow removal of the 
disordered remainder of the N-terminal domain in the full-length protein after cleavage.  In 
addition, I engineered a hexa-histidine tag in the insert region to facilitate affinity purification.  I 
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also engineered a construct in which the predicted disordered region in the insert was removed, 
with the intention of generating a ‘minimal’ Wnt protein construct for crystallography. 
 
 
Figure 3.2  DWnt5 constructs used for expressing DWnt5 proteins from Drosophila Schneider 2 
cells.  The full-length DWnt5 is composed of a signal peptide, a large N-terminal domain that is 
removed by cleavage in generating the mature protein, and a Wnt-homologous domain with an 
insert domain of ~150 residues that is unique among all Wnt-family proteins. 
 
I purified DWnt5 protein that had been secreted by transfected S2 cells using a low-resolution 
cation exchange step (SO3 column), followed by a high-resolution cation exchange step (SO3 
column), a hydroxapatie (CHT) column and finally a gel-filtration column, as described in detail in 
Section 3.9.2 below.  These purification steps led to reasonably pure protein that gave two major 
bands on Coomassie-stained SDS-PAGE gels.  Western blotting confirmed that both bands 
contained a key epitope close to the C-terminal end of the N-terminal region.  In order to 
determine which species correspond to these two bands, I used mass spectrometry to ‘sequence’ 
these two bands.  Each band was extracted from the SDS-PAGE gel, destained, reduced, and 
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digested with trypsin.  The sample was then loaded to an Orbitrap ESI-MS spectrometer, and 
spectra were collected using standard protocols.  The resulting peptides were compared 
unbiasedly with a Drosophila proteome database.  As illustrated in Figure 3.3, the spectral counts 
analysis of the MS data suggest that the two major bands on the gel are indeed DWnt5 proteins.  
However, the upper band appears to contain predominantly the N-terminal domain of full-length 
DWnt5 based on peptide counts, whereas the lower band comprises primarily the ‘mature’ Wnt 
homologous domain-containing protein that should result from the cleavage of N-terminal portion.  
Why a protein containing primarily the N-terminal region would run at the higher molecular weight 
is not clear. 
 
Figure 3.3  Coomassie Blue-stained gel of purified DWnt5 protein (left) and mass spectroscopic 
analyses of the two major DWnt5 bands on the gel (right).  The mass spectrometry experiments 
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were performed at the Proteomics Facility in the Wistar Institute.  A in-house developed script 
was used to analyze the raw data and to generate peptide plots. 
Although our purification still has significant room to improve, the DWnt5 sample is sufficiently 
pure for most biophysical assays of activity.  In order to further purify the protein, an orthogonal 
purification step will need to be added, perhaps employing a different tag, or a column with 
different chemistry. 
3.3 DWnt5 binds directly to Drl 
In parallel to expressing and purifying DWnt5, we succeeded in expressing the isolated 
extracellular regions of Drosophila Drl (sDrl), Drl-2 (sDrl-2) and Dnt (sDnt) by secretion from 
insect cells (see Section 3.9.1).  Using surface plasmon resonance (SPR), we were able to 
demonstrate direct interactions between each of these proteins and wildtype purified DWnt5 
(Figure 3.4, work done by Dr. Fumin Shi in the lab).  Either sDrl or DWnt5 was covalently 
immobilized on a Biacore CM5 chip, and the potential interacting molecule was flowed over the 
chip while monitoring resonance signal.  By performing SPR assays in two ways – with either 
immobilized ligand or immobilized receptor fragment, we were able to eliminate the possibility of 
that the apparent binding arises from contaminating proteins or artifactual interactions with the 
Biacore chip, and can conclude confidently that DWnt5 binds directly to the extracellular region of 
Drl family RTKs (with a sub-micromolar binding affinity).  
In addition to assessing Drl family binding of wild-type DWnt5, I used similar binding 
assays to analyze binding of the engineered DWnt5 proteins described in the previous section.  
SPR data suggest that the engineered DWnt5 binds to Drl with an affinity comparable with that 
measured for wild-type DWnt5 (Figure 3.4 B).  Due to the higher yield and quality of the 
engineered DWnt5 protein, unless otherwise explicitly stated, the engineered DWnt5 protein was 
used in the rest of the experiments described in this chapter (the engineered construct without 
thehexa-histidine tag).   
It is worth noting that, the binding affinity is likely to be higher than the apparent Kd 
reported for the SPR assays in Figure 3.4, since the DWnt5 protein sample is a mixture of the N-
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terminal domain (which we do not expect to bind receptor) and the Wnt homologous domain (for 
which binding signals are expected). 
 
Figure 3.4  (A) SPR assays of DWnt5 binding to the extracellular regions of Derailed (sDrl), 
Derailed-2 (sDrl-2) and Doughnut (sDnt) (work done by Dr. Fumin Shi in the lab).  Left: DWnt5 
was immobilized on a CM5 chip, and sDrl/Dnt proteins were flowed across the resulting surface 
at different concentrations to measure the surface response unit (RU).  Binding affinities were 
estimated by fitting the data points to a simple single-site specific binding model.  Right: The 
complementary binding experiment in which sDrl or its homologues were immobilized and DWnt5 
was flowed across the chip at different concentrations.  (B) The engineered DWnt5 exhibits 
similar Drl binding affinity compared to the wildtype protein.  
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3.4 Structure and conformational dynamics of sDrl 
Since we were able to purify both DWnt5 and sDrl, and to verify that they interact directly using 
SPR studies, we used these Drosophila proteins as a model system to characterize Ryk/Wnt 
interactions more generally.  We first utilized X-ray crystallography to study the structure of the 
receptor extracellular region, in parallel with hydrogen exchange studies to visualize the dynamics 
of the sDrl WIF domain.  Our crystallographic efforts led to a 2.2 Å resolution crystal structure of 
sDrl-2 (work done by Fumin Shi in the Lemmon laboratory and illustrated in Figure 3.5).  The 
sDrl-2 WIF domain (cyan in Figure 3.5) consists of two α helices and nine β strands, and closely 
resembles the structure of the WIF domain in hWIF-1 domain.  In hWIF-1, a DPPC molecule was 
found co-crystalized in the hydrophobic cavity between the two sheets and α helices (yellow 
cartoon in Figure 3.5).  The existence of this lipid molecule suggested that hWIF might interact 
with lipidated Wnt molecules through this hydrophobic cavity (Malinauskas et al. 2011).  By 
contrast, there is neither a lipid molecule nor a central cavity in the sDrl-2 structure, arguing that 
the basis for Wnt binding may be different in this case.  Moreover, the hydrophobic residues 
mediating the interactions with DPPC in hWIF are not conserved in the sDrl-2 structure.  Thus, 
although sDrl-2 exhibits a similar structure to the hWIF1 WIF domain, it seems likely to bind to 
DWnt5 by a different mechanism. 
 It is worth noting that the two α helices in hWIF-1 crystal structure differ slightly in length 
and orientation from their counterparts in the solution NMR structure of hWIF-1 (Figure 3.5, red 
and yellow cartoons) (Liepinsh et al. 2006).  In the hWIF-1 crystal structure, helix α1 and α2 
appear shifted inwardly and outwardly, respectively, in order to accommodate the bound DPPC 
molecule.  In sDrl-2, although no DPPC was bound in the structure (and there is no cavity to 
accommodate it), the positions of α1 and α2 are very similar to those in hWIF-1 crystal structure.  
This may suggest that these two helices are mobile, and may play some role in Drl/DWnt5 
interactions.  Given the potential importance of these two helices, I next performed hydrogen 
deuterium exchange (HX) coupled with mass spectrometry (HX-MS) experiments to characterize 
the conformational dynamics of the sDrl WIF domain. 
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Figure 3.5  Crystal structures of WIF domains.  Left: crystal structure of the Derailed-2 WIF 
domain; Middle: NMR structure of hWIF-1 WIF domain (PDB: 2D3J); Right: crystal structure of 
hWIF-1 WIF domain (PDB: 2YGN).  
In HX-MS studies, the backbone amide hydrogen exchange rate is characteristic of the local 
environment of the amide group.  Generally speaking, amide hydrogens in unstructured regions 
exchange faster than those in structured region (in a hydrogen bond), and amides in structurally 
rigid regions exchange slower than those in structurally dynamic regions (Skinner et al. 2012).  By 
discerning these differences, the hydrogen exchange rate can provides rich information for both 
structure and conformational dynamics of proteins.  I performed HX-MS studies on sDrl 
N63Q/N143Q, a double mutant that lacks two N-glycosylation sites (and therefore has better 
peptide coverage compared to wild-type sDrl) yet fully retains DWnt5 binding capacity.  As shown 
in Figure 3.6, sDrl-derived peptides exhibit a wide range of exchange rates.  For instance, in the 
peptide of residues 134-147 (upper red loop in Figure 3.6), more than half of the amide 
hydrogens were completely exchanged within 10 seconds, suggesting that this region is likely to 
be dynamic and largely unstructured.  On the other hand, residues in the β-strands have low 
exchange rates, indicating that they are relatively stable and rigid, as expected.  Interestingly, the 
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region spanning residues 27-66 (pink in Figure 3.6) displayed a fast exchange rate despite 
including two α helices and two β strands.  In particular, two peptides (residues 52-55 and 52-56, 
shown in pink in Figure 3.6) spanning helix α2 in the model displayed an exchange rate that is 
only slightly lower than that of unstructured peptides.  These data suggest that this region, 
especially around helix α2, is highly dynamic in solution and might constantly sample different 
conformations, even though it appears to be fully folded in the crystal structure of sDrl-2 and its 
derived homology model of sDrl.  
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Figure 3.6  Conformational dynamics of the Drl WIF domain measured by hydrogen exchange 
rates.  For each peptide, the exchange time to exchange half of the protons on the peptide was 
estimated and used to characterize the ‘speed’ of the exchange.  Peptides were clustered based 
on this characteristic time and colored on a sDrl WIF domain homology model based on the lab’s 
structure of the sDrl2 WIF domain.  
3.5 MD simulations of DWnt5 structure 
It took 30 years to get the first molecular picture of Wnt molecule.  In 2012, the Garcia lab 
published the first crystal structure of Wnt.  This structure of Xenopus Wnt8 in complex with (and 
co-expressed with) mouse Frizzled8 CRD domain provided the first view of how Wnt family 
proteins fold, and unveiled a novel mechanism of Wnt/CRD interactions.  The XWnt8 protein is 
composed of two domains, the N-terminal domain (NTD) and a C-terminal domain (CTD).  NTD is 
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largely composed of a helical bundle with a β sheet and a key serine residue (S187) modified with 
a palmitoleic acid acyl chain.  The CTD is composed of a long β strand and an unstructured loop 
with disulfide linkages stabilizing the structure.  The overall shape of XWnt8 resembles a hand – 
a ‘thumb’ and an ‘index finger’ protruding from the ‘palm’ to pinch the two opposite sites of the 
CRD domain that it binds (Janda et al. 2012).   
Despite the significance of this crystal structure, much remains to be learned molecularly.  
For instance, this crystal structure was obtained by co-expressing and co-purifying XWnt8 and 
the mFz8 CRD domain, raising the question as to whether this structure truly represents a 
biologically-relevant complex structure, or might be a kinetically-trapped intermediate.  The ‘loose’ 
interface suggests this possibility.  It is also worth noting that the association appears 
substantially driven by hydrophobic interactions between the long acyl chain on the Wnt molecule 
and the hydrophobic groove on the CRD.  During the biogenesis of Wnts, they are typically first 
acylated, and then either transported for further processing, or directly secreted.  There are 
known ‘chaperone’ type molecules that ‘shield’ the acyl chain before the Wnt finds its binding 
partners, one example being the SWIM protein (Mulligan et al., 2012), a member of the lipocalin 
family.  However, in the co-expression of XWnt8 with mFz8, the mFz8 CRD may function as a 
chaperone molecule to bury the acyl chain of XWnt8, and it is possible that the binding mode 
seen crystallographically may not reflect the binding mode that occurs when the Wnt molecule 
binds to a Fz CRD at the cell surface.  It is equally possible that there is no such Wnt chaperone 
protein.  However, in this case, the XWnt8 structure in the complex shown in Figure 3.7 cannot 
reflect the structure of this Wnt alone in solution.  The long palmitoleic acid chain cannot directly 
protrude into the solvent due to its hydrophobicity.  Therefore, the Wnt must alter its conformation 
(or oligomerization state) from that seen in the XWnt8/mFz8 structure to hide its acyl chain and 
remain solubilized.  In addition, DWnt5 may adopt a different conformation since the conserved 
serine in DWnt5 is not modified (Fumin Shi, unpublished data).  To test these hypotheses and to 
shed more light on the possible structures of Wnt proteins, I conducted molecular dynamics (MD) 
simulations to study the structure and conformational dynamics of Wnt molecule. 
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 I first built a homology model of DWnt5 based on the isolated structure of Xenopus Wnt8 
in the crystal structure.  The resulting homology model resembles XWnt8 except that it has no 
acyl chain.  Next, I performed 50 nanoseconds of MD simulations to allow the homology model to 
‘relax’ in water solvent by sampling its conformational space.  Analysis over the trajectory of the 
molecule suggests that the starting conformation of DWnt5 is not likely to be the stable 
conformation, since the structure of DWnt5 quickly diverged from the conformation at the 
beginning of the simulations – and arrived at a completely different conformation after ~30 ns.  In 
the last 20 ns of the simulations, the overall conformation of DWnt5 did not change significantly, 
as can be manifested by the local fluctuations of the RMSD value (Figure 3.7).  Figure 3.7 plots 
the RMSD (root-mean-square deviation) value of the main-chain carbon coordinates with respect 
to the lowest-energy conformation. The plateau in the plot beginning at ~30 ns indicates the 
convergence of the ‘free’ molecule (not bound to a Fz CRD domain) to a different and more likely 
conformation of DWnt5.  
 Our MD simulations suggest that DWnt5 – without lipid modification – is likely to adopt a 
different conformation than that seen in the XWnt8/mFz8 crystal structure.  In the MD trajectory, 
the ‘thumb’ and ‘index finger’ appear to attempt to ‘grab’ whatever lies between them.  Without a 
CRD in this location, however, the ‘thumb’ and ‘index finger’ ended up making direct contact.  
These observations, summarized in Figure 3.7, lead to a hypothesis that Wnt molecules 
constantly sample conformations by reorienting their ‘thumb’ and ‘index finger’.  For Xenopus 
Wnt8 (and most other Wnts), the thumb is equipped with a very ‘sticky’ chain to grab hydrophobic 
molecules, whereas for DWnt5 a different mechanism might be used for the finger to cooperate in 
‘grabbing’ the binding partner. 
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Figure 3.7 (A) Crystal structure of Xenopus Wnt8 binding to mouse Fzd CRD domain from the 
Garcia lab (Janda et al. 2012).  (B) Molecular dynamics (MD) simulations of DWnt5 in solution. 
Top: plot of the root-mean-square deviation of main-chain atoms in each snapshot with respect to 
the lowest-energy conformation.  Bottom: representative conformations of DWnt5 in the MD 
simulations trajectory.  In the first 30 nanoseconds, DWnt5 is actively sampling different 
conformations by swinging the ‘thumb’ and ‘index finger’.  In the last 20 nanoseconds, DWnt5 
converged on a stable conformation in which the ‘thumb’ and ‘index finger’ contact each other 
directly. 
3.6 Ligand binding interface on Drl 
One key question that we would like to address concerns how Drl recognizes DWnt5.  Knowing 
the structure of the WIF domain in Drl and having a homology model of the Wnt do not provide 
much insight into the structural nature of the complex, and the interactions used.  In order to 
understand how the Drl WIF domain interacts with a non-lipidated DWnt5 molecule, we employed 
both mutagenesis analysis and HX-MS approaches to map the DWnt5 binding interface on sDrl.   
 I performed HX-MS assays for both Drl alone and Drl/DWnt5 complex.  The principle 
underlying the HX-MS approach is that the binding interface of a molecule is exposed to solvent 
when the components are studied alone, but is shielded by its binding partner in the complex.  
Therefore, in HX-MS experiments, peptides showing a decreased exchange rate in the complex 
tend to be located in the binding interface.  As shown in Figure 3.8b, upon DWnt5 binding the 
most significant changes of H/D exchange rates for Drl lay in the region of helix α1, strand β1 and 
part of β2 (residues 2-42) together with helix α2 (residues 52-56).  To a lesser extent, the loop 
connecting strand β2 and helix α2, the loop between strand β3 and β4, as well as strand β3, β4 
and β7 also displayed a decreased rate of exchange.  On the other hand, amide hydrogens 
residing in the rest of the WIF domain (strand β5, β8, and β9) and the C-terminal tail (residues 
162-194) showed essentially no change in protection upon ligand binding.  Therefore, our HX/MS 
data suggest that the regions showing most significant change of hydrogen exchange rate upon 
DWnt5 binding – helices α1, and α2, strand β1 and β2 – are likely to encompass the interface of 
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Drl binding to Dwnt5.  These regions coincide with those that appear to be highly dynamic in 
Figure 3.6.  Therefore, we hypothesize that the dynamic nature of the identified region (helices 
α1, and α2, strand β1 and β2) may play a role in mediating DWnt5 binding.  
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Figure 3.8  Identification of DWnt5 binding interface on Drl WIF domain. A: Representative Drl 
peptides showing significant protection upon DWnt5 binding.  B: cartoon representation of 
conserved residues in a Drl model.  Sidechains of the conserved residues are shown in sticks, 
and colored according to their regions. C: Changes in hydrogen exchange rates of Drl peptides 
upon DWnt5 binding were computed, grouped and colored on a Drl model.  D: SPR-based 
binding assays of point mutations of Drl, measured by flowing the mutants through DWnt5-
immobolized chip (Kd shown in the table). 
 In parallel to HX-MS analysis of Drl binding interface, we introduced point mutations to 
Drl WIF domain and used SPR-based binding assays to test the effect of each mutation on 
DWnt5 binding.  We picked six residues (E40, L41, F56, V58, E126, and I154) located on an 
evolutionarily conserved surface to mutate to either lysine or glutamate (Figure 3.8 B).  SPR 
results suggested that mutating E126 or I154 had little effect on DWnt5 binding – suggesting that 
the corresponding region (in elements β8 and β9) is not involved in Wnt binding.  Y52E, F56E 
and V58E mutants all showed reduced DWnt binding (~ 50 fold), and an E40K mutant showed 
~10-fold reduction of binding (Figure 3.8 D).  These mutational studies are in excellent agreement 
with the HX-MS results, further supporting the conclusion that the receptor binding interface is the 
splayed corner/helical region and sandwich surface (colored region in Figure 3.8 C), which 
encompasses helices α1 and α2 as well as strand β1 and part of β2. 
 In vivo assays done by our collaborators in Lee Fradkin’s lab also support our identified 
Drl/DWnt5 binding interface.  Drl directs axon pathfinding in fly embryo development.  In an in 
vivo study, wild type or F56E-mutated Drl was introduced into the chromosomal site of Drl to 
generate transgenic flies.  DWnt5-dependent commissural axon switching during embryonic 
development was then assessed.  Whereas wild type Drl was sufficient to drive the majority of 
neurons to cross midline normally through the posterior commissure to switch to the adjacent 
anterior commissure, overexpression of the F56E mutant (mutated in the binding interface) did 
not support axon switching (unpublished data), suggesting that the mutation abolished Drl’s 
signaling capacity – presumably due to a loss of DWnt5 binding. 
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3.7 Efforts to identify binding interface on DWnt5  
My MD simulations of DWnt5 suggest that the unbound, non-acylated DWnt5 molecule may 
adopt a conformation that differs from that for XWnt8 seen in the XWnt8/mFz8 complex crystal 
structure.  This raises an important question: what is the binding site on DWnt5 that interacts with 
the Drl WIF domain?  Is it in a different location from the interface on XWnt8 that interacts with 
the mFz8 CRD ?  Indeed, given the lack of lipid modification, the binding interface on Wnt for Drl 
WIF domain binding may be significantly different from that for CRD binding.  In order to address 
this question, I initiated efforts to perform HX-MS analysis to map the WIF domain-binding 
interface on DWnt5. 
 Although such an approach successfully led us to the Drl/DWnt5 binding interface on Drl, 
my pursuit of the interface on DWnt5 itself turned out to be difficult.  The biggest challenge is a 
technical one.  In a typical HX-MS experiment setup, the protein sample needs to be denatured 
and then cleaved by proteases (usually pepsin) to generate many overlapping peptides for LC-
MS/MS analysis.  The cleavage procedures need to be conducted at low-temperature in a low-pH 
solution for a very short period of time, in order to minimize back exchange of amide protons 
which confounds the method – and the deuterium incorporated at amide groups starts to 
exchange back with solvent protons immediately once the sample is removed from D2O solution.  
At the same time, all of the disulfides need to be cleaved, since the mass spectrometer cannot 
faithfully determine the primary sequence of disulfide-containing peptides.  Unfortunately, the low-
temperature and low-pH conditions disfavor the disulfide reduction reactions required for this.  
The problem is further aggravated when the protein sample has disulfide-rich region, because 
complete reduction of multiple disulfides in one peptide is much less likely than reducing one 
disulfide per peptide.  Indeed, my data suffered greatly from this problem when attempting to 
collect HX-MS data for DWnt5.  Figure 3.9 illustrates my initial peptide coverage map of DWnt5.  I 
was able to identify ~ 100 peptides, over the region of the protein containing no disulfides.  As 
can be seen in Figure 3.9, the peptides corresponding to disulfide-rich regions were poorly 
identified.  Unfortunately, these regions are also the most interesting regions since they constitute 
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the ‘thumb’ and ‘index finger’ that ‘pinch’ the frizzled CRD domain in the XWnt8/mFz9 complex 
structure. 
 I aimed to improve peptide coverage using two different approaches.  First, I screened 
conditions for enhancing HX-MS compatible disulfide reduction.  In a typical HX-MS experiment, 
~10-50 mM TCEP (tris-2-(carboxyethyl)phosphine) was used as a reducing agent in the 
quenching solution (used to stop the HX reaction – see Section 3.9.4), which is usually buffered 
at pH 2.4.  Increasing the concentration of TCEP in this solution could in principle speed up the 
reduction reaction.  However, TCEP is a strong acid (in the form of TCEP-HCl), and a high 
concentration of TCEP significantly alters the acidity in the solution.  After screening various 
combinations of TCEP concentration, buffer concentration and optimal pH value, I arrived at a 
condition containing 500 mM TCEP, pH 2.8 with 500 mM glycine/HCl as buffer agent.  Under this 
condition, I was able to maximize the number of reduced peptides while not having significant 
back exchange effects.  Secondly, I optimized data acquisition in order to collect MS spectra for 
as many reduced peptides as possible.  In the MS setup used for these studies (and most 
Orbitrap mass spectrometers), the LC-MS/MS data collection uses a scheme called data 
dependent acquisition (DDA).  That is, at each slice of time, a fixed number of precursor ions are 
selected based on their signal intensities – and are subjected to a second stage of tandem mass 
spectrometry.  Because of incomplete reduction, disulfide-containing peptides tend to have lower 
abundances compared to those without disulfides, and thus tend to show lower m/z intensity in 
the initial mass spectrum.  As a result, even though they are partially reduced, their relatively low 
abundance in the initial spectrum causes the disulfide-containing peptides not to be selected by 
the DDA scheme.  To tackle this issue, I changed the DDA rule so that all reduced peptides are 
selected once detected – no matter how low abundant they are.  In order to implement this DDA 
rule, the elution time of these peptides must be known, so that DDA can select the relevant ions.  
The complete list of all reduced peptides and their elution time is compiled by performing several 
rounds of regular MS/MS experiments with a fully reduced protein sample.  At the same time, I 
compiled another list containing high-abundance contaminant ions.  With these two lists, I could 
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instruct the DDA scheme to ignore high-intensity contaminant ions and select only those (lower-
level) reduced peptides that we are interested in. 
 Figure 3.9 summaries the new coverage map of DWnt5 after incorporating these two 
approaches.  The coverage was significantly improved, as expected – with ~180 peptides 
representing the DWnt5 molecule (i.e. ~80 more peptides).  More importantly, the disulfide-rich 
region (‘thumb’ and ‘index finger’) are better covered.  I next performed H/D exchange 
experiments in an effort to identify the Drl-binding interface on DWnt5.  Despite my efforts – and 
partial success – in improving the coverage map, I found in the H/D exchange experiment itself 
that many low-abundance peptides disappeared.  This is likely due to the further spreading of the 
isotopic distribution of those peptides upon HX that effectively reduces the intensity of the peaks 
further, and makes them harder to detect.  Among the peptides that I could detect, I was unable 
to find any that showed a significantly altered H/D exchange rate upon Drl binding, suggesting 
that these covered regions are not likely to be in the binding interface (Figure 3.10).   
 
 
Figure 3.9  DWnt5 peptide coverage.  Compared to the original DWnt5 peptide coverage map 
(top, ~ 100 peptides), the new coverage (bottom, ~ 180 peptides) is significantly improved by 
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using optimized reduction conditions and specific rules for data acquisition.  The cysteines are 
explicitly labeled along the residue number to indicate the disulfides.   
 
Figure 3.10  Hydrogen exchange data of peptides colored in red have been fully collected, which 
showed unaltered exchange rate upon binding of Drl WIF domain, suggesting these regions in 
red are not likely to be the binding interface for Drl.   
3.8 Conclusions 
In this chapter, I aimed to study the molecular basis for Ryk/Wnt signaling, in particular trying to 
understand how the Wnt molecule binds to Ryk family extracellular region.  We used the 
Drosophila Drl/DWnt5 system as a model to characterize the molecular mechanisms of Wnt5 
binding to Ryk WIF domain.  We were able to generate milligrams of purified DWnt5 protein, and 
characterized the surface of the Drl WIF domain to which it binds.  Using a combination of 
hydrogen exchange experiments and MD simulations, we also characterized the structure and 
conformational dynamics of Drl WIF domain and DWnt5 structure.  Our efforts to identify the 
binding interface on DWnt5 failed to locate the surface of the DWnt5 molecule that associates 
with the Drl WIF domain, due to the limited peptide coverage of DWnt5.  However, the limited HX 
data we collected so far implied the regions that are unlikely to be the binding interface (the red 
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regions in Figure 3.10).  While the exact Drl binding interface (and mechanism) on DWnt5 
remains to be revealed, our MD simulations suggest that DWnt5 might exhibit different 
conformation and/or conformational dynamics compared to Xenopus Wnt8 in the crystal 
structure, therefore there might exist a novel binding mechanism for Drl/DWnt5 binding.  
 
3.9 Experimental procedures 
3.9.1 Expression and purification of Drl, Drl2 and Dnt 
A PCR product encoding the 6xHis tagged Drl extracellular region (sDrl:  residues 1-242) was 
subcloned into the pFastBac1 plasmid (Invitrogen).  The extracellular regions of Drl-2 (sDrl-2:  1-
183) and Dnt (sDnt:  1-208) with a C-terminal 6xHis tag were also subcloned into pFastBac1 in 
the same way (done by Dr. Fumin Shi in the lab).  Recombinant baculoviruses were generated 
using the Bac-to-Bac system (Invitrogen) as instructed by the manufacturers to infect Sf9 insect 
cells.  Cell medium was harvested three days after infection and subjected to diafiltration at 4˚C 
against buffer (50 mM HEPES pH 7.5, 150 mM NaCl).  Histidine-tagged protein was then 
collected from the medium using a Ni-NTA affinity column (Qiagen).  For sDrl purification, the Ni-
NTA resin with bound protein was washed twice with low-imidazole buffer (20 mM HEPES pH 
7.5, 150 mM NaCl and 15 mM imidazole) and sDrl protein was then eluted from the Ni-NTA resin 
using buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl and 100 mM imidazole.  sDrl 
protein was further purified using a UnoQ anion exchange column (BioRad), loading the protein 
on to the column in 20 mM HEPES pH 7.5 and 70 mM NaCl, and eluting with a gradient from 70 
mM to 1 M NaCl in this buffer.  A Superose 12 sizing column (GE Healthcare) was used for a final 
purification step, run in 10mM HEPES pH 7.5 containing 150mM NaCl.  The final protein yield 
was ~ 1mg/liter of medium.  Other sDrl variants and Drl homologs are purified with a similar 
strategy.  All purifications were performed at room temperature. 
3.9.2 Expression and purification of DWnt5 
DNA encoding full-length DWnt5 was sub-cloned in pUAST plasmid (gift from the Lee Fradkin 
lab).  For expression of engineered Dwnt5 proteins, similar pUAST constructs were generated 
 
 
92 
using Quick Change (Stratagene) mutagenesis.  Drosophila S2 cells were then stably transfected 
with a mixture of three plasmids (i) pUAST-DWnt5, (ii) pAc-Gal4 and (iii) pCoHygro 
(10µg:10µg:1µg) using the calcium phosphate method, and were selected in Schneider’s medium 
(Sigma) supplemented with 10% fetal calf serum (Sigma, Cat# F0643) and 300 µg/ml hygromycin 
(Cellgro) for 3 weeks.  Schneider’s cell medium was then replaced with ESF921 serum-free 
medium (Expression Systems) for subsequent cell culture.  For DWnt5 expression, cells were 
seeded at 2x106 cells/ml in spinner flasks.  After 5 days of growth at 24˚C, spinning at 2,000 g, 
medium (~3 liters) was harvested and flowed through a 4 ml Fractogel SO3 (EMD) cation 
exchange resin at 4˚C.  The column was then washed twice with 10 ml of wash buffer (20 mM 
HEPES pH 7.5, 250 mM NaCl).  DWnt5 was eluted from the SO3 column with 3x 4 ml elution 
buffer (20 mM HEPES pH 7.5, 900 mM NaCl).  The protein solution was then diluted with 3 
volumes of 20 mM HEPES pH 7.5 buffer to lower the NaCl concentration to <250 mM.  All 
subsequent purification steps were performed at room temperature.  The protein sample was next 
loaded onto a self-packed 2 ml Fractogel SO3 column pre-equilibrated with 20 mM HEPES, 
pH 7.5 containing 150 mM NaCl, developed with a gradient from 150 mM to 1 M NaCl in 20 mM 
HEPES pH 7.5 (DWnt5 elution peak around 650 mM NaCl).  Eluted fractions were then diluted 
again with 3 volumes of 20 mM HEPES pH 7.5 buffer, loaded onto a ceramic hydroxyapatite, type 
1 (CHT2-1) column (BioRad) equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl, 2.5 mM 
NaH2PO4, 2.5 mM K2HPO4.  A 0-100% gradient of Buffer B (250 mM NaH2PO4, 250 mM K2HPO4 
and 150 mM NaCl, pH 7.5) was used to elute the protein.  Finally, eluted fractions were pooled 
together, concentrated, and loaded onto a Superose 6 column (GE Healthcare) with running 
buffer containing 10 mM HEPES pH 7.5 and 150 mM NaCl.  Judged by its ability to binding to Drl, 
purified DWnt5 protein could be flash frozen in the presence of 10% glycerol with no significant 
aggregation or loss of sDrl-binding activity upon thawing. 
 
3.9.3 Molecular dynamics simulations of DWnt5 
For MD simulations of DWnt5, a homology model of DWnt5 was generated based on the 
Xenopus Wnt8 crystal structure (PDB: 40fa), using the software Modeller (Webb and Sali 2014).  
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The disulfide linkages in DWnt5 were determined by comparing those with the disulfides in 
XWnt8 crystal structure.  The homology model of DWnt5 was then energy-minimized, first in 
vacuum and then in a solvent box with constraints on the water molecules, and finally in a solvent 
box without solvent constraints.  The system was then slowly heated up from 0 K to 300 K over 
the course of 3 nanoseconds, followed by constant temperature equilibrium, constant pressure 
equilibrium run at 300 K and 101.325 kPa for 50 nanoseconds.  Amber99SB force field was used 
for the protein molecule (Cornell et al. 1995).  Trajectory analysis was performed using the VMD 
package (Humphrey, Dalke, and Schulten 1996) and in-house developed Tcl scripts. 
3.9.4 Hydrogen exchange experiment of Drl/DWnt5 
For HX-MS studies of sDrl, the H/D exchange (HX) reaction was initiated by mixing the sDrl 
N63Q/N143Q double mutant protein stock (28.5 µM) into 96% D2O solution containing 150 mM 
NaCl at a ratio of 1:4 (v:v).  For the study of sDrl/DWnt5 complex, a protein mixture containing 
28.5 µM sDrl and 29.5 µM DWnt5 was diluted into 96% D2O (150 mM NaCl).  The final 
concentrations of sDrl and DWnt5 in the exchange reaction were 5.7 µM and 5.9 µM, 
respectively.  In both studies, the pD of the HX reaction solution was estimated to be 7.2 (pHread + 
0.4).  The HX reactions were carried out at 0°C.  At each specific time point (10 s, 102 s, 103 s, 
104 s and 105 s), an aliquot of 15 µl of the reaction mixture was quenched by adding 45 µl quench 
solution (1.5 M GdmCl, 50 mM TCEP, 0.8% formic acid and 10% glycerol, pH 2.2).  As controls, 
non-deuterated (‘all-H’) and fully deuterated (‘all-D’) samples were prepared in the same way.  All 
samples were frozen in liquid nitrogen immediately after adding quench solution.  For the studies 
of binding interface on DWnt5, a quenching solution containing 1.5 GdmCl, 500 mM TCEP, 0.8% 
formic acid, 500 mM glycine/HCl and 10% glycerol, at pH 2.8 was used to promote disulfide 
reduction. 
Prior to data collection, the frozen samples were quickly thawed on ice, and injected at a 
flow rate of 100 µl/min into a cooled chamber maintained at 0°C.  Inside the chamber, the protein 
sample was digested by immobilized pepsin (Sigma) beads packed in column housings 
(2 cm × 2 cm, IDEX).  The digested peptides were flowed through a Piccolo microbore C18 
column (trap column) to desalt the peptide fragments.  An acetonitrile gradient (10-55% 
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acetonitrile, 0.1% TFA) was then used to elute the peptides off the trap column and into an 
analytical C18 column (5 cm × 0.3 mm, Higgins Analytical).  The eluent was directly flowed into a 
mass spectrometer (Thermo LTQ Orbitrap XL) for electrospray ionization.  A tandem MS (CID 
mode) run was carried out for the ‘all-H’ sample in order to identify the primary sequence of 
digested peptides. 
The SEQUEST algorithm (Bioworks, version 3.3.1) was used to identify peptides from 
tandem MS data.  The MATLAB-based software ExMS (Kan et al. 2011) was used to validate the 
peptide assignment and subsequently to compute the centroid of isotopic distribution of each 
deuterated peptide.  An ‘All-D’ sample was included to calibrate back-exchange of the deuterated 
samples.  The detailed ExMS-based data collection and processing workflow were described by 
Kan et al. (Kan et al. 2011).  NumPy and Matplotlib were used to export ExMS results to the 
Python environment for further data analysis and plotting.  To assess the difference in HX rates 
for sDrl –derived peptides in the absence and presence of DWnt5, the difference in number of 
exchanged deuterons was calculated for each peptide at each time point.  The maximum 
difference among all of the time points was further divided by the number of amide hydrogen 
atoms on the peptide.  This computation results in a weighted relative difference of amide 
hydrogen exchange rate of each sDrl peptide.  This approach takes into consideration the wide 
range of HX rates and the possibly multiple secondary structure components within one peptide, 
and therefore represents the change of amide hydrogen protection upon DWnt5 binding.  To 
visualize the differences, each peptide was color-coded on sDrl homology model according to the 
‘weighted relative difference’.  An in-house PyMOL (Delano 2002) script was used to create the 
heat maps of the model. 
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Chapter 4 The role of the carboxy-terminal tail of the EGF 
receptor in kinase activity regulation and linking to the 
downstream signaling network 
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4.1 Introduction 
The carboxy-terminal region of the EGF receptor (EGFR), commonly referred to as the ‘C-tail’, 
plays a crucial role in EGFR-mediated cell signaling.  The C-tail contains all of the known 
autophosphorylated tyrosines in EGFR except for one tyrosine in the kinase domain activation 
loop (Y845).  The phosphotyrosines (pYs) function as docking sites for downstream signaling 
molecules (Gajiwala 2013).  Early studies revealed that the recruitment of these downstream 
signaling molecules is mediated by their SH2 (Src Homology 2) domains and PTB 
(phosphotyrosine binding) domains, which both specifically recognize phosphotyrosines in 
particular sequence contexts (Pawson, Gish, and Nash 2001; Schlessinger and Lemmon 2003).  
Following the discovery of the SH2 domain, extensive studies were conducted in order to 
characterize the binding properties of different SH2 domains in the human proteome.  Many 
different SH2 domains were identified and structurally characterized – from proteins with a variety 
of functions – revealing the broad array of SH2 domain roles in the human proteome.  
Phosphopeptides mimicking phosphotyrosine-containing sequences in receptors were used to 
study the binding affinity and specificity of SH2 domains (Zhou 1993; Songyang and Cantley 
2004).  These efforts lead to the discovery of a proposed ‘code’ that governs SH2 domain binding 
affinity and specificity, with the 3-4 residues immediately C-terminal to the phosphotyrosine 
defining SH2 domain binding specificity. 
Phosphopeptide binding to SH2 domains provides an explanation for how one receptor 
can initiate multiple distinct signaling cascades.  For example, in EGFR, multiple 
phosphotyrosines are arrayed – with different sequence contexts – in such a way that they can 
recruit different downstream binding molecules, possibly with several different SH2 domains 
binding to each EGFR molecule.  The Y992 (using mature protein numbering) site has a ‘code’ 
such that the PLCγ SH2 domains will bind when the tyrosine is phosphorylated, whereas the 
signature sequences flanking Y1068 and Y1086 are associated with binding to the Grb2 SH2 
domain.  This view in which EGFR recruits multiple downstream molecules is now included in 
textbooks.  However, there are several unresolved questions that this textbook view does not 
take into account or address.  For example, current knowledge of the binding affinities and 
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specificities of SH2 domain-mediated interactions is all derived from studies of short 
phosphopeptides.  It is unclear, though, whether phosphopeptides as short and unstructured 
mimetics faithfully recapitulate phosphoproteins in their interactions with these modules.  
Moreover, the phosphopeptides studied experimentally are short, and typically contain only one 
phosphotyrosine – whereas phosphoproteins such as the EGFR C-tail contain multiple 
phosphorylated tyrosines.  It is unclear whether or not these multiple phosphotyrosines in EGFR 
can all bind simultaneously to distinct SH2 domain-containing molecules and initiate different 
signaling cascades.  If so, it is also unknown whether binding of SH2 domains to a single C-tail 
molecule is independent or cooperative, that is, whether binding of one SH2 domain will impact 
the binding of a second (and subsequent) SH2 domain to another phosphotyrosine in the same 
molecule. 
The textbook view also considers the EGFR C-tail as a fully unstructured protein, and 
focuses its function solely on SH2 domain recruitment.  However, there is a body of evidence 
suggesting that the EGFR C-tail is neither completely disordered nor restricted in its function to 
SH2 domain binding.  For instance, using FRET-based approaches it was shown that 
phosphorylation induces conformational changes in the C-tail region, suggesting that the C-tail 
may actually possess some structure (Lee and Koland 2005; Lee, Hazlett, and Koland 2006).  In 
addition, it was reported that sequential deletion of C-tail residues from EGFR results in a 
hyperactive receptor in cell-based assays (Walton et al. 1990; Alvarez et al. 1995).  This finding 
suggests that the C-tail may have an auto-inhibitory function.  Indeed, such a phenomenon in 
which part of the intracellular region in a receptor autoinhibits its kinase domain is not uncommon 
in other RTKs.  The focus of the work described in this Chapter was to discern some details of the 
structure of the EGFR C-tail – asking whether it is completely unstructured or bears some 
conformational features and samples unique conformational ensembles that might contribute to 
its autoinhibitory function.  Another key goal was to understand how C-tail phosphorylation 
impacts its conformation and influence on tyrosine kinase activity. 
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4.2 The EGFR C-tail adopts a unique conformational ensemble 
4.2.1 Circular dichroism spectra of EGFR C-tail protein 
Although the EGFR C-tail is generally considered to be intrinsically disordered, the fact that its 
progressive deletion increases the kinase activity of EGFR hints that the C-tail may have some 
unique conformational features or elements that interact with the kinase domain to limit its activity 
(through autoinhibitory interactions).  In order to test this hypothesis, I first utilized circular 
dichroism (CD) spectroscopy to study the solution conformation of an EGFR fragment that 
contains the complete C-tail (EGFR 960-1186), expressed in E. coli (see Section 4.8.1).  CD 
spectra indeed suggested little in the way of α-helical or β-sheet features (Figure 4.1).  I was 
unable to determine whether there was a fraction of CD signal corresponding to any secondary 
structure, because the random-coil CD signal dominates the spectrum to a degree that does not 
allow faithful extraction of the underlying fractional secondary structure signals (if any exist).   
 Given that the majority of C-tail region lacks secondary structure in solution, I next asked 
the question as to whether this region displays similar random coiled characteristics in a 
molecularly ‘crowded’ environment more reflective of that found inside cells.  It is now widely 
recognized and appreciated that the environment inside cells is tremendously different from the 
dilute solutions typically used for in vitro experiments.  A typical intracellular environment contains 
biomolecules at mass concentrations of up to 300-400 mg/ml (~40% by mass) – a full two orders 
of magnitude higher than in dilute solutions typically used by biochemists.  Proteins can exhibit 
significantly altered conformations and structural stabilities inside cells compared to those in 
dilute solution.  Indeed, intrinsically disordered proteins can show different conformational 
features in molecular crowding conditions (Sotomayor-Pérez et al. 2013; Flaugh and Lumb 2001; 
Cino, Karttunen, and Choy 2012).  I used a solution containing polyethylene glycol (PEG 20K, 
25% m/v), an inert polymer, to mimic the molecular crowding conditions, and collected CD 
spectra of EGFR C-tail in this solution.  Interestingly, the molar ellipticity shown in the resulting 
CD spectrum increased at 220 nm and decreased at 203 nm (Figure 1, cyan curve).  This shift 
indicates an small increased amount of α-helical elements. 
 
 
103 
 
Figure 4.1 Circular dichroism spectra of EGFR C-tail protein in dilute solution (magenta) and 
molecular crowding environment mimicked by 25 % PEG 20,000 (cyan).  The difference spectrum 
(red) suggests a slight shift of C-tail conformation under molecular crowding conditions, 
associated with the acquisition of some helical features. 
4.2.2 Small-angle X-ray scattering analysis of EGFR C-tail protein 
We also used small-angle X-ray scattering (SAXS) to investigate the spatial extent and low-
resolution structure of the EGFR C-tail.  In SAXS analysis, the pairwise distance distribution (P(r)) 
curve can provide a low-resolution structural view of the molecule in solution, providing a map of 
the lengths of all inter-electron vectors in the structure.  The P(r) curve illustrated in Figure 4.2 
suggest an extended structure, potentially as ‘beads on a strong’, with a maximum dimension 
(Dmax) of 130 Å, compared with the expected value of approximately 40 Å (estimate) for a well-
folded globular ~26 kDa protein.  It is worth noting that C-tail samples at different concentrations 
showed slightly different P(r) curves.  This may be due to a slightly altered conformational 
ensemble that C-tail adopts at different concentrations (a linear Guinier region in all these curves 
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eliminates the possibilities of protein aggregation at high concentrations).  In addition, we 
conducted shape reconstruction from these P(r) curves using the software DAMMIF (Franke and 
Svergun 2009).  The envelopes indicate that the EGFR C-tail adopts a rather elongated structure.  
These data are also consistent with gel filtration chromatograms of the C-tail, which also imply a 
large hydrodynamic radius.  
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Figure 4.2 Top: pairwise-distribution curves (P(r)) of EGFR C-tail protein in solution.  Black, red 
and blue curves show the P(r) curves of protein at concentration of 2 mg/ml, 5 mg/ml and 10 
mg/ml, respectively.  The corresponding estimated Dmax values are 130 Å, 135 Å and 140 Å.  
Bottom: representative reconstruction envelops of C-tail protein.  These shapes illustrate 
unstructured yet elongated conformations with ‘beads-on-a-string’ features. 
Taken together, CD spectroscopy and SAXS analyses suggest that, although the C-tail 
protein exhibits little secondary structure, it does explore a restricted conformational ensemble in 
solution.  In other words, not all possible conformations are equally sampled by the C-tail, and the 
sampled distribution is subject to perturbation by protein concentration and the environment. 
4.3 Identification of regions in the EGFR C-tail that are not completely 
disordered 
Although our CD and SAXS studies suggest a restricted conformational ensemble, these studies 
provide no detailed structural information.  For a higher resolution view of the C-tail structure, we 
employed hydrogen deuterium exchange coupled with mass spectroscopy (HX-MS) to assess the 
solution dynamics of the protein.  As mentioned in the previous Chapter, HX-MS monitors the 
exchange rate of amide hydrogens in the protein backbone with hydrogens (or deuterons) in the 
solvent.  The rates measured provide information on the local environment and dynamics of 
amide protons.  Those in stable hydrogen bonds, such as those in secondary structures, show 
slow exchange rates, whereas amide hydrogens in disordered regions exchange much more 
rapidly.  I undertook HX-MS studies on EGFR C-tail protein as well as EGFR-ICR protein, which 
contains the complete intracellular region (with kinase domain and C-tail region, but without the 
intracellular juxtamembrane region). 
I first performed hydrogen exchange experiments covering an exchange time course 
ranging from 10 s to 1x105 s.  This range covers exchange rates for a broad spectrum of 
hydrogens, from unstructured amides to those present in stable secondary structure.  These 
experiments revealed that there are no amides in the C-tail region that show exchange rates 
significantly lower than those of unstructured peptides.  As shown in Figure 4.3 for EGFR-ICR, all 
 
 
106 
amide protons in all peptides within the C-tail region were completely exchanged with deuterium 
within seconds.  This piece of data is consistent with our CD spectroscopy result – showing that 
the C-tail does not have any obvious secondary structure when studied in dilute solution. 
 
Figure 4.3 Hydrogen/deuterium exchange level of peptides in EGFR-ICR protein 10 second (top) 
and 100 second (bottom) after the start of exchange reaction. 
Even though our HX-MS analysis didn’t reveal any well-structured regions, several 
peptides consistently stood out as being slightly protected (peptides that are boxed in the 10 
second data in Figure 4.3).  Although this decrease itself is too slight to be considered significant, 
it prompted us to further the study.  Specifically, in order to distinguish these peptides 
unambiguously from the rest of the fully unstructured ones I utilized a higher time-resolution 
approach established in Walter Englander’s laboratory here at University of Pennsylvania, namely 
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stopped-flow HX-MS.  In contrast to regular HX-MS, stopped-flow HX-MS enables analysis of 
events with a time course down to milliseconds.  Therefore, using this technique it is possible to 
distinguish amides in completely disordered peptides from amides that are slightly protected – 
such as those in loop regions or in unstable secondary structures.  In my stopped-flow HX-MS 
studies, two regions in the EGFR C-tail clearly stood out, while the peptides from the rest of the 
protein showed virtually same exchange rates as theoretical rates calculated from unprotected 
peptides.  Figure 4.4 illustrates hydrogen exchange profiles of peptides corresponding to residues 
979-992 and 1056-1068.  Amides in these two regions exchange approximately 10 fold slower 
compared to their theoretical exchange rate as disordered peptides. 
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Figure 4.4  Representative peptides in stopped-flow HX-MS analysis of EGFR C-tail protein.  Left 
column: peptides exhibiting the same exchange rates as calculated rates for unprotected 
peptides. Right column: peptides that show a 10-fold protection. 
To the best of our knowledge, my stopped-flow data argue for the first time that certain 
regions in the EGFR C-tail are not completely disordered.  Instead, they may form a conformation 
that involves short-lived hydrogen bonds.  In other words, those hydrogen bonds significantly 
reduce the conformational space that the C-tail samples.  It is worth noting that the two slightly 
protected regions both contain well known important tyrosines in EGFR (Y992 and Y1068), which 
are binding sites for the PLCγ and Grb2 SH2 domains respectively.  Therefore, it is possible that 
phosphorylation or SH2 domain binding may affect (or be altered by) the conformations in these 
regions. 
4.4 Phosphorylation of EGFR C-tail promotes receptor dimerization 
Our stopped-flow HX-MS analysis leads to the conclusion that the EGFR C-tail adopts a unique 
conformational ensemble – not all parts of the protein are equally ‘unstructured’.  I next asked 
whether phosphorylation of the C-tail perturbs the conformational dynamics, hypothesizing that C-
tail phosphorylation might serve as switch to regulate its influence on EGFR activity.  Indeed, as a 
precedent for such an effect, a recent study showed that multiple phosphorylation of the protein 
4E-BP2 induced a disordered-to-helical folding transition, which in turn altered the affinity of its 
binding to a substrate (Bah et al. 2014).  To investigate this question, my goal was to determine 
whether phosphorylation alters the structure of the C-tail, or its interactions with the kinase 
domain.  Another key goal was to investigate the interactions of SH2 domains with 
phosphorylated C-tail rather than restricting these studies to phosphopeptides as has typically 
been the case. 
4.4.1 Preparation of phosphorylated C-tail protein 
I first developed an approach to prepare the isolated phosphorylated EGFR C-tail.  Using vesicles 
containing lipids with Ni-NTA head groups, both E coli-derived purified C-tail protein and EGFR 
kinase domain (both 6xHis-tagged) were co-enriched onto the vesicle, significantly increasing the 
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local concentration of the substrate (C-tail) with respect to the kinase domain, and therefore 
promoting the phosphorylation reaction.  Native gel, Phos-tag gel (Kinoshita et al. 2006), and 
mass spectrometry analyses all suggest that the resulting phosphorylation product was heavily 
phosphorylated to near completion (Figure 4.5). 
 
Figure 4.5 A:  Native gel and Phostag gel assays monitoring phosphorylation of EGFR C-tail by 
EGFR’s kinase domain.  B: MALDI-TOF spectra of unphosphorylated and phosphorylated C-tail. 
The mass difference between unphosphorylated and phosphorylated samples corresponds to 
approximately to 8.5 phosphate groups per C-tail molecule on average. 
4.4.2 Analytical ultracentrifugation sedimentation equilibrium experiment of 
phosphorylated EGFR-ICR and isolated C-tail 
Our SAXS analysis of phosphorylated C-tail showed no significant conformational change upon 
phosphorylation when compared to the unphosphorylated protein (data not shown), suggesting 
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that phosphorylation of the C-tail alone does not induce formation of stable secondary structures.  
Nevertheless, we hypothesized that phosphorylation of the C-tail might affect its interaction with 
the kinase domain in full-length receptor – either intramolecularly or intermolecularly.  In other 
words, we hypothesized that phosphorylation of the C-tail might regulate its auto-inhibitory 
influence.  To test this hypothesis, we generated EGFR-ICR protein (containing the kinase 
domain and C-tail region) and phosphorylated it using a similar approach to that used for 
preparing phosphorylated C-tail.  Mass spectrometry suggests all the major sites in EGFR-ICR 
are phosphorylated. 
 We first performed analytical ultracentrifugation sedimentation equilibrium (AUC-SE) 
experiments to characterize phosphorylated EGFR-ICR.  Surprisingly, we found that 
phosphorylation of EGFR-ICR causes it to sediment as a significantly species, as manifested by 
the increased slope in a log plot of AUC-SE data (Figure 4.6 Top).  When these data are fit to a 
simple monomer/dimer equilibrium, the fitting is consistent with a Kd for dimerization of ~15 µM 
for the fully phosphorylated EGFR-ICR protein, whereas dimerization of unphosphorylated EGFR-
ICR is undetectable (implying a Kd > 250 µM).  Since we know both unphosphorylated and 
phosphorylated EGFR kinase domains are monomeric in solution, and no dimerization can be 
detected for EGFR C-tail whether phosphorylated or not (Figure 4.6 bottom), these data suggest 
that phosphorylation of the EGFR C-tail promotes inter-molecular interactions between the kinase 
domain and the (phosphorylated) C-tail region, which promotes dimerization of the already-
activated receptor.  Intriguingly, this would serve as a positive feedback event (activation-induced 
phosphorylation promoting further dimerization and activation), so should impart some switch-like 
character to the EGFR in its response to ligand. 
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Figure 4.6.  Logarithm plots of AUC-SE data. Top: Log plot of unphosphorylated, phosphorylated 
and kinase-dead EGFR-ICR proteins (done by Sung-Hee Choi in the lab).  Phosphorylation of 
EGFR-ICR results in a line with increased slope, suggesting a degree of oligomerization.  Bottom: 
Log plot of unphosphorylated and phosphorylated C-tail proteins. Both samples show lines of 
same slope in the plot. 
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4.4.3 HX-MS analysis of phosphorylated EGFR-ICR protein 
In order to understand how the phosphorylated C-tail might promote dimerization, I performed 
HX-MS to map regions of EGFR-ICR that are responsible for this interaction.  I performed three 
HX-MS reactions in parallel: 
(1) unphosphorylated (his-tagged) EGFR-ICR 
(2) unphosphorylated (his-tagged) EGFR-ICR clustered on Ni-NTA vesicles and 
(3) phosphorylated (his-tagged) EGFR-ICR protein enriched on Ni-NTA vesicles. 
By comparing the HX-MS results from these three sample, the goal was to identify regions in 
EGFR-ICR that are involved in dimerization when phosphorylated – but not affected dimerization 
(on Ni-NTA vesicles) alone.  As shown in Figure 4.7, my HX-MS data unveiled two regions (a.a. 
688-699 and a.a. 764-774) that showed increased protection upon phosphorylation and 
clustering.  Figure 4.7 illustrates HX profiles of overlapping peptides in these two regions.  The 
hydrogen exchange rates for these peptides followed the order: “reaction 1 > reaction 2 > 
reaction 3”.  This suggests that EGFR-ICR dimerization/clustering leads to some protection, and 
that phosphorylation further promotes the protection (or enhances dimerization).  Judging by the 
degrees of change in exchange rates, we infer that the interactions involving these two regions or 
EGFR-ICR are not tight – anticipating that strong interactions would result in slower rates.  In 
addition, we did not find any phosphopeptides within the C-tail region that showed altered HX 
rates upon phosphorylation or dimerization.  This could have due origins:  (1) the HX differences 
in the C-tail region may simply not be large enough to be evident in regular HX-MS experiments, 
and/or (2) the intermolecular interactions may be mediated by phosphate groups on the C-tail, so 
no direct backbone hydrogen bond formation is involved (so no significant HX changes result). 
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Figure 4.7  Hydrogen exchange profiles of peptides in EGFR-ICR phosphorylated and enriched 
on vesicles.  Peptides in two regions in EGFR-ICR (A-D: a.a. 688-699, E-H: a.a. 764-774) 
showed an increased protection upon protein dimerization, and this was further enhanced upon 
protein phosphorylation. 
As mentioned above, the C-tail appears to play some auto-inhibitory function in the full-
length receptor.  Our findings, on the other hand, suggest that phosphorylation of the C-tail could 
enhance EGFR activity by promoting dimerization of the receptor.  The C-tail thus plays two 
seemingly opposite roles in regulating EGFR kinase activity.  This controversy can be reconciled 
by hypothesizing that EGFR requires an ultra-fast yet tightly controlled switch.  In other words, the 
auto-inhibitory role of the C-tail may prevent EGFR from being inadvertently activated by other 
kinases or by another unliganded EGFR molecule.  However, once the ligand-induced receptor 
dimer is formed, a phosphorylated C-tail may not only release its auto-inhibitory check, but might 
also further promote kinase activation once the C-tail is phosphorylated, by enhancing 
dimerization of the receptor.  In this guise, the phosphorylation-promoted enhancement would 
only occur in the correct context, i.e. in a ligand-induced dimer.  Effectively, phosphorylation of 
the C-tail in this model would provide a positive feedback mechanism for EGFR activation, 
rendering it more switch-like. 
4.5 Binding of SH2 domains to EGFR C-tail protein 
It is generally presumed in the field that the question of how and which SH2 domains bind to the 
activated EGF receptor has been ‘solved’.  Upon phosphorylation, the EGF receptor recruits 
downstream signaling molecules to initiate various signaling cascades, such as the Ras/MAPK 
and PI3K/Akt pathways.  Even though this view is well established in textbooks, it is clear that a 
more detailed mechanistic view is missing;  the current textbook view does not account for the 
unique conformational dynamics and effects of phosphorylation of the C-tail found in our studies.  
Moreover, the stoichiometry of SH2 domain binding to the EGFR C-tail has not been established, 
and it is not known whether SH2 domain-containing proteins bind independently to the 
phosphotyrosines in the C-tail, or show some negative (or positive) cooperativity.  Indeed, some 
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studies have suggested that Cbl and Grb2 bind cooperatively to the EGFR C-tail (Sigismund et 
al., 2013). 
We reasoned that binding of an SH2 domain to the phosphorylated C-tail should 
influence or perturb its sampling of the conformational ensemble, which in turn might favor or 
disfavor the binding of other SH2 domains to additional sites in the C-tail.  In addition, restrictions 
in the conformational ensemble may result in SH2 domain binding to a given phosphotyrosine in 
the C-tail being either stronger (if a favorable conformation is stabilized) or weaker (if not) than 
binding to a short phosphopeptide.  Thus, binding affinities of SH2 domains to full-length 
phosphorylated C-tail or EGFR-ICR might be substantially different from those measured for 
phosphopeptides.  The hypothesis that recruitment of one SH2 domain to the C-tail affects 
binding of another SH2 domain to a different pY in the same protein – by perturbing the 
conformational ensemble – has never been tested.  In fact, even the stoichiometry of SH2 domain 
binding to the EGFR C-tail has never been assessed, because the phosphopeptides used in 
previous studies have only contained one phosphotyrosine (or two at most) (Songyang and 
Cantley 2004).  In order to test these hypotheses, I aimed to study SH2 domain binding to 
phosphorylated C-tail protein that spans the entire SH2 domain-binding region.  I expressed a 
handful of relevant SH2 domains in E. coli and purified them into homogeneity.  I then studied 
binding of these SH2 domains to phosphorylated C-tail protein. 
4.5.1 SPR analysis of SH2 domain binding to phosphorylated EGFR C-tail  
I used surface plasmon resonance (SPR) to analyze SH2 domain binding.  SPR requires only 
small amounts of protein sample.  Moreover, it is an ideal technique for quantitative competition 
assays.  I immobilized phosphorylated C-tail on a CM5 chip as described in Section 4.7.6, and 
singly tested binding of individual SH2 domains to the C-tail protein.  We measured binding by the 
SH2 domains from Grb2, PLCγ (N-terminal), PLCγ (C-terminal), and PI3K. Table 4.1 summarizes 
the binding affinity derived from the SPR data. 
 
Table 4.1 Summary of dissociation constant of SH2 domains binding to phosphorylated EGFR C-
tail 
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SH2 domain Kd,app (µM) 
Grb2 0.64 ± 0.18 
PLCγ1-N 18.4 ± 1.2 
PLCγ1-C 0.63 ± 0.12 
PLCγ1-NC 0.28 ± 0.06 
PIK3R-N 18.0 ± 1.8 
PIK3R-C 15.0 ± 1.3 
PLCγ1-C (10 µM Grb2) 88.4 ± 18.4 
Grb2 (5 µM PLCγ1-C) 142 ± 30 
 
The first result evident from these data is that the Kd values obtained for SH2 domain binding to 
the EGFR C-tail are not dramatically smaller than the micromolar range values measured with 
short phosphopeptides .  Although the Grb2 SH2 domain showed a sub-micromolar Kd, this is 
consistent with values obtained in peptide experiments (Marengere et al. 1994).  The finding that 
the PI3K SH2 domains exhibit relatively low binding affinities (18.0 and 15.0 µM for the N-terminal 
and C-terminal SH2 domain, respectively) is also consistent with peptide studie (Zhou 1993).  By 
contrast, my SPR data for the PLCγ SH2 domains was quite surprising.  The C-terminal SH2 
domain from PLCγ1 binds much more tightly to phosphorylated EGFR C-tail than does the PLCγ 
N-terminal SH2 domain (Kd for N-SH2: 18.4 µM, Kd for C-SH2: 0.63 µM).  It is generally reported 
that the N-terminal SH2 domain of PLCγ binds to receptors, while the C-terminal SH2 interacts 
with a phosphotyrosine residue intra-molecularly (although the opposite result is also reported 
sporadically in the literature) (Wahl et al. 1990; Kim et al. 1991; Gresset et al. 2010).  My SPR 
data, however, clearly argue that the full-length EGFR C-tail protein preferentially binds to the C-
terminal SH2 domain of PLCγ1.  I did run mass spectrometry of my samples to rule out the 
possibility that the N-terminal and C-terminal SH2 domain samples were accidentally swapped 
during the experiments. 
 Interesting, when I titrated the Grb2 and PLCγ1-C SH2 domains to a high concentration, I 
could detect additional binding events, although with a much lower binding affinity.  I was able to 
fit the binding curves to a model that consists of multiple binding sites.  For both the Grb2 and 
PLCγ1-C SH2 domains, the additional binding shows a Kd value of approximately 200 µM.  
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Estimation from the measured Bmax value suggests that four molecules of each SH2 domain bind 
to the phosphorylated EGFR C-tail through this low affinity binding, whereas one molecule of SH2 
domain binds with a sub-micromolar affinity.  Although our SPR analysis cannot unequivocally 
determine the binding stoichiometry, and the caveat that this binding might have a non-specific 
component cannot be dismissed, these results do suggest that multiple SH2 domains can bind to 
a single phosphorylated EGFR C-tail, and possibly with distinct affinities.  This also provides an 
explanation for the ‘rebinding’ of SH2 domains observed in single-molecule experiments of full-
length receptor (Oh et al. 2012). 
 In order to test whether binding of one SH2 domain to the EGFR C-tail affects binding of 
a second, I performed a competition assay using Grb2 and PLCγ1-C SH2 domains, both of which 
showed sub-micromolar Kds in my prior SPR experiments.  I titrated one SH2 domain onto a 
surface bearing the phosphorylated EGFR C-tail in the presence of a high concentration (5-
10 µM) of the other.  Since Grb2 and PLCγ1-C SH2 domains are though to bind to different 
phosphotyrosine sites (pY1068 and pY992 respectively), if these two SH2 domains bind 
independently to the C-tail, it is to be expected that the presence of an excess of another SH2 
domain should not affect the binding curve – and that it will appear similar to that measured for 
binding of a single SH2 domain.  Quite surprisingly, my competition assay results suggest the 
opposite.  In the presence of 10 µM Grb2 SH2 domain, the PLCγ1 C-SH2 domain appears to bind 
phosphorylated EGFR C-tail with a very low affinity, yielding a Kd value of 88.4 µM (Figure 4.8).  
Similarly, the Kd measured for binding of the Grb2 SH2 domain is increased from 0.64 µM when 
studied alone to a Kd of 142 µM when the experiment is performed in the presence of 5 µM 
PLCγ1-C SH2 domain.  These data clearly argue that the Grb2 and PLCγ1-C SH2 domains 
compete for binding to the phosphorylated EGFR C-tail.  Since their Kd values are similar for their 
respective sites, it seems very unlikely that simple competition for the same set of sites would 
cause the presence of 5-10 µM competitor to elevate Kds for the Grb2 and PLCγ1-C SH2 
domains to the 100 µM range.  Rather, given that the Grb2 and PLCγ1-C SH2 domains also have 
distinct binding sites on the C-tail, it seems possible that binding of one SH2 domain to its specific 
site on the C-tail alters the C-tail conformation (or conformational dynamics) in a way that 
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disfavors binding of the other SH2 domain in a form of negative cooperativity – contrary to the 
positive cooperativity suggested for Grb2 and Cbl (Sigismund et al., 2013). 
 Although this phenomenon requires more investigation, including studies of HX of the 
phosphorylated C-tail (or EGFR-ICR) upon SH2 domain binding, the apparent competition 
between the Grb2 and PLCγ1 SH2 domains suggests that the activated EGFR might be biased 
towards particular pathways – such that a Grb2-bound receptor is diminished in its ability to 
activated PLCγ signaling and vice versa.  Indeed, competition between Grb2 and PLCγ signaling 
has been reported in other contexts – notably in the case of FGFR2 signaling (Timsah et al.  
Ladbury, 2014), although through competition for a different type of binding site in this case. 
 
Figure 4.8 SPR competition binding assays of Grb2 and PLCg-1C SH2 domains. Left: Binding 
curve of Grb2 SH2 domain binding to immobilized phosphorylated C-tail (Kd = 142 µM). Right: 
Binding curve of PLCg-1C SH2 domain binding to phosphorylated C-tail (Kd = 88.4 µM). 
 
4.5.2 SAXS analysis of SH2 domain binding 
Although SPR data suggest the existence of both high-affinity and low-affinity binding sites for a 
single SH2 domain on the EGFR C-tail, this approach does not allow us to observe these 
interactions directly, provides no structural information, and may suffer from surface binding 
artifacts.  To study SH2 domain binding to the EGFR C-tail in solution, I further analyzed the 
interactions using small angle X-ray scattering (SAXS).  I chose Grb2 SH2 domain for the SAXS 
studies because it is one of the widely studied SH2 domains and its ‘binding code’ is well 
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understood.  In SAXS experiments, the forward scattering intensity (I0) is a function of the 
concentrations and masses of all the species in solution.  By titrating one molecule into a solution 
containing a constant concentration of its binding partner, it is possible to measure the weight-
averaged molecular mass of all of the species in the solution (assuming a simple mixture), and 
from that the binding affinity and stoichiometry can be extrapolated.  Such an approach was 
previously used successfully to discover the 2:2 stoichiometry of EGF binding to EGF receptor 
(Lemmon et al. 1997).   
 I prepared mixtures of the Grb2 SH2 domain and phosphorylated EGFR C-tail at different 
molar ratios of 1:0, 1:0.5, 1:1, 1:1.5 and 1:2 (C-tail:SH2), with a fixed concentration of 
phosphorylated C tail (50 µM).  I then measured the forward scattering (I0) of each sample by 
extrapolating a Guinier plot back to zero angle.  The resulting I0 values were normalized for mass 
concentration of protein, and plotted with respect to the added molar ratio of Grb2 SH2 domain.  
As shown in Figure 4.9, the normalized I0 plot peaked at a molar ratio of 1:1, suggesting that 1:1 
is the binding stoichiometry in solution.  I did not observe the additional weaker binding events in 
these SAXS experiments – which were performed at a significantly lower concentration (50 µM) 
than their estimated Kd (~200 µM). 
 
Figure 4.9  SAXS I0 titration of Grb2 SH2 domain binding to phosphorylated EGFR C-tail protein.  
The peak I0 centered at ratio 1 suggests a 1:1 binding stoichiometry. 
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Both my SPR and SAXS analyses suggest that Grb2 has just one relatively high-affinity binding 
site on the phosphorylated EGFR C-tail.  Based on peptide experiments, however, it is generally 
considered that Grb2 has two canonical binding sites in the EGFR C-tail: pY1068 and pY1086 
(Zhou 1993).  The fact that my studies suggest only a 1:1 stoichiometry may reflect a half-of-the-
sites negative cooperativity in which binding of the Grb2 SH2 domain to one site renders the 
other site in the C-tail inaccessible for binding – or altered in conformation such that the affinity of 
Grb2 SH2 domain binding is greatly reduced.  Either simple steric hindrance (given the short 
distance between the two sites) or a perturbed conformational ensemble could lead to the 
observed 1:1 stoichiometry. 
4.6 EGFR signaling network with multiple SH2 domains involved 
The EGF receptor is a node for many intracellular signaling pathways and networks.  Indeed, one 
can construct a highly wired graph by incorporating protein species that have been reported to 
interact directly and indirectly with EGFR (Oda et al. 2005).  Such a graph involves components 
involved in virtually all of the essential processes of living cells.  Despite its central role, EGFR 
has relatively few core functions to process its signal inputs (multiple ligands), and to produce 
numerous distinct outputs (downstream events such as cell differentiation and proliferation).  
Moreover, these activities partially overlap with other ErbB family receptors (Jones et al. 2006; 
Schlessinger 2000).  Thus, a key question arises as to how EGFR can regulate so many types of 
cell events with a not-so-complicated ‘processing core’.   
 To tackle this question, it is now becoming clear that understanding EGF receptor 
signaling – or signaling by any RTK – requires quantitative analysis at systems level (Lemmon 
and Schlessinger 2010).  Components involved in EGFR signaling are highly interconnected via 
various positive and negative feedback mechanisms.  Thus, understanding EGF receptor 
signaling network is extremely challenging.  Firstly, modeling a highly connected system is 
fundamentally difficult.  Mathematically speaking, it involves many NP-complete decision 
problems, that is, they are mathematically proven to be extremely difficult to solve.  Secondly, 
even though a generation of computational biologists has started to develop approximate 
approaches that can efficiently model signaling networks, such methods require a huge set of 
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quantitative parameters, such as protein-protein binding constants, association/dissociation rate 
constants, etc..  Many of these parameters are derived from simplified experiments, some are 
based just on assumptions, and few have temporal or spatial information that is crucial for a 
complete deterministic model.  Thus, this methodology – using simplified data and assumptions 
to model complicated systems – may be fundamentally flawed.  I would argue that this is indeed 
the case in EGF receptor signaling simulations.  A typical simulation setup usually utilizes SH2 
domain binding constants derived from peptide experiments.  In addition, the binding 
stoichiometry and binding cooperativity of multiple SH2 domains are usually not considered.  I 
hypothesize that these finer-grained details should play important roles in regulating the 
downstream signaling networks, and thus are not negligible – so neglecting them is a major 
problem. 
 In order to test this hypothesis, I performed ordinary differentiation equations (ODEs) -
based network simulations.  Unlike other simulations(Kholodenko et al. 1999), I explicitly included 
the possibility that the EGF receptor could simultaneously recruit multiple different SH2 domains 
and that their binding could be cooperative.  To implement this model, I used a rule-based 
approach to generate all ODEs (Sekar and Faeder 2012).  This approach defines rules that 
describe possible reactions, rather than the reactions themselves.  Doing so can avoid the 
practical issue that the number of species and reactions grows exponentially with respect to the 
number of modification sites.  As illustrated in Figure 4.10, I considered three different SH2 
domain-containing proteins, PLCγ Grb2 and Shc (which also contains a PTB domain).  They bind 
to EGFR Y992, Y1068 and Y1148 sites respectively.  The rest of the parameters in our model, 
such as ligand binding constant and dephosphorylation rate, are the same as literature values 
(Kholodenko et al. 1999). 
 I first adjusted the parameters to match the Kholodenko model of EGFR signaling 
(Kholodenko et al. 1999) to test the correctness of my methodology.  Indeed my simulation 
results resembled that of Kholodenko model, suggesting that the model could degrade to a 
simplified ODE model when I turn off multiple domain binding.  I next tested how multiple SH2 
domain binding could affect the simulation results.  To do so, I added rules to the model 
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specifying the binding constant that describes binding of a second SH2 domain to a receptor 
molecule with another SH2 domain already bound.  I can adjust this binding constant to be 
weaker or stronger than a typical SH2 domain/peptide binding, thus effectively introducing a 
negative or positive binding cooperativity, respectively.  As shown in Figure 4.10, introducing a 
layer of multiple SH2 domain binding significantly affects signals.  Although it still exhibits a 
single-peaked transient, a weaker negative binding cooperativity (i.e. multiple SH2 domain 
binding) in the simulation resulted in a much more sustained signal after the signal spike, 
whereas a strong negative binding cooperativity (effectively mutually exclusive binding of SH2 
domains) showed a much lowered sustained signal level.  In addition, the intensity of the spike in 
the simulation of multiple SH2 domain binding increases almost 50% compared to the intensity of 
a model with strong negative binding cooperativity.  
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Figure 4.10 Top: An illustration of the model used in ODE simulations.  Rules that govern all 
allowed  interactions are indicated by blue lines. Bottom: Phosphorylation levels with respect to 
time, as simulated by the model configured for three different scenarios. 
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Although the EGF receptor uses a relatively simple mechanism, namely recruiting SH2 
domains, to propagate downstream signals, my simulation data suggest that even this simple 
mechanism involves complexity when I take into account binding stoichiometry and cooperativity.  
To the best of our knowledge, these data for the first time point out that EGF receptor 
phosphorylation levels could differ significantly (the Y axis values of the plots in Figure 4.10, 
bottom) when the number of recruited SH2 domains is different, and when the recruited SH2 
domains have cross-talks.  It is especially worth noting that differences of the sort observed in 
these simulations, i.e. in the ratio of transient signal to sustained signal, has been suggested to 
be responsible for key decision-making processes in cells (e.g. differentiation versus 
proliferation).  Although my simulations are still greatly simplified, my efforts to explicitly include 
SH2 domain binding stoichiometry and cooperativity do demonstrate that peptide-based data and 
the simple assumptions typically applied are not sufficient for a quantitative understanding of 
EGFR signaling networks. 
4.7 Conclusions and future work 
In this chapter, I investigated the roles of the EGFR C-tail, a region that is typically linked to 
recruitment of downstream signaling molecules.  The literature, together with my own studies, 
argue that the C-tail, as a 230-residue protein, exhibits many additional properties that simple 
peptide-based studies cannot recapitulate.  For instance, using CD, SAXS and HX-MS 
approaches I showed that the C-tail adopts a restricted conformational ensemble in which certain 
conformations are likely to be favored.  I further identified several segments in the C-tail that are 
not completely unstructured.  These regions may play a role in autoinhibition of EGFR by the C-
tail.  In addition, we discovered that phosphorylation of the C-tail promotes dimerization of EGFR-
ICR.  Using HX-MS, I discovered two regions in the kinase domain that are likely to be involved in 
intermolecular kinase/C-tail interactions.  My data, taken together, provide new insight into the 
biophysical basis of the C-tail’s regulatory roles in the EGF receptor. 
I also investigated SH2 domain binding to the phosphorylated EGFR C-tail.  My aim was 
to determine whether the C-tail can recruit multiple SH2 domains, and if so, whether this binding 
is independent or cooperative.  My SPR-based SH2 domain binding assays and SAXS-based 
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stoichiometry determination both suggested that the Grb2 and PLCγ1-C SH2 domains each have 
one submicromolar high-affinity binding site on the EGFR C-tail – and provided preliminary data 
that these binding events are negatively cooperative.  Using rule-based ODE simulations, I further 
demonstrated that these findings are not only currently missing in the field, but more importantly, 
can potentially regulate the signaling outcomes.  As shown in my ODE simulations, SH2 domain 
binding stoichiometry and cooperativity can directly affect the balance between transient and 
sustained signaling – a key factor that decides cell fate. 
While our work on the EGFR C-tail unveiled many interesting aspects that were previously 
unknown, parallel studies showing similar results also emerged.  For instance, Fortian et al used 
a quantum dot-based approach to characterize the stoichiometry of EGFR signaling assemblies 
in live cells (Fortian and Sorkin 2014).  Sigismund et al showed that Grb2 and c-Cbl (which 
contains a pseudo-SH2 domain) positively cooperate to initiate receptor degradation via ubiquitin-
proteosome pathway (Sigismund et al. 2013).  These data, although still scant in the field, all 
point to the suggestion that the C-tail of EGFR is much more complicated than a simple extended 
polypeptide chain as it is typically drawn.  More systematic analyses of all SH2 domains and 
phosphoproteins are needed in order to fully understand the EGF receptor C-tail, its properties, 
and its role in the EGFR signaling network. 
4.8 Methods 
4.8.1 Expression and purification of EGFR C-tail, TKD and ICR proteins 
The EGFR C-tail protein (EGFR 960-1186 using numbering for mature protein) was expressed 
with an N-terminal histidine tag from a pET28 construct in E. coli.  Protein was extracted from 
crude cell lysate using a Ni-NTA affinity column, and then further purified using a Uno-Q (Bio-
Rad) anion exchange column (using a gradient salt concentration from 70 mM to 1M in Tris 
buffer, pH 8.0 ) and a Superose 6 (GE Healthcare) gel filtration column in a buffer containing 150 
mM NaCl, 3 mM βME and 20 mM Tris-HCl, pH 8.0.  N-terminally histidine-tagged EGFR TKD 
(a.a. 672 – 998) and ICR (a.a. 672-1186) proteins were expressed from baculovirus-infected Sf9 
cells.  Baculoviruses were generated using a ‘Bac-to-Bac’ system and all the recommended 
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conditions were followed.  The infected Sf9 cells were harvested 3 days after infection.  The cell 
pellet was first washed in cold PBS solution (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 
1.8 mM KH2PO4) and were then lysed by sonication in 50 mM HEPES, pH 7.8, 150 mM NaCl, 5 
mM β-mercaptoethanol and 1x protease inhibitor cocktail (Roche).  After removing the cell debris 
by centrifugation at 40,000 g for 45 minutes, the supernatant was incubated with Ni-NTA agarose 
beads (Qiagen) for 1 hour at 4 °C.  The mixture was then loaded onto a column.  The beads were 
washed by a gradient of imidazole.  Eluted protein was further purified first by ion exchange 
chromatography (TAME column) and then using a Superose 6 gel-filtration column.  In all 
chromatography processes, buffers containing 20 mM HEPES pH 7.6 ~ 7.8, 250 mM NaCl and 1 
mM TCEP was used.  TCEP and 250 mM NaCl were essential for EGFR-ICR proteins. 
4.8.2 Circular dichroism spectroscopy of EGFR C-tail 
Purified C-tail protein was concentrated to 160 µM (O.D. ~4.0).  A cuvette with 0.1 cm path was 
used to hold the sample.  Buffer solution containing 10 mM potassium phosphate and 100 mM 
potassium fluoride was used to minimize the background absorbance in the low wavelength 
region.  A buffer containing 20% PEG 20k was prepared the day before the experiment to allow 
for the dissolve of PEG.  Circular dichroism spectroscopy was performed on an AVIV model 202 
CD spectrometer.  Collected data were smoothed and plotted using an in-house developed script.  
4.8.3 Preparation and characterization of phosphorylated C-tail 
EGFR C-tail protein was phosphorylated using the purified EGFR kinase domain in the presence 
of vesicles containing 10% Ni-NTA-DOGS in a DOPC background (Zhang et al. 2006).  A typical 
reaction solution contained vesicles up to 1 mM (100 µM Ni-NTA-DOGS, 50 µM 
available/exposed Ni-NTA head groups) and a mixture of C-tail and kinase domain ( 3:1 molar 
ratio).  ATP and Mg2+ were both added to the solution to a final concentration of 8 mM to allow 
phosphorylation.  The reaction was allowed to proceed for 5 hours at room temperature and was 
subsequently quenched by 50 mM EDTA solution.  The quenched mixture was then loaded onto 
a Superose 6 gel-filtration column (GE Healthcare) in order to separate C-tail and kinase domain. 
C-tail eluted first from the gel filtration column due to its large hydrodynamic radius.  
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The phosphorylation status of the EGFR C-tail was characterized by Western blot assays 
using pY20 antibody and EGFR pY1086 specific antibodies.  Native gels using a Tris-HCl buffer 
system  and Phostag-Zn2+ based  gels (Kinoshita et al. 2006)were also employed to monitor the 
completeness of phosphorylation reaction.  MALDI-TOF mass spectrometry was additionally used 
to measure the intact mass of phosphorylated C-tail by mixing the protein with sinapinic acid (SA) 
at 1:1 ratio in 50% acetonitrile solution (0.1% TFA). 
4.8.4 Hydrogen deuterium exchange coupled with mass spectrometry studies 
For the HX-MS studies of the EGFR C-tail, kinase domain, and EGFR-ICR proteins, the hydrogen 
exchange reaction was initiated by mixing the protein into 96% D2O solution containing 150 mM 
NaCl.  The protein sample and the D2O solution were mixed at a 1:4 (v:v) ratio.  The final 
concentration of the proteins was around 3 µM.  In all HX reactions, the pD of the solution was 
estimated to be 7.2 (pHread + 0.4).  The HX reaction was carried out at 0 °C.  At each specific time 
point (10 s, 102 s, 103 s, 104 s and 105 s), an aliquot of 24 µl reaction mixture was quenched by 
adding 36 µl quench buffer (1.5 M GdmCl, 50 mM TCEP, 0.8 % formic acid and 10% glycerol).  
Non-deuterated (‘all-H’) and fully deuterated (‘all-D’) samples were prepared in the same way.  All 
samples were frozen in liquid nitrogen immediately after adding quench buffer and stored at -
80°C.  Prior to data collection, frozen samples were quickly thawed on ice and injected at a flow 
rate of 100 ml/min into a cooled chamber maintained at 0 °C.  Inside the chamber, the protein 
sample was digested by immobilized pepsin (Sigma) beads packed in a column housing (2 cm x 
2 cm, IDEX).  The digested peptides were flowed through a Piccolo (Nest) C18 column (trap 
column) to desalt the peptide fragments.  An acetonitrile gradient (10-55%, 0.1% TFA) was then 
used to elute the peptides off the trap column and into an analytical C18 column (5 cm x 0.3 mm, 
Higgins Analytical).  The effluent was directly flowed to an ESI-MS Orbitrap mass spectrometer 
(Thermo LTQ Orbitrap XL). 
The SEQUEST algorithm (Bioworks, version 3.3.1) was used to identify peptides from 
tandem MS data.  MATLAB-based software ExMS was used to validate the peptide assignment 
and subsequently to compute the centroid of isotopic distribution of each deuterated peptide.  The 
‘All-D’ sample was included to calibrate back-exchange of the deuterated samples.  The detailed 
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ExMS-based data collection and processing workflow were described in (Kan, 2011).  NumPy 
and Matplotlib (Hunter, 2007) were used to export ExMS result to the Python environment for 
further data analysis and plotting. 
 For HX studies of EGFR-ICR on vesicles, EGFR-ICR protein was first clustered on a 
vesicle to allow for phosphorylation reaction.  A typical phosphorylation reaction occurred in a 
solution containing 1 mM lipid as vesicles (10% Ni-NTA-DOGS/DOPC), 20 mM HEPES pH 7.5, 
150 mM NaCl, 8 mM ATP, 8 mM Mg2+ and 50 µM EGFR-ICR protein.  Upon completion of the 
reaction, EDTA (final conc. 50 mM) was added to the solution to quench the reaction prior to the 
onset of hydrogen exchange reaction. 
4.8.5 AUC studies of phosphorylated EGFR-ICR and C-tail proteins 
Sedimentation equilibrium experiments were performed using EGFR C-tail proteins.  Freshly 
prepared proteins (see above sections for expression and purification) from size-exclusion 
chromatography were immediately pooled and concentrated.  For phosphorylated protein, an 
extra SEC column was used following completion of phosphorylation reaction.  Proteins were 
concentrated to 16 µM (O.D. 0.3) and 32 µM (O.D. 0.6) and loaded in 6-sector center piece AUC 
assemblies.  Experiments were performed in a Beckman XL-A ultracentrifuge equipment at 4 °C 
using 15,000,18,000 and 21,000 rpm speeds.  Data were collected at 280 nm absorbance with a 
0.001 cm scan step.  Scans were continued until the reach of equilibrium monitored by SedFit 
software.   
4.8.6 SPR binding assays of SH2 domains 
SPR experiments were performed on a BiaCore 3000 instrument (GE).  Phosphorylated C-tail 
protein was immoblilized onto CM5 sensor chip using amine coupling chemistry.  Briefly, the 
phosphorylated C-tail protein was diluted in pH 3.5 buffer (20 mM Glycine-HCl) to a final 
concentration of 1 µM.  The final pH of the sample was adjusted to between 3.5 and 4.0.  The 
resulting solution was allowed to flow across an EDC-NHS activated CM5 chip at 5 µl/min for a 
total volume of 100 µl as recommended by the manufacturer.  The chip surface was then 
quenched with 1M ethanolamine.  Typically, about 8000 RU of C-tail was immobilized onto the 
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sensorchip surface.  SH2 domain proteins were sequentially injected until steady state binding 
was achieved, and were then allowed to dissociate from chip surface after each injection in HBS-
EP running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005% v/v Surfactant 
P20).  RU values recorded from steady state binding were then used to fit binding curves using a 
simple specific binding model in Prism software.  More advanced multiple SH2 domain binding 
models were fitted in iPython notebook using an in-house developed curve-fitting routine. 
4.8.7 SAXS I0 analysis of Grb2 binding to phosphorylated C-tail 
Fresh proteins from SEC columns were immediately pooled and concentrated.  For C-tail 
characterization, C-tail protein (1 mg/ml) in 150 mM NaCl, 20 mM HEPES pH 7.5 was used.  For 
SH2 domain binding analysis, Grb2 SH2 domain and phosphorylated C-tail proteins in 150 mM 
NaCl, 20 mM HEPES pH 7.5 and 0.1 mM TCEP were mixed prior to data collection.  All SAXS 
data were collected on a Rigaku PSAXS S-Max3000 small-angle X-ray scattering system 
equipped with a Osmic mirror optics, an evacuated sample chamber kept at 4 °C, and a gas-filled 
multi-wire detector.  A Rigaku MicroMax-007 HF microfocus rotating anode generator was used 
as X-ray source.  The raw data were first averaged and reduced using SAXSGUI software (ver. 
2.5.7).  The resulting data were analyzed by using ATSAS Primus software.  P(r) curves were 
calculated in Gnom (ver. 4.7).  Shape reconstructions were conducted using the software Dammif 
and Damaver (Franke and Svergun 2009). 
4.8.8 ODE simulations of EGFR signaling network 
ODE simulations were performed using an implementation of rule-based network simulation 
software BioNetGen (ver. 2.2.0-stable) installed on a linux workstation.  Perl 5.10 and Java 
Runtime Environment 1.6 were configured to support the simulations.  The BNGL language was 
used to set up the models and interactions in the network.  Parameters were used according to 
Kholodenko model (Kholodenko et al. 1999).  As conventions, all mole units were converted to 
molecule unit if applicable.  The details of the model configuration used in the study can be found 
in our public web archive: https://www.dropbox.com/sh/00cqegpwnpxpk9h/AADXAyuKAsl3-
PX1jNtBQHjOa?dl=0 
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Chapter 5 Developing computational tools for biophysical 
studies of receptor tyrosine kinases 
(This chapter desribes collaborative work done with Dr. Camilla Oxley in the Lemmon laboratory)  
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5.1 Introduction 
The field of biophysical research heavily relies on state-of-the-art technology.  In parallel, data 
processing and analysis programs are also in great demand.  Unfortunately, many of these 
programs lag behind the experimental technology.  Academic software tends to be developed in a 
‘quick-and-dirty’ way, as manifest by the use of outdated programming techniques and non-
professional software design.  The lack of sophisticated software tools creates a burden for 
biologists in processing and analyzing data with ever-increasing scale and complexity.  Recently, 
SBGrid, a software consortium for structural biology, aimed to solve these problems by providing 
a collection of commonly-used structure biology programs with a simple installation procedure 
(Morin et al. 2013).  Unfortunately, the SBGrid model itself also suffers from typical academic 
software problems too.  In order to make compilation and installation on multiple platforms 
straightforward, it has to deliver the most generic versions of all software – for most Linux/Unix 
platforms, it provides programs pre-compiled for the i386 platform, hence failing to take 
advantage of the performance of today’s powerful hardware (especially the 64 bit platform and 
multiprocessing capability).  The generic versions of programs come with limited room for 
customization as well.  Moreover, the ‘SBGrid approach’ doesn’t change the inherent drawbacks 
of each program. 
In this Chapter, I document several pieces of computer programs that I developed 
alongside my wet lab research work in order to facilitate data processing and analysis for small-
angle X-ray scattering (SAXS).  The programs are written with the principles of software 
engineering in mind, and use modern technologies that are typically found in numerical 
computations in other scientific and engineering disciplines.  All the programs run on multiple 
platforms, including Windows, Linux/Unix and Macintosh.  Instead of ‘re-inventing the wheel’, my 
programs are designed on top of commonly used SAXS program suites in the field, treating the 
existing software as the core calculation engine and adding new features to it.  In addition, I 
briefly describe the collaborative work on studying the molecular basis for Drosophila 
EGFR/Kekkon-1 interactions, using SAXS-based approaches and programs designed for these 
studies. 
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5.2 A framework for SAXS data processing and analysis 
5.2.1 Principle of small-angle X-ray scattering  
SAXS is a powerful technique for studying structures and dynamics of biomolecules.  It 
complements X-ray crystallography and nuclear magnetic resonance (NMR) approaches in that it 
can directly measure samples in solution, and does not need isotopic labeling.  Combined with 
other approaches, SAXS can be used to discern the oligomeric state biomolecules and binding 
affinity of partners in complexes, to calculate low-resolution shape and conformational dynamics 
of proteins, to determine spatial distributions of domains connected by flexible linkers and to 
facilitate protein docking and virtual drug screening, etc. (Jacques and Trewhella 2010).  SAXS is 
based on scattering of X-rays from a single molecule – waves scattered from different parts of a 
molecule result in phase shift and an intensity of scattering pattern.  In dilute solution, the SAXS 
diffraction pattern is a rotationally-averaged pattern of all molecules (interference from widely-
separated solutes only occurs at very small angles and only becomes significant in concentrated 
solution).  Several factors contribute to SAXS signals, including the protein concentration, the 
volume of the individual protein, the contrast between the biomolecule and the solvent, and the 
scattering from a single rotationally-averaged protein.  The following formula describes the 
relationships between these factors and the intensity of the scattered radiation: 
𝐼 𝑞 ∝   !
!
𝑉!"#$%&'! (𝜌! − 𝜌!)!𝐹(𝑞)𝑆(𝑞)                                               (1) 
where 𝑞 = 4𝜋 sin 𝜃 /𝜆 (sometimes s is used denote q), called momentum transfer, is a function 
of the scattering angle; !
!
 denotes the number of biomolecules per unit volume; 𝑉!"#$%&'( is the 
volume of individual protein; 𝜌! and 𝜌! are the ‘electron density’ of the biomolecule and the 
solvent.  𝐹(𝑞) is the Form factor describing the rotationally-averaged scattering of a single 
protein. 𝑆(𝑞) is the structure factor (not to be confused with the ‘structure factor’ in 
crystallography) that describes inter-particle behavior and is approximately one for dilute solution.  
It is worth noting that the scattering intensity is proportional to the square of the volume of the 
molecule, that is R6 in terms of the radius (R) of the molecule.  As a result, large molecules 
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scatters much more strongly than small particles.  In addition, the difference of the density 
between particle and solvent (the (𝜌! − 𝜌!) term, sometimes called contrast) directly affects the 
intensity. 
 One important parameter of SAXS is I(0), the forward scattering intensity. In order to 
understand the physical meanings of I(0), it is worthwhile to show the relationship between the 
intensity and the scattering angle.  Assuming a particle is centrally-symmetric, then the intensity 
I(q) can be expressed as a one-dimensional integral: 
𝐼 𝑞 =    𝜌(𝑟)𝑒!!!∙!!
!
= 4𝜋 𝜌(𝑟) !"#  (!")
!"
𝑟!𝑑𝑟
!
                                  (2) 
 For a sphere with uniform density, we have  
𝜌 𝑟 =    1  ,            𝑟   ≤ 𝑅0  ,            𝑟   > 𝑅                                                         (3) 
 Solving the integral (2) using (3), we have  
𝐼 𝑞 = 4𝜋 !"# !" !!"#$%(!")
(!")!
!
                                                        (4) 
 Plugging q= 0 into equation (4), we have  
𝐼 0 = !
!
𝜋𝑅!
!
                                                             (5) 
In above derivation, we define the density to be one electron per unit volume in the 
molecule.  Therefore, (5) indicates that the square root of I(0) equals the volume of (and the 
number of electrons in) a particle.  Therefore, the absolute value of I(0) is also a direct 
measurement of the mass (squared) of the particle. 
Unfortunately, I(0) cannot be directly measured.  There are two different approaches to 
obtain the I(0) value indirectly.  The first approach is through the Guinier plot.  If we expand 
equation (4) at q=0 using Taylor’s expansion, we get an approximate equation: 
𝐼 𝑞 ≈ 𝐼 0 𝑒!
!
!!!
!!!                                                             (6) 
where Rg is the radius of gyration.  If we plot the logarithm of I(q) as a function of q2, the 
slope is −𝑅!!/3, and the intercept is I(0).  Therefore, if we plot the Guinier plot of SAXS data and 
extrapolate Guinier region to get the intercept, we can obtain I(0). 
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The second way to get I(0) comes from the indirect Fourier transform (IFT) of the SAXS 
experimental data.  To see that, we have 
𝐼 𝑞 =   4𝜋 𝑝 𝑟 !"# !!"#
!!"#
d𝑟!!"#!                                                (7) 
It follows by Fourier transform that: 
𝑝 𝑟 =    !
!
!!!
𝑞!!! 𝐼(𝑞)
!"#  (!")
!"
d𝑞                                                (8) 
Therefore, I(0) can be obtained by: 
𝐼 0 =   4𝜋 𝑝(𝑟)d𝑟!!"#!                                                    (9) 
P(r) is called the pair-wise or radial distance distribution, the SAXS analogue of the 
Patterson function in crystallography.  Using P(r), IFT can yield both Rg and I(0). 
Compared to the Guinier plot approach, the second approach (using real-space values) 
has the advantage that it is less sensitive to inter-particle interactions and protein aggregation. 
5.2.2 Current SAXS data processing and analysis programs 
A typical SAXS experiment setup first requires conducting multiple data collections for both the 
samples and the matching buffer.  The intensity of excess scattering from the protein molecules is 
then obtained by subtracting the buffer signal from the sample solution signal (assuming the X-
ray source is stable).  For Guinier plot analysis, a data transformation from I(q) vs. q to log(I(q)) 
vs. q2 results in the Guinier plot.  From that, the Rg and I(0) values can be obtained.  Perhaps the 
most popular program used for this step is PRIMUS from the ATSAS suite (Petoukhov et al. 
2012).  Another piece of software gaining popularity is RAW, developed at MacCHESS (Volkov et 
al. 2003; Skou, Gillilan, and Ando 2014).  However, any spreadsheet-like software suffices to 
manipulate data transformation for Guinier plot. 
 In order to obtain Rg and I(0) values from the entire data set, one needs to perform IFT 
on the experimental data.  Perhaps the single most popular program for this purpose is GNOM 
from the ATSAS package (Petoukhov et al. 2012).  GNOM can be run in a terminal window using 
either interactive mode or batch mode.  In interactive mode, each parameter needed for the 
calculation will be prompted, such as the unit of q, the guessed value of Dmax, etc..  In batch 
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mode, these parameters are compiled in an input file.  The output of GNOM files is usually a 
single text file that contains the P(r) curve data, the statistics of the IFT calculations and other 
detailed information.  P(r) needs to be zero at the two ends of the plot (and positive everywhere 
else).  Since the IFT results do not necessarily have these properties, one usually needs to 
specify a guessed value of Dmax and let GNOM force the P(r) values to reach zero at the two ends 
of the P(r) curve.  Therefore, a typical analysis of one set of experimental data using GNOM 
requires multiple trials and error to find the correct Dmax value.  Unfortunately, this process is not 
only tedious but also subjective – since judgment of the best Dmax value is largely based on the 
IFT statistics and the shape of the P(r) curve.  A systematic scan of possible Dmax values – with 
objective comparison of the resulting statistics in each case – is important in obtaining the correct 
Rg, Dmax, and I(0) values as well as the P(r) curve from SAXS data. 
 Another common type of data processing for SAXS is three-dimensional shape 
reconstruction.  The resulting low-resolution shape (‘envelope’) can be used to visualize the low-
resolution structure of the molecule and to facilitate partial model docking into a ‘most probable’ 
envelope.  A typical approach is to use beads or ‘dummy residues’ to mimic the shape of the 
particle (Volkov and Svergun 2003).  The theoretical scattering can be calculated from the particle 
composed of dummy residues.  Minimizing the difference between the observed scattering and 
the calculated scattering with respect to the positioning of the dummy residues leads to a low-
resolution envelope that shows the same scattering profile as the experimental data.  
Mathematically, this optimization is not guaranteed to converge on one solution (unless the 
hypersurface is a convex function).  Therefore, multiple runs of shape reconstruction from a 
single set of experimental data typically leads to different envelopes.  The practice is to run shape 
reconstructions multiple times for a single piece of data, and then to average the results to get a 
‘most likely’ shape.  Along the averaging process, the deviations among the calculated shapes 
are also calculated and described by average normalized spatial discrepancy (NSD) value.  The 
nature of this shape reconstruction approach implies that the calculation also requires multiple 
iterations of trial and error.  In addition, each iteration is computationally expensive.  For those 
popular programs used for shape reconstruction, such as DAMMIN and DAMMIF (Franke and 
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Svergun 2009), each run can only process one set of parameters.  Also, although today’s 
computers are all equipped with multi-core processors, those programs can only run in serial 
mode – using one core at a time. 
 In order to address the drawbacks in the programs mentioned above, I implemented a 
suite of programs that facilitate SAXS data processing, analysis and visualization.  These 
programs are multi-platform compatible.  Most importantly, they exploit all possible automation 
processes and fully utilize the computing resources (potentially all cores on a computer). 
5.2.3 Developing a new layer of programs to facilitate SAXS data processing and 
analysis 
The EZsaxs suite I developed contains three major components, each of which can be used 
separately for a specific purpose, or can be combined to form a data processing pipeline (Figure 
5.1).  The first component, EZsaxs (same as the suite name), is used to perform indirect Fourier 
transform (IFT) of experimental scattering data.  The second component, EZanalysis, is used to 
analyze and visualize the output results from EZsaxs.  The third component, EZshape, is used for 
three-dimensional data reconstructions.  In addition, there are a few scripts developed to ease the 
data truncation process, and an I(0) titration simulator that is equipped with numerical 
computation capabilities in order to simulate I(0) titration experiment involving multiple species 
and equilibria. 
 
 
Figure 5.1 The overall architecture of the EZsaxs suite, which is composed of three separate 
programs EZsaxs, EZanalysis and EZshape, auxiliary scripts, and an I0 titration simulator.  These 
programs can be used separately for a specific purpose, or can be combined to use as a data 
processing and analysis pipeline. 
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While the core of EZsaxs is same as GNOM, it builds many features on top of GNOM in 
order to facilitate data processing automation.  The key principles behind EZsaxs are to automate 
the ‘trial and error’ process, and to organize the results for easy analysis later (manually or in 
EZanalysis).  The majority of EZsaxs is written in the Python programming language.  Similar 
approaches have been used to expand the function of GNOM.  In particular, the design of EZsaxs 
is in part inspired by the program developed in Tainer lab (Hura et al. 2009), although EZsaxs 
contains more features.  The current interface of EZsaxs (and EZanalysis and EZshape) is 
command-line (or terminals), however, implementing a graphic user interface (GUI) is 
straightforward, as all the underlying functions are already implemented in various modules. 
 The best way to illustrate the power of EZsaxs is through an example.  Suppose one has 
a folder of data files from SAXS experiments.  These data are all buffer-subtracted, and properly 
truncated (for which EZsaxs suite has scripts to automate too).  The next step would be to use 
GNOM to try all reasonable Dmax values and other parameters to generate a series of GNOM 
result files.  Suppose that one would like to try all possible Dmax values from 90 Å to 150 Å, with a 
5 Å step size.  One also would like test whether or not to force the end of P(r) curve to zero (not 
zeroing the end of the P(r) curve helps to identify the best Dmax value).  Assuming there are 10 
different data files in the folder, that is ((150-90) / 5 + 1 ) x 2 x 10 = 260 GNOM runs.  Between 
each run, one needs to adjust the parameter accordingly for the next run.  Using EZsaxs, one 
only needs to type one command in the terminal, and all the 260 runs will be done within 
seconds.  The command is as follows: 
$EZsaxs –B .dat –di 90 –do 150 –ds 5 –zi yes –ze no 
In this command, ‘-B’ specifies the file extension for all the data files (10 files in the above 
example), ‘-di’ specifies the start value of Dmax, ‘-do’ specifies the last guess of Dmax value, ‘-ds’ 
specifies the step of Dmax increase.  In addition, ‘-zi’ and ‘-ze’ specify whether to try to ‘non-zero’ 
the beginning and the end of P(r) curve. 
 Even better, in this example, the resulting 260 output files are automatically organized 
into different sub-folders with files properly named.  
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 In a typical data processing flow, the next thing to do is to open all of the 260 files and to 
examine the IFT statistics (such as total estimate, chi-square value, etc..) and P(r) curves.  This is 
not only time-consuming but also error-prone.  With EZanalysis, nothing in particular needs to be 
done after EZsaxs and it is ready to analyze and visualize the IFT results of all 260 files. 
 EZanalysis will automatically go into each result file and extract useful information, such 
as IFT statistics, P(r) curve data, back-calculated experimental data based on the P(r) curve, the 
Kratky plot and so on.  In addition, EZanalysis automatically groups this information according to 
parameters used in EZsaxs.  For instance, the total estimate of each IFT run will be grouped in a 
file along with the Dmax value used for that run.  It will also overlay P(r) curves based on whether it 
is ‘zeroed’ or not.  Figure 5.2 illustrates some of the plots generated by EZanalysis.  Again, to 
obtain all of this information, only one command is required and hundreds of resulting files will be 
analyzed, grouped and plotted. 
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Figure 5.2  Sample plots generated by EZanalysis.  A: the experimental (green) and back-
calculated (blue line) scattering data (top) and Kratky plot (bottom) for different Dmax values. B: 
Plots of total estimate (TE) and Chi2 values with respect to Dmax values. C: Sample plot of 
 
 
144 
superimposed P(r) curves with ‘non-zeroed’ intensity at Dmax.  The correct Dmax produces a P(r) 
curve which does not significantly ‘bounce back’ at the Dmax value.  In these curve series, the blue 
line represents the best Dmax value (130 Å in this example).  
 The EZanalysis program helps identify the Dmax value that best fits the experimental data.  
After EZanalysis processing, one usually has a few P(r) curves in hand with which shape 
reconstruction is desired.  The EZshape program in EZsaxs suite facilitates this process.  
Internally, EZshape can use various engines including DAMMIN, DAMMIF and GASBOR.  A 
typical shape reconstruction needs at least ten runs in order to get convincing results.  In one 
command, EZshape can automatically detect the number of processors available in the system 
and distribute the calculation task among those cores.  In addition, one can specify multiple 
parameters for shape reconstruction through EZshape, such as which engine to use, the 
resolution of the calculation (number of dummy atoms), and whether to include symmetry 
constraints.  Just like EZsaxs, EZshape can be run in batch mode – multiple files in a folder can 
be processed simultaneously.  After all the calculations are completed, EZshape will cluster the 
results, copy them into a sub-folder and then run DAMAVER internally to compute the averaged 
shape and NSD value, along with the back-calculated scattering curve based on that shape.   
 In all the modules of EZsaxs package, data files do not need to be modified.  Rather, at 
each new step, the data files are copied to a subfolder and renamed properly.  In addition, the 
input files are always automatically backed up ‘behind the scenes’ before the start of any 
computations.  This ensures that no file corruption can happen at any point during the EZsaxs 
computations. 
5.3 An Example:  Using SAXS approaches to study Drosophila EGFR/Kekkon-1 
interactions 
5.3.1 Drosophila EGFR is negatively regulated by Kekkon-1 
In Drosophila, EGFR is accompanied by Argos and Kekkon-1 that antagonize EGFR signaling as 
feedback inhibition mechanisms (Derheimer et al. 2004; Alvarado, Rice, and Duffy 2004; Klein et 
al. 2004).  Argos is a secreted protein that sequesters the Drosophila EGFR (dEGFR) ligand 
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Spitz, functioning as a ligand sink (Klein et al. 2004).  Kekkon-1 (Kek1), a transmembrane 
glycoprotein in Drosophila, was found to modulate dEGFR signaling through an inhibitory 
feedback loop (Ghiglione et al. 1999).  Genetic studies suggest that the extracellular region of 
Kek1 is required for its dEGFR inhibitory effect, but it is unclear whether there is direct interaction 
between dEGFR and Kek1 (Figure 5.3).  Understanding this interaction molecularly should reveal 
a new class of regulatory mechanisms for EGFR signaling, and has the potential to provide 
important new insight into the development of EGFR inhibitors in humans – where they could 
have value in cancer treatment.  
 
Figure 5.3  Kekkon-1 is a transmembrane protein in Drosophila that negatively regulates 
Drosophila EGFR signaling.  Model of the intact dEGFR extracellular region (left) based on a 
crystal structure of dEGFRΔV and a crystal structure of the extracellular portion of Kekkon-1 
+ ? 
I 
II 
III 
IV 
V 
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(right) are shown in cartoon representation (Oxley et al. in preparation).  The molecular basis for 
dEGFR/Kek1 interactions has yet to be understood. 
5.3.2 Kekkon-1 directly binds to dEGFR  
Genetic analyses indicated that the influence of Kek1 on dEGFR signaling can be abolished by 
extracellular mutations (Alvarado et al., 2004a,b), suggesting that the extracellular regions of the 
two molecules may interact.  Subsequent work in the Lemmon laboratory by Camilla Oxley and 
Diego Alvarado has shown that the isolated extracellular region of Kek1 (sKek1) interacts directly 
with the extracellular region of dEGFR (s-dEGFR), as assessed using sedimentation equilibrium 
analytical ultracentrifugation (SE-AUC) and other approaches (unpublished data).  In 
sedimentation velocity analytical ultracentrifugation (SV-AUC) studies, the dEGFR/Kek1 binding 
stoichiometry was determined to be 1:1 (unpublished data).  Kek1 could inhibit dEGFR by two 
possible types of mechanisms: (i) Kek1 could compete with ligand for binding to dEGFR ligand - 
thus blocking the ability of dEGFR to signal; (ii) Kek1 could bind to a different site on dEGFR and 
block ligand-induced receptor dimerization, while still allowing ligand to bind.  One such place 
would be dimerization arm of the receptor, which mediates the receptor-receptor interactions in 
the active dimer complex.  Binding assays showed that Kek1 cannot bind to a ligand-induced 
receptor dimer, but can bind to a dimerization-deficient receptor mutant with an altered sequence 
in its dimerization arm – and addition of excess Spitz does not influence this binding.  Moreover, 
Spitz can bind equally well to the dEGFR extracellular region itself and to a preassembled s-
dEGFR/sKek1 complex.  These data suggest that indeed Kek1 binds to the dimerization arm 
region of dEGFR and does not compete ligand binding. 
 In order to shed more light on the molecular basis for Kek1 binding to dEGFR, we 
performed SAXS-based binding analysis to further confirm the binding affinity and stoichiometry, 
and to characterize the binding mode by constructing low-resolution envelopes to describe the s-
dEGFR/sKek1 complex structure. 
 
 
147 
5.3.3 Kekkon-1 and dEGFR forms a ‘side-by-side’ complex through bivalent interactions 
Previous AUC analysis of sKek1 binding to different truncation mutants of dEGFR suggested that 
sKek1 binds to both domain II and V of s-dEGFR.  However, these AUC experiments were 
performed at relatively low concentrations.  At high concentrations of sKek1, it is possible that two 
sKek1 molecules can bind to one s-dEGFR at domain II and V.  In order to study the binding of 
sKek1 to s-dEGFR in solution at high concentrations, and to test whether the Kek1/dEGFR 
interaction is bivalent, we performed I(0)-based titration experiment to characterize the binding 
affinity and stoichiometry.  A similar approach has been used to determine the binding 
stoichiometry of EGF to sEGFR in forming a 2:2 dimer (Lemmon et al. 1997).  In the case of s-
dEGFR/sKek1, however, the data interpretation is more complex.  Whereas the molecular weight 
of the EGF ligand (~6 kDa) could essentially be neglected in studies of its binding to the 
~100 kDa sEGFR molecule, we cannot neglect the molecular weight of sKek1 (45 KDa) 
compared to s-dEGFR (115 KDa).  In addition, the dimerization arm mutant of dEGFR used in our 
SAXS binding analysis doesn’t completely abolish s-dEGFR dimerization.  At high concentration, 
there is still significant dimer formed by the mutated s-dEGFR variant.  Since large molecules 
scatter much more strongly than small molecules in SAXS, we cannot simply neglect the 
dimerization of the receptor in our SAXS analysis. 
 We collected SAXS data for mixtures of sKek1 and dimerization arm-mutated s-dEGFR 
at molar ratios of 1:0, 1:2, 1:1, 1.5:1, 2:1 and 3:1, with a constant concentration of s-dEGFR in all 
these samples.  Using the EZsaxs suite, we analyzed these data and extracted the I(0) values for 
each sample.  Next, we aimed to ‘fit’ the data guided by the binding model.  To do so, we 
developed an I(0) simulator that can incorporate complex binding models with arbitrary numbers 
of species and binding equilibria.  For this specific data set, we developed the following model: 
𝑅!  ⟺   𝑅  +   𝑅,                                            Kd=K1                                                  (1) 
𝑅𝐿⟺   𝑅  +   𝐿,                                            Kd=K2                                                  (2) 
𝑅𝐿𝐿  ⟺   𝑅𝐿  +   𝐿,                                        Kd=K3                                                  (3) 
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R is s-dEGFR, and L is sKek1.  Reaction (1) denotes s-dEGFR dimerization, with a dissociation 
constant K1.  Reaction (2) and (3) represent 1:1 binding (K2) and 1:2 binding (K3 for the second 
ligand) of s-dEGFR (receptor) and sKek1 (ligand), respectively.  
 Next, we write the concentrations of all species, except the free receptor and ligand, in 
terms of the free concentrations of receptor and ligand and dissociation constants.  Specifically, 
𝑅!   =   
! ⋅[!]
!!
                                                                             (10) 
𝑅𝐿   =    ! ⋅[!]
!!
                                                                             (11) 
𝑅𝐿𝐿   =    !" ⋅[!]
!!
=    ! ⋅ !
!
!!⋅!!
                                                          (12) 
 It follows from equations (10) – (12) that: 
𝑅!"! = 𝑅 +   2 ⋅ 𝑅! + 𝑅𝐿 + 𝑅𝐿!                                         (13) 
= 𝑅 +   2 ⋅ ! ⋅ !
!!
+    ! ⋅ !
!!
+    ! ⋅ !
!
!!⋅!!
                                    (14) 
𝐿!"! = 𝐿 + 𝑅𝐿 + 2 ⋅ 𝑅𝐿!                                                     (15) 
= 𝐿 +      ! ⋅ !
!!
+   2 ⋅ ! ⋅ !
!
!!⋅!!
                                                          (16) 
 Note that Rtot and Ltot are the total concentrations of receptor and ligand (in all relevant 
species).  These are two known values.  Therefore, from (14) and (16), we can solve [R] and [L] 
in the form of K1, K2, K3, Rtot and Ltot (considering these values to be constants for each 
experiment). 
 Having solved [R] and [L], we can then solve the concentrations of all the species ([R2], 
[RL] and [RLL] in this model).  Now that the concentrations of all the species are known, we can 
then compute I(0) and normalized I(0), using the following relationships: 
𝐼! ∝    𝑐! ⋅𝑀!!!                                                                        (17) 
𝐼!,!"#$ ∝   
!!⋅!!
!
!
!!"!⋅!!!!!"!⋅!!
                                                                (18) 
 In (17) and (18), ci and Mi are the molar concentration and molecular weight of species i, 
respectively.  Note the denominator in (18) is the total mass of species in the solution, which is a 
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constant value for a given sample.  We normalized the I(0) value calculated in (17) by the total 
mass of all the species in the solution to get the normalized I(0) value.  Importantly, the right hand 
side of equation (18) is the weight-averaged molecular mass of the system in disguise.   
The above derivations showed that, given a model and the dissociation constants, one 
can calculate the theoretical I(0) titration curve.  In other words, minimizing the difference of 
theoretical and observed I(0) values with respect to the dissociation constants will provide the 
best-fitting values for those constants.   
We implemented this ‘fitting’ routine in our I(0) simulator.  By fitting the experimental data 
(Figure 5.4), we obtained the following best fit dissociation Kd’s: K1 = 1.5 mM, K2 = 3 µM, 
K3 = 5 M.  These values suggest that s-dEGFR homodimerization is significantly reduced to 
millimolar Kd by using the dimerization arm mutant, that 1:1 (s-dEGFR:sKek1) binding has a Kd of 
about 3 µM, and that the second binding event is very weak (with a Kd in the molar range).  These 
data were consistent with previous AUC-based binding analyses.  In addition, our dissection of 
the I(0) data indicated that scattering by the 1:1 s-dEGFR:sKek1 complex constitutes ~86% of the 
total scattering signal, arguing that we can use the SAXS data to run shape reconstruction to 
approximate the low-resolution shape of this complex (the shapes of other species in the solution 
should be negligible). 
Using EZsaxs and EZshape, we calculated the P(r) curves and the low-resolution 
envelopes for the receptor alone and the complex.  Table 5.1 illustrates the geometry parameters 
derived from these analyses.  Interestingly, the Dmax values of the receptor and the complex are 
the same, indicating that binding of Kek1 to dEGFR does not affect the long axis of the receptor.  
In other words, Kek1 binds to the ‘side’ of the receptor – with the long axes of the two molecules 
close to parallel in the complex.  In order to visualize the possible interaction modes of s-
dEGFR/sKek1, we fit models of s-dEGFR and sKek1 into the envelope by using the SITUS 
software (Wriggers 2010).  As shown in Figure 5.4D, the sKek1 molecule indeed contacts both 
domain II and domain V of s-dEGFR.  The overall low-resolution molecular shape appears to be 
‘bulky’ compared to the docked complex model.  This is likely due to the glycosylation of both 
molecules, since glycans also scatter X-ray and are known to add ‘bulk volume’ to shape 
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reconstructions (Guttman et al. 2013).  The local conformational fluctuations may also contribute 
to the bulkiness of the envelope.  Despite these complexities in the analysis, it is evident that the 
two molecules align along their long axes to form the complex.  
 
 
Figure 5.4  SAXS analyses of sKek1 binding to the s-dEGFR dimerization arm mutant.  A: I0 
values were measured for samples of s-dEGFR alone and with increasing concentrations of 
sKek1.  The concentration of s-dEGFR was 50 µM for all samples. The titration peaked at a 1:1 
ratio, suggesting the binding stoichiometry is 1:1.  The simulated red line is our best fitting for the 
data (Kd = 3 µM for formation of the 1:1 complex).  The simulated grey line represents 
hypothetical I0 titration data expected for a 2:1 stoichiometry of sKek1/s-dEGFR binding. 
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B:  P(r) curves for s-dEGFR alone and the s-dEGFR/sKek1 complex at 50 µM.  The Dmax values 
for both particles are 160 Å.  C,D:  Low-resolution molecular envelopes of s-dEGFR (C) and the 
1:1 complex (D).  The model of intact s-dEGFR and the crystal structure of sKek1 were docked 
into the envelope to help visualize the likely binding mode. 
 
Table 5.1 Summary of Dmax, Rg and total estimate values for s-dEGFR and the s-dEGFR/sKek1 
complex 
 s-dEGFRdim-arm2 s-dEGFRdim-arm2/Kek1 complex 
Dmax (Å) 160 ± 5 160 ± 5 
Guinier Rg (Å) 52 ± 0.83  56.2 ± 0.93  
GNOM Rg (Å) 53.4 ± 0.75  56.4 ± 1.1  
TE 0.93 ± 0.008 0.88 ± 0.05 
 
5.4 Conclusions 
In this chapter, I described the EZsaxs suite, a collection of programs developed for SAXS data 
processing and analysis.  EZsaxs is designed with the need of the real-world problems in mind.  It 
contains easy-to-use interfaces to customize data processing, provides routines to plot and 
visualize results, and automates many of the tedious data manipulations.  We demonstrated the 
application of SAXS-based approaches to the study of molecular basis for s-dEGFR/sKek1 
interactions.  SAXS data analysis was heavily relied on in order to characterize the s-
dEGFR/sKek1 binding stoichiometry and affinity, and to unveil the low-resolution structure of the 
s-dEGFR/Kek1 complex.  These studies led us to the findings that sKek1 binds to s-dEGFR with 
a 1:1 stoichiometry and a Kd value of approximately 3 µM.  SAXS envelopes suggest a ‘side-by-
side’ s-dEGFR/sKek1 binding mode where Kek1 simultaneously contacts both domain II and 
domain V in s-dEGFR and blocks receptor dimerization.  These findings revealed a new inhibitory 
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mode of EGFR regulation, and provided a new avenue towards targeting and inhibiting EGFR-
mediated signaling. 
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6.1 Conclusions 
The receptor tyrosine kinases (RTKs) have been extensively investigated over the last three 
decades.  These efforts led to the discovery of the general regulatory and signaling mechanisms 
of many RTKs.  However we argued that there exists significant diversity among RTKs – different 
RTKs utilize subtly (but importantly) distinct mechanisms for receptor activation and downstream 
signaling.  As discussed in Chapter 1, understanding this diversity is crucial for fully 
understanding the molecular basis for activation and regulation of RTKs, and the RTK-mediated 
cell signaling network – and for devising new ways to intervene when these processes go awry in 
disease. 
In Chapter 2, I investigated into the anaplastic lymphoma kinase (ALK) sub-family of 
RTKs, aiming to understand how these receptors are activated.  Despite the grouping or ALK into 
the insulin receptor (IR) super-family, I showed that the activation mechanism of ALK differs 
significantly from that of IRs.  Using biophysical approaches, we proposed a model delineating 
how heparin, a recently-reported ligand, activates the receptor.  We also discussed the potential 
activation mechanisms for both mammalian and Drosophila ALK by integrating all that we have 
learnt so far.  Finally, we suggest a model where multiple ligands and co-ligands may co-regulate 
ALK. 
In Chapter 3, we focused on those RTKs that are also Wnt receptors.  In particular, we 
studied the Drosophila ortholog of human Wnt5 protein, DWnt5, and its receptor Derailed (Drl).  
We managed to express milligrams of bioactive DWnt5, thus effectively overcoming a barrier that 
has hindered biochemical and biophysical studies of Wnt for decades.  Next, we employed 
hydrogen deuterium exchange approaches and mutagenesis analysis to identify the binding 
interface on Drl.  These studies revealed a new binding mode of WIF domain binding to (non-
lipidated) Wnt protein.  We also used molecular dynamics (MD) simulations to study the structure 
and conformational dynamics of DWnt5, and uncovered unique conformational dynamics that 
DWnt5 exhibits. 
In Chapter 4, we shift our attention to the intracellular region of RTKs.  Among the 
‘RTKome’, many receptors have in their carboxy-terminus a disordered region (‘C-tail’) that 
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harbors the phosphorylation sites that link to downstream signaling molecules responsible for 
network activation.  We investigated the C-tail of EGF receptor, showing that C-tail is not 
completely disordered.  Rather, it adopts a relatively restricted conformational ensemble.  In 
addition, we showed that phosphorylation of the EGFR C-tail promotes receptor dimerization.  We 
identified regions in the kinase domain that are likely to contact C-tail region upon 
phosphorylation, thus suggesting a possible structural explanation for phosphorylation-promoted 
receptor dimerization.  In addition, we studied the binding of downstream SH2 domains to 
phosphorylated C-tail.  We discovered that the affinity of SH2 domain binding to C-tail differs 
slightly from SH2 domain binding to short phosphopeptides.  In addition, using surface plasmon 
resonance approach, we identified the negative cooperativity of binding of Grb2 and PLCγ SH2 
domains – that is, binding of one SH2 domain to one phosphotyrosine site negatively impacts the 
binding of the second SH2 domain to a different pTyr site.  Using ordinary differentiation equation 
(ODE) – based simulations, we further showed that this binding effect could regulate the 
dynamics of receptor signaling levels.  While our studies so far are limited to only several SH2 
domains, the principle we discovered is potentially applicable to other SH2 domains as well – 
suggesting that C-tail not only recruits downstream signaling molecules but also regulates kinase 
activity and downstream signaling. 
 In Chapter 5, we presented our work on developing novel tools to facilitate biophysical 
studies of RTKs.  In order to take advantage of small-angle X-ray scattering techniques to study 
the ligand binding of receptors, and the low-resolution structure of receptors and receptor 
complexes, we developed a series of programs that allow for sampling of large parameter space 
in the process of data analysis.  We described our work of Drosophila EGFR (dEGFR) and its 
binding partner Kekkon1.  Using SAXS and our programs, we identified the binding affinity and 
stoichiometry of s-dEGFR/sKek1.  In addition, based on the low-resolution structure of the s-
dEGFR/sKek1 complex derived from SAXS, we proposed a structural model where Kekkon1 
contacts domain II and V in the extracellular region of dEGFR and thus blocks receptor 
dimerization. 
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6.2 Future directions 
6.2.1 Extend current investigations to full-length receptors  
Our work on EGFR reveals additional functions of the C-tail region – in addition to harboring the 
phosphorylation sites to which signaling molecules bind, the C-tail also regulates receptor activity 
and downstream signaling directly.  Although these findings are important, to truly fit them into a 
broad mechanistic view of EGF receptor (and other RTKs), one needs to extend these studies to 
the intact receptor – full-length receptor comprising of all the components including the 
ectodomain, transmembrane helix as well as the intact intracellular region (juxtamembrane region, 
kinase domain and C-tail).  Therefore, the next question, based on what we have determined so 
far about EGF receptor and the C-tail in particular, would be to study the regulation of receptor 
activity and of SH2 domain binding to the receptor’s C-tail in the context of full-length receptors 
reconstituted in synthetic membrane systems such as liposome, detergent micelle, and 
‘nanodiscs’ (Bayburt, Grinkova, and Sligar 2002).  Similar approaches have been applied to other 
membrane proteins and receptors, such as G-protein coupled receptors (Bayburt et al. 2007), 
chemoreceptors (Boldog et al. 2006), and limited studies of EGFR in this context have been 
reported (Mi et al. 2008).  We aim to re-assess the conformational dynamics of the C-tail in the 
context of the full-length receptor, to test whether the C-tail exhibits additional 
structural/dynamical features in intact EGFR, and to determine the extent to which C-tail 
phosphorylation regulates receptor dimerization and kinase activity (when additional components 
are present).  One approach to address this question is to employ hydrogen exchange mass 
spectrometry as we did for the soluble C-tail protein, but using the intact membrane-reconstituted 
receptor.  A systematic analysis of hydrogen exchange profiles of the full-length receptor could 
reveal additional interactions between the C-tail and other components of the receptor in this 
context.  In parallel, we can take advantage of HX and modern mass spectrometric approaches to 
study any differences in the dynamics of EGFR C-tail phosphorylation in response to the different 
EGFR ligands.  The extracellular ligand-binding region of EGF receptor is well known for its ability 
to bind various ligands to differentially invoke downstream signaling events.  In this experimental 
setup, we are in a position to really tackle the question as to how different ligand-binding signals 
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are propagated through membrane to cause (potentially) different phosphorylation of the C-tail – 
and how the negative cooperativity of ligand binding in the extracellular region might translate to 
altered structure and dynamics in the intracellular region.  These studies would significantly 
extend our current understandings of EGF receptor, which is largely derived from studies of 
individual components of the receptor separated from their native context. 
 
6.2.2 Identify novel RTK binding partners 
Our work discussed in previous chapters revealed several novel ligand-binding mechanisms of 
RTKs, such as the binding mode of heparin/ALK and the Wnt5 binding interface on the Ryk WIF 
domain.  However, these findings cannot rule out other possible ligands and ligand-binding 
mechanisms for these receptors.  For instance, our biophysical studies on heparin/ALK binding 
pointed out a possible heparin-induced receptor dimerization model.  It is, however, possible that 
there exist other ALK ligands that can bind to heparin/ALK complex (or compete with heparin).  
Notably, how jelly belly (jeb) binds to Drosophila ALK still remains unclear, and we speculate that 
jeb may need a co-ligand, such as heparin, to bind to fly ALK.  The recent discovery of a secreted 
protein as a novel LTK ligand (Zhang et al. 2014) also suggests that there might exist similar 
molecules that target the corresponding region in the related ALK receptor.  In addition, the 
complement of domains in the extracellular region of ALK suggests its interactions with other 
unknown proteins.  Therefore, seeking novel ligands and co-receptors for ALK remains to be 
important.  Both hypothesis-driven and exploratory approaches can be applied for this purpose.  
For example, based on our studies of heparin/ALK binding, we propose that heparin may induce 
formation of a pre-dimer, but that other ligands may be required to fully activate the receptor.  
Therefore, we can assess the binding of other proposed ALK ligands to heparin-induced ALK 
dimer using biochemical and biophysical approaches, and test receptor activation by these 
molecules in the presence of heparin using biochemical and cell-based assays.  In addition, high-
throughput screening of potential receptor-activating ligands in the extracellular proteome, the 
approach that led to the discovery of the LTK ligands (Zhang et al. 2014), may also be used to 
identify potential ALK ligands and co-ligands. 
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 Similar to ALK, there might exist additional molecules that interact with Ryk or Wnt/Ryk 
complexes.  In fact, our work suggests that the binding mode of Wnt/Ryk appears to be different 
from that of Wnt/CRD, leading to the hypothesis that Wnt might be a multivalent ligand that can 
bind to several different receptors simultaneously.  To test this hypothesis, we aim to extend our 
hydrogen exchange studies (which identifies the binding interface on Drl) to characterize the 
binding interface of WIF domain and CRD on Wnt.  If these two binding interfaces on Wnt are 
distinct, then Wnt is likely to be a multi-valent ligand, and understanding the formation of hetero-
complex would thus be crucial for unraveling Wnt signaling. 
 In addition to the studies of Wnt binding, we also aim to understand how Ryk, being a 
‘dead-kinase’, transduces extracellular cues to downstream signaling events.  This is an 
important question, since most of the Wnt-binding RTKs turn out to be pseudokinases (the only 
exception is MuSK, or Muscle-Specific Kinase) (Mendrola et al. 2013).  For Ryk/Drl, two Src-
family kinases Src64B and Src42A (Wouda et al. 2008) appear to be involved in DWnt5/Drl 
signaling.  While the detailed mechanism is still lacking, it is suggested that Drl, although kinase-
dead, can still allosterically activate other kinases.  Similar mechanisms have been reported for 
kinase domains outside the RTK group.  For example, STRADα (Ste20-related adaptor α) is a 
pseudokinase, but can bind to LKB1 kinase (and the MO25 adaptor) and allosterically activate it 
(Zeqiraj et al. 2009).  To test the hypothesis that Drl can function similarly, we aim to employ 
proteomic approaches to identify possible binding partners of DWnt5/Drl complex in cells, and 
then use biophysical and structural biology approaches to study how the pseudokinase domain of 
Drl, upon DWnt5 binding, might activate its binding partner.  These studies could reveal novel 
mechanisms that complement the current view of RTK-mediated signaling. 
6.2.3 Investigate RTKs at the systems level 
Our work on various RTKs suggests that there are different levels of regulation across the RTK 
family – from ligand binding to the activation of kinase domain, to the recruitment of downstream 
signaling molecules.  These diverse regulatory mechanisms add extra complexity to the 
understanding of RTK signaling.  To fully appreciate this complexity, we argue that one needs to 
integrate the biochemical and structural studies using a ‘systems approach’.  For example, our 
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work on the EGFR C-tail suggests that there exists binding specificity and cooperativity in SH2 
domain assembly.  To understand how these effects contribute to cell decision-making, we need 
to feed our binding data to a systems model.  As discussed in Chapter 4, we have performed 
ordinary differential equation (ODE) – based modeling to study the spiked and sustained receptor 
signaling level controlled by SH2 domain binding.  Despite having provided some insights into 
EGFR-mediated signaling, such a model is severely limited in that it only considers the short-term 
signal, and oversimplifies some important factors such as a variety of phosphatases and protein 
degradation machineries in cells (in our model, there is only one dephosphorylation rate 
parameter to account for ‘background phosphatase activity’).  In order to further our 
understanding of the role of the C-tail in signaling, we need to collect data for more molecular 
events and then analyze them in a systems manner.  For example, we may also investigate SH2 
domains binding to the C-tail region in the full-length EGF receptor directly using in vivo single-
molecule approaches.  Oh et al has studied the binding kinetics of SH2 domains to EGF receptor 
by using total internal reflection (TIR) microscope (Oh et al. 2012).  Using similar approaches, we 
can verify our findings of SH2 domain binding to C-tail on the cell membrane (within TIR 
illumination field).  In addition, single-molecule studies in cells should allow us to study virtually all 
combinations of SH2 domains, as long as they are differentially tagged.  Using this approach, we 
should be able to collect a huge number of parameters for systems-level analysis.  Moreover, 
cell-based assays could be used to introduce perturbations to interrogate the regulations of the 
network.  For example, we can measure phosphorylation and binding events with different levels 
of certain phosphatases, therefore assessing the effect of phosphatases on signaling dynamics.  
Or, we can over-express a specific signaling molecule or a subset of proteins belonging to one 
pathway, effectively assessing the impact of one pathway to the entire network.  Finally, we would 
hope also to extend these studies to other ErbB family receptors and RTKs, to ultimately gain 
insights into the cell signaling network mediated by RTKs. 
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